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Abstract
Critically ill patients of all ages suffer from high burden of neurocognitive impairment during
(i.e. delirium) and following (i.e. long term cognitive impairment) critical illness that is
associated with worse patient and healthy system outcomes. Ischemia has emerged as a
plausible mechanism given the high prevalence of hypotension and shock, ischemic injury on
neuroimaging, and impairment of cerebral autoregulation in these patients. However, the
burden of ischemic insults during critical illness and mechanisms responsible for these insults
are poorly described. Furthermore, while baseline impairment in cerebrovascular function
can render patients more vulnerable to ischemia, such baseline functional assessments in
patients with high risk of critical illness have not been considered. Finally, the operational
limitations of existing cognitive batteries preclude routine linkage of ischemic insults and
baseline impairment in cerebrovascular function with neurocognitive outcomes. In this work
we carried out three studies to address these knowledge gaps. In the first study, we showed
that critically ill patients with respiratory failure or shock experience deviations in cerebral
blood flow velocity consistent with ischemia or hyperemia for 17-24% of the observation
time. These deviations occurred irrespective of the state of cerebral autoregulation and were
not explained by concurrent changes in blood pressure or CO2. These deviations represent a
plausible ischemic insult that may explain high prevalence of ischemic injury in previous
neuroimaging and histopathologic studies, and warrants further research to understand the
underlying mechanism and link with neurocognitive outcomes. In the second study, we
showed that hemodialysis patients have baseline impairment in cerebrovascular function
prior to onset of critical illness, which may render them more vulnerable to ischemic injury
during critical illness as a result of perturbation in cerebral blood flow shown in our first
study. In our third study, we optimized an existing comprehensive web-based cognitive
battery for monitoring cognitive outcomes in ICU patients, which should enable future
linkage of ischemic insults and baseline impairment in cerebrovascular function from our
first two studies with neurocognitive outcomes, as well enable routine clinical monitoring of
cognitive recovery in ICU survivors.
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Summary for Lay Audience
Patients who are admitted to the intensive care units (ICU) often suffer from neurocognitive
impairment both during and following their critical illness. During ICU stay, this
neurocognitive impairment known as delirium is associated with increased risk of dying and
prolongs the time that the patient stays on the ventilator and in hospital. Following discharge,
many patients suffer from long-term cognitive impairment that can slow patient recovery and
return to work and puts a huge burden on caregivers and society. Low brain blood flow
during ICU stay is one potential mechanism that may be responsible for these neurocognitive
impairments. However, the burden of low brain blood flow and responsible mechanisms are
not well described. Furthermore, some patients may have impairment in the function of the
brain blood vessels prior to ICU admission, which can make them more vulnerable to
developing brain injury during critical illness. Finally, current cognitive tests that assess
neurocognitive impairment are complex, expensive and take a long time, which makes it
challenging to study the relationship between low brain blood flow and brain blood vessel
function with neurocognitive impairment. In our first study, we showed that patients who are
admitted to the ICU with low blood pressure or breathing failure spend up to one quarter of
the time with low brain blood flow that is not counteracted by brain protective mechanisms.
This may explain why many ICU patients develop brain injury and neurocognitive
impairment. In the second study, we showed that dialysis patients have impaired baseline
function of brain blood vessels prior to critical illness. This impairment can make them more
vulnerable to brain injury during critical illness as a result of low brain blood flow that we
showed in the first study. In the third study, we optimized an existing comprehensive webbased cognitive battery for monitoring neurocognitive outcomes in ICU patients. This tool
will enable future studies of the relationship between low brain blood flow and brain blood
vessel function with neurocognitive impairment, and routine clinical monitoring of cognitive
recovery in ICU survivors.
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Chapter 1
1

General Introduction

1.1 Neurocognitive impairment across a continuum of
critical illness
Critical illness related neurocognitive impairment comprises a spectrum of acute and
long-term disorders that occur during or following admission to the intensive care unit.
Excluding direct injury to the brain as a result of trauma or large stroke, it can broadly
present as coma, delirium or long-term cognitive impairment. Regardless of the
presentation, neurocognitive impairment during critical illness has important
consequences for patient, their families and caregivers, the healthcare system, and the
broader society.
At the patient level, acute neurocognitive impairment (e.g. delirium) is associated with
increased risk of dying 1 and development of long-term cognitive impairment,2 which inturn impedes patients’ functional recovery and affects their quality of life.3 For families
and caregivers, the newly acquired cognitive disabilities and functional dependency in
their loved ones translate into significant psychological and emotional stress and financial
burden, loss of employment, lifestyle interference and low health-related quality of life.4
At the healthcare system level, delirium is associated with increased length of mechanical
ventilation and increased length of stay,1 which translate into higher healthcare costs,
while at societal level long-term cognitive impairment prevents previously able
economically active people from returning to the workforce, placing the burden of the
care and sustenance on their families, caregivers and the state.
Given ageing of the global populations 5 and increase in the number of intensive care unit
(ICU) survivors due to projected increase in the incidence of critical illness 6 and
reduction in ICU mortality, the consequence of critical illness related neurocognitive
impairment represent a public health problem that requires urgent and innovative
solutions. In the current chapter, we will review the current body of knowledge related to
acute (delirium) and long-term cognitive impairment, examine potential mechanisms that
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may be responsible for this dysfunction, and identify current knowledge gaps that will be
addressed in this body of work.

1.1.1 Terminology and definitions
ICU-related neurocognitive impairment can be broadly classified into coma, delirium and
long-term cognitive impairment. In order to understand the differences between these
states, it is important to consider two primary neurologic functions: 1) arousal or
wakefulness, and 2) awareness of self and the environment. Arousal is anatomically
localized to reticular activating system – a network of neurons that projects from
brainstem to thalamus and cerebral cortex and is responsible for mediating arousal and
sleep wake cycles. Awareness requires function and interplay of multiple cognitive
domains including perception, attention, memory and executive function. Impairments in
these two neurologic functions give rise to neurocogntive syndromes in critical illness.
In the acute critical care settings, a number of terms have been used to describe
neurocognitive impairment including delirum, encephalopathy and sepsis-associated
encephalopathy. Delirium was defined in the American Psychiatric Association's
Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV as the disturbance in
consciousness with inattention that develops over a short period of time due to a general
medical condition and is not explained by pre-existing, established or evolving
dementia.7 In the recent revision of this manual (DSM-V), the reference to consciousness
was replaced with disturbance in attention and awareness.8 Furthermore, new criteria
include an additional disturbance in cognition (Criterion C - e.g. memory, orientation,
language, visuospatial ability, perception) and that disturbances in attention, awareness
and cognition are not due to severely reduced level of arousal such as coma. In light of
these changes, European and American Delirium Societies published a statement that
patients with reduced arousal who are unable to complete cognitive testing should still be
classified as having delirium unless they are clearly comatose.9 While critical care
literature continues to use terms such as encephalopathy and sepsis-induced
encephalopathy, it remains unclear whether these entities are clinically or
pathophysiologically different from other causes of ICU delirium. As a result, to reduce
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confusion, there is a call to use the term “delirium” uniformly to describe the syndrome
of acute cognitive impairment in the ICU.10

1.1.2 Coma
1.1.2.1 Definition and clinical features of coma
Coma is a severe disruption of arousal and awareness functions and is differentiated from
transient states such as syncope or concussion by its duration of greater than one hour.
Comatose patients are unable to feel, speak or move in response to verbal, light or painful
stimuli. They lack normal sleep wake cycles, may have altered brainstem reflexes,
electric brain activity, and brain metabolism. Diagnosis of coma should exclude potential
confounders that may mimic coma including intoxication, severe electrolyte
abnormalities, sedatives, muscle relaxants, and seizures.

1.1.2.2 Causes of coma
Coma causes can be grouped into primary brain disorders and systemic causes. Primary
brain causes include traumatic or cerebrovascular brain injury, neurologic infections,
seizures or brain tumors. Systemic causes include cardiorespiratory arrest, pharmacologic
and toxic exposures, sepsis, severe metabolic and physiologic derangements, and
endocrine insufficiency.

1.1.2.3 Epidemiology of coma in the ICU
While epidemiology of coma is well described in neurological or neurosurgical
population, it is less well understood in the ICU. The prevalence of non-traumatic coma
varies between 28 and 75%.11 Coma is also common in patients receiving mechanical
ventilation, where it occurs in 15-20% of patients, as well as elderly patients and those
presenting with sepsis, with rates of over 30% and 16% respectively.12. Given that coma
is potentially a by-product of sedation required to tolerate mechanical ventilation, the
prevalence of non-sedation related coma may be lower than stated.
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1.1.2.4 Outcomes in coma
Coma is considered a transitional state that eventually evolves towards resumption of
consciousness, vegetative state, minimally conscious state or brain death.12 In vegetative
state patients regain partial signs of arousal including spontaneous opening of the eyes,
but they do not regain awareness of the self or the environment, failing to respond to
external stimuli, fixate gaze or track objects. If this persists for more than 1 month, the
patients are classified as being in the persistent vegetative state. Minimally conscious
state differs from vegetative state in that the patient does has occasional, inconsistent but
clear signs of self or environmental awareness. They may sporadically follow commands,
respond to familiar objects or voices, attempt to imitate meaningful speech or engage in
purposeful movement. Brain death is complete and irreversible cessation of brain and
brainstem function characterized by absence of arousal, awareness, cranial nerve
function, motor responses and spontaneous breathing.
Coma is an important prognostic factor in patients with brain injury. It is an important
predictor of death in functional outcomes in patients with traumatic brain injury,13,14
cardiac arrest,15,16 and stroke.17,18 It is also one of the strongest independent predictor of
death and length of stay.19 The Glasgow Coma Scale on admission was identified as the
leading predictor of mortality in a large cohort of over 15,000 critically ill patients,20
which explains why it is integral component in most intensive care unit prognostic
models.20–27

1.1.3 Delirium
1.1.3.1 Definition and clinical features
Delirium is defined as an acute or fluctuating change in mental status with inattention,
accompanied by either by disorganized thinking or altered level of consciousness.7
Unlike coma, patients with delirium retain elements of arousal and awareness. Delirium
is sub-classified based on psychomotor status into 1) hyperactive delirium, characterized
by agitation and combativeness, 2) hypoactive delirium, characterized by lethargy and
withdrawal, and 3) mixed delirium, that shares features of both hyperactive and
hypoactive delirium and fluctuates between these two types over time.28 While all three
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types of delirium have been shown to be common in the critical ill, hypoactive and mixed
delirium may be more prevalent and are likely less commonly identified due to lack of
agitation.29 Patients that meet some, but not all, diagnostic criteria for delirium are often
thought of as having sub-syndromal delirium. The outcomes for patients with subsyndromal delirium fall in between those with full delirium and patients who have no
delirium, suggesting a continuum of neurocognitive impairment severity.

1.1.3.2 Epidemiology of ICU delirium
Delirium occurs in 20-40% of non-critically ill hospitalized patients.30 In the intensive
care units, the prevalence is higher with rates as high as 80% reported in both medical
and surgical critically ill patients.1 The reported prevalence varies depending on the
severity of illness and the instruments used to diagnose delirium. In a recent randomized
controlled study comparing protocolized sedation with protocolized sedation plus daily
sedation interruption, delirium was diagnosed in 53.8 % of patients. Median time to onset
of delirium was 3.5 days from enrollment in the study and delirium lasted a median of 2
days. Antecedent factors that were independently associated with the onset of delirium
included use of restraints, administration of antipsychotic medications, and the dose of
midazolam.31

1.1.3.3 Risk factors for ICU delirium
A number of risk factors have been identified that may predispose patients to developing
delirium in the ICU. Data from a large multicenter study identified male sex,
surgical/trauma diagnosis, history of tobacco or alcohol use as risk factors for delirium. 31
A recent systematic review of the literature identified 11 risk factors for developing ICU
delirium that were associated with strong or moderate level of evidence. These included
age, dementia, hypertension, pre-ICU emergency surgery or trauma, severity of illness
(Acute Physiology and Chronic Health Evaluation II) score, mechanical ventilation,
metabolic acidosis, delirium on the prior day, coma and multiple organ failure. Use of
dexmedetomidine for sedation was associated with a lower delirium prevalence.
Interestingly, gender was not identified as a risk factor for ICU delirium in this study.32
Sleep deprivation may play a role in the pathogenesis of ICU delirium. A recent
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systematic review demonstrated that non-pharmacologic (e.g. noise reduction) and
pharmacologic sleep interventions are associated with a reduction in the incidence and
duration of ICU delirium, as well as shorter duration of ICU stay.33

1.1.3.4 Consequence of ICU delirium
A recent systematic review and meta-analysis comparing delirious and non-delirious
patients in the ICU showed that delirium was associated with higher relative risk of death
(risk ratio of 2.19) and this association persisted even when analysis was adjusted for the
severity of illness. Delirium was also associated with longer durations of mechanical
ventilation, hospital and ICU lengths of stay,34 which explains why it also results in
higher costs of care.35 The effects of delirium are not limited to ICU admission. In a large
prospective observational study, ICU delirium was independently associated with worse
global cognitive function and executive function at 3 and 12 months after discharge,36
suggesting a potential mechanistic link between acute ICU delirium and long-term
cognitive function.

1.1.4 Long-term cognitive impairment
Long-term cognitive impairment is a common complication of critical illness. The
reported prevalence of long-term cognitive impairment varies depending on the etiology
of critical illness, time of assessment and cognitive instruments used.37

1.1.4.1 Definition and clinical features
Long-term cognitive impairment has been defined as a perceived (subjective) or
measured (objective) impairment on one or more cognitive domains. While a few studies
have used patient or caregiver subjective perception of cognitive impairment, the
majority of studies have used some cognitive instrument to measure patient performance
and compare it to age- and sex- matched healthy controls.37 In the latter studies, cognitive
impairment was defined if patient scores were 1-2 standard deviations below those from
healthy controls. In a recent systematic review, we showed that the reported prevalence
of cognitive impairment varies depending on the type of cognitive instrument used. For
example, the use of single cognitive tests such as Trails Making Tests A/B or a dementia
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screening battery such as a Mini-Mental State Examination (MMSE) is associated with a
lower prevalence of cognitive impairment compared to comprehensive multi-domain
cognitive batteries.37 Given that ICU-related long-term cognitive impairment affects
multiple domains, the use of single tests or simple screening batteries will likely
underestimate the incidence of cognitive impairment in ICU survivors.
Unlike Alzheimer’s dementia, which tends to affect delayed memory more than any other
domains, critical illness cognitive impairment affects multiple cognitive domains
including attention, memory, and executive function.36,38,39 Also, unlike Alzheimer’s,
cognitive impairment after critical illness is not limited to older individuals, and affects
patients across the age spectrum.36. For majority of patients, the severity of cognitive
impairment is comparable to that of mild cognitive impairment, with median global
cognitive scores at 3 and 12 months being 1.5 standard deviations below population
norms. However, at 3 months, 40% of patients had global cognitive scores that were
worse than those seen in moderate traumatic brain injury, while 26% had scores
comparable to patients with mild Alzheimer’s disease. These severe deficits persisted at
12 months, with 34 and 24% patients having global scores that were comparable to
moderate traumatic brain injury and mild Alzheimer’s disease respectively.36

1.1.4.2 Epidemiology of critical illness cognitive impairment
The prevalence of long-term cognitive impairment in ICU survivors varies depending on
the type of cognitive assessment (subjective vs objective), the cognitive instrument used
(higher prevalence with comprehensive batteries that assess multiple cognitive domains),
timing of assessment (higher prevalence immediately following ICU discharge), and ICU
patient population (higher prevalence in patients with the Acute Respiratory Distress
Syndrome, or ARDS).37
Studies utilizing objective measures of cognition report higher prevalence of cognitive
impairment than studies using subjective reports from patients and caregivers. However,
while the prevalence of cognitive impairment measured using objective measures
decreases with time from the ICU discharge, the prevalence of subjectively reported
cognitive impairment increases. This suggests that ICU survivors may be initially
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unaware of their newly acquired cognitive deficits. If true, this implies that some patients
may lack insight into their cognitive deficits despite objective cognitive impairment at the
time of discharge, either due to attribution of their cognitive deficits to the overall illness
or poor self-appraisal.40,41 Given that cognitive function is an important determinant of
functional recovery,42,43 failure to detect cognitive impairment at the time of discharge
may result in missed therapeutic opportunity for some patients who may benefit from
targeted cognitive interventions.
Studies that utilize comprehensive cognitive batteries report higher prevalence of
cognitive impairment compared to studies that use simple dementia screening batteries
such as the MMSE. For example, at ICU discharge the mean prevalence of cognitive
impairment using MMSE was 36% compared to 61% if comprehensive cognitive
batteries are used. Similarly, at 12 months following ICU discharge were 18 and 43%
respectively.37 Given that MMSE was developed as a screening tool for dementia, which
mostly involves memory domain of cognition, it may not be sensitive for detecting multidomain cognitive impairment commonly seen in the ICU. Furthermore, it may also be
prone to floor/ceiling effects.
The prevalence of cognitive impairment in ICU survivors appears to decrease with time
from the ICU discharge. However, due to high attrition rate in some studies, it is hard to
determine whether this reduction in the prevalence of cognitive recovery or a result of
loss of patients with worse cognitive scores from study cohorts. In most studies, cognitive
assessments occur at several discrete time points, most commonly at discharge, and at
three, six and twelve months. Given that no rationale for the choice of these time interval
is provided, it is likely that these intervals reflect the operational and resourcing
framework of previous studies.44 Specifically, since most studies utilize pen and paper
cognitive tests, repeated testing requires patients to return to clinic, which may be
challenging for some ICU survivors given functional limitations, unwillingness to return
to hospital for post-traumatic associations, and geographic dispersion of patients relative
to tertiary care centres where most of these clinics are located. Moreover, administration
of pen and paper cognitive batteries requires trained personnel, which is both costly and
time consuming. As a result, repeated testing of cognition in ICU survivors with pen and
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paper tests is limited to discrete time points and is not practical for large scale natural
history studies of cognitive recovery in these patients.
Survivors of ARDS appear to have higher prevalence of cognitive impairment in the first
3 months following ICU discharge compared to other ICU survivors (approximately 80
vs 50%).37 This difference disappears at the 6 month mark and by 12 months there were
no differences in the prevalence of cognitive impairment between different patient
populations. While higher illness severity, longer duration of mechanical ventilation and
ICU stay, lower oxygen (O2) and higher carbon dioxide (CO2) levels in ARDS patients
may all contribute to worse cognitive outcomes, this hypothesis requires further
evaluation with properly designed natural history studies. Loss of patients to follow up
and inability of sicker patients to return to clinic for in-person cognitive testing are major
barriers to such natural history studies and need to be addressed in order to enable future
research in this area.

1.1.4.3 Risk factors for long-term cognitive impairment
Pre-existing cognitive function is often unknown in critical illness survivors. However,
in one study, the prevalence of pre-existing cognitive impairment was higher in
hospitalized patients who required admission to the ICU compared to those who did not
(35 vs 18%).45 In that study, patients who had pre-existing cognitive impairment and
required ICU admission were older, male and had higher initial severity of illness scores
compared to ICU patients without pre-existing cognitive impairment. This suggests that
older patients who are admitted to the ICU may have higher prevalence of cognitive
impairment.
Given that critical illness is a sudden, unpredictable event, it is often not feasible to
obtain baseline assessment of cognitive function prior to onset of critical illness. This
remains a major limitation of many studies. Some studies employ screening
questionnaires such as Informant Questionnaire on COgnitive Decline in the Elderly to
rule out patients with pre-existing cognitive impairment or dementia.36 In one study,
however, baseline cognitive function was measured and compared to that following
hospitalization of sepsis in elderly patients. Non-sepsis hospitalizations served as
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controls. The prevalence of moderate to severe cognitive impairment increased 10.6% in
sepsis survivors, while there was no change in patients with non-sepsis hospitalizations.
This increase in cognitive impairment was associated with a higher rate of functional
limitations.46 These results suggest that an episode of critical illness may result in de novo
cognitive impairment.
Genetic factors, such as the presence of the Apolipoprotein E4, a well-known risk factor
for Alzheimer’s disease, may increase the risk of acute and potentially long-term
cognitive impairment in critical illness. For example, in one study, presence of the
Apolipoprotein E4 allele was the strongest predictor for the duration of delirium (odds
ratio of 7.3). This odds ratio was higher than that for age (1.02), severity of illness score
(0.98), diagnosis of sepsis, acute respiratory distress syndrome or pneumonia (1.73),
duration of coma(1.32) or total dose of benzodiazepines (1.00).47
Hypoxemia, especially in ARDS patients, has been shown to correlate with the degree of
cognitive impairment. In one study, the duration and degree of hypoxemia correlated with
the severity of cognitive impairment in attention, memory, intelligence, speed of
processing, visuospatial skills and executive function scores.48 Similarly, lower partial
pressure of oxygen in arterial blood was associated with cognitive impairment in a subset
of patients from a large randomized controlled study examining conservative versus
liberal fluid therapy in acute respiratory distress syndrome.49 However, the effect of
hypoxemia on the brain may not be uniform across different ICU populations. In trauma
patients, there was no association between hypoxemia and incident delirium or cognitive
impairment at 1 years after discharge.50 Similarly, in a cohort of 64 mixed medical and
surgical critically ill patients, brain imaging revealed atrophy in 26 patients, but this was
not associated with hypoxemia.51 This suggests that mechanisms linking hypoxemia and
cognitive impairment in ARDS may be different from the mixed medical surgical ICU
population.
Sepsis has been associated with development of new cognitive impairment. In a large
prospective study, Iwashyna et al showed that elderly patient who are hospitalized for
severe sepsis have a 10% increase in the prevalence of moderate to severe cognitive
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impairment compared to pre-hospitalization. The incidence of severe sepsis was highly
associated with progression to moderate to severe cognitive impairment (odds ratio 3.34).
The cognitive changes were accompanied by development of ~1.5 new functional
limitations. These cognitive and functional changes persisted for at least 8 years after
episode of sepsis, suggesting persistent burden of new cognitive and functional
disability.46 In contrast, a control group of elderly adults who experienced non-sepsis
hospitalization had no change in the prevalence of moderate to severe cognitive
impairment and developed fewer (~0.4) new functional limitations. In another study,
sepsis survivors had greater loss of left hippocampal volume compared to healthy
controls, and this was associated with impairment in verbal learning and memory. Sepsis
survivors also showed more low-frequency activity on electroencephalography,
suggesting generalized brain dysfunction.52
Glucose dysregulation has been associated with development of cognitive impairment.
Using data from a randomized control trial comparing high vs. low tidal volume
ventilation for acute respiratory distress syndrome, Hopkins et al. showed in a
multivariate analysis that patients with highest blood glucose exceeding 8.5 mmol/L and
those with variation in glucose exceeding 0.9 mmol/L were at higher risk of developing
cognitive impairment (odds ratios of 2.96 and 3.26 respectively).53 In surgical ICU
population, patients who experienced hypoglycemic episodes and those that did not
showed impairment in several cognitive domains compared to healthy controls. However,
in the visuospatial skills domain, the impairment in hypoglycemic group was greater than
in non-hypoglycemic group.54
Delirium is an important independent risk factor for long-term cognitive impairment. In
a cohort of mixed medical and surgical ICU patients, a multivariate analysis that included
delirium and coma duration, as well as mean daily doses of sedative and analgesic
medications as independent variables, longer duration of delirium was an independent
predictor for worse global cognitive scores at 3 and 12 months after discharge.36 In
another study, duration of delirium was associated with worse cognitive outcomes after
adjusting for age, education, pre-existing cognitive impairment, severity of illness, severe
sepsis and total exposure to sedatives in the ICU. In contrast, duration of mechanical
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ventilation did not predict worse cognitive outcomes, suggesting that duration of delirium
is not merely a surrogate for duration of mechanical ventilation.55
Sedative and analgesic medication exposure has been considered as a risk factor for
development of cognitive impairment. However, in the largest study to date, the mean
daily dose of benzodiazepines, propofol, dexmedetomidine and opiates was not
associated with worth cognitive outcomes at 3 and 12 months.36 Furthermore, daily
interruption and reduction of sedation had no effect on the delirium duration 56 or
cognitive outcomes at 12 months,57 despite reducing duration of coma, mechanical
ventilation, ICU and hospital length of stay, and 1-year mortality.56
Sleep deprivation appears to contribute to ICU delirium, and strategies to promote sleep
in the ICU appear to reduce incidence and duration of the ICU delirium.33. Whether poor
sleep or strategies aimed at improving sleep in the ICU affect long term cognitive
outcomes is unclear.58

1.1.4.4 Consequences of long-term cognitive impairment
Cognitive function is one of the best predictors of life quality, including academic and
work success, levels of happiness and even life expectancy.59–62. Given the expected
increase in the number of ICU survivors due to projected increase in the incidence of
critical illness 63 and reduction in ICU mortality, ICU-related cognitive impairment is an
important public health problem that requires urgent and innovative solutions.
Cognitive impairment in ICU survivors has been associated with anxiety, depression and
post-traumatic stress disorders.3 These ICU survivors also suffer from high rates of
unemployment 64 and impaired quality of life,65,66 placing a huge burden on the
caregivers and society. At 12 months following ICU discharge, 40% of ICU survivors
remain unemployed,64 which is comparable or worse than in patients with traumatic
brain injury67 or stroke.68 After returning to work, a third of survivors experience job loss,
while up to two thirds of survivors experience occupation change, often with worsening
employment status.64 These findings were persistent across geographical regions and
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states of economies, suggesting that factors other than societal or economics play a role.
It is conceivable that impairments in cognition may prevent previously able and
employed individuals from returning to work and being able to complete their work
duties as effectively as prior to their ICU illness. Given that gradual return to work,
modified work schedule and job retraining have been shown to help with return to work
in ARDS survivors,69 future studies should explore whether combination of cognitive and
vocational rehabilitation can mitigate these problems.

1.2 Mechanisms of ICU-related neurocognitive impairment
While the exact mechanisms behind ICU-related neurocognitive impairment are still
unclear, a number of pathogenesis hypotheses have been put forward.70

1.2.1 The neuroinflammation hypothesis
This hypothesis proposes that delirium is a clinical manifestation of acute brain injury
that occurs as a result of systemic inflammatory response. High levels of inflammatory
markers such as C-reactive protein, procalcitonin, and interleukin-8 have been detected in
patients who develop ICU delirium.71–74 Systemic inflammation can have several effects
including: 1) Activation of endothelium and coagulation systems leading to thrombosis of
the microcirculation and impairment in brain perfusion;75,76 2) In animal models, a proinflammatory cytokine tumor necrosis factor-a has been shown to result in disruption of
the blood-brain barrier and translocation of leukocytes and cytokines into the central
nervous systemic leading to ischemia and neuronal death;77 3) Activation of microglia
(resident brain macrophages) can result in further neuronal injury and apoptosis via
expression of adhesion molecules, production of pro-inflammatory cytokines
(interleukin-1b, tumor necrosis factor α, insulin like growth factor 1), metalloproteinases,
reactive oxygen species, and increase in inducible nitric oxide synthase.76,78 These
inflammation driven changes can impair cognition by affecting synaptic plasticity and
long-term potentiation, as well as reducing brain synaptic connectivity via upregulation
of the inhibitory gamma-aminobutyric acid (GABA) receptors.70 Upregulation of GABA
receptors may explain why administration of benzodiazepines (GABA receptor A
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agonists) for sedation in the intensive care units is associated with higher rates of
delirium than sedation with other agents such as propofol or dexmedetomidine.79
Inflammation may also contribute to the long-term cognitive impairment. Systemic
inflammation during acute critical illness may activate brain microglial cells.80,81
Activated microglia sustain a state of chronic neuroinflammation that contributes to
ongoing brain injury. Clinically this may manifest as failure of cognitive recovery in ICU
survivors.

1.2.2 The cholinergic hypothesis
This hypothesis focuses on the effect of acetylcholine deficiency in critical illness.
Acetylcholine is an important neurotransmitter in both central and peripheral nervous
systems. Among other things, it is responsible for modulation of the inflammatory
response, microglia and other neurotransmitter pathways. Acetylcholine level are low in
critical illness due to: 1) decreased production as a result of choline and acetyl-CoA
deficiencies, 2) inhibition of acetylcholine release by opiates, and 3) inhibition of
acetylcholine receptors by anesthetic and anticholinergic medications.82 In the central
nervous system, this leads to decreased inhibition of microglia via acetylcholine receptor,
leading to propagation of neuroinflammation and resultant neuronal death.78 Given that
acetylcholine is critical for modulating of other neurotransmitter pathways, there is
excess of dopamine, norepinephrine and serotonin signalling, which contributes to
hyperactive delirium. In the peripheral nervous system, acetylcholine release via the
vagus nerve inhibits release of pro-inflammatory cytokines including interleukins 1, 6
and tumor necrosis factor-a. As a result of acetylcholine deficiency, there is increased
release of these pro-inflammatory cytokines in critical illness, which contributes to
neuroinflammatory brain injury.70

1.2.3 Monoamine axis hypothesis
This hypothesis postulates that excess of activating neurotransmitters dopamine,
norepinephrine and serotonin results in overstimulation of the central nervous system,
leading to clinical presentation of hyperactive delirium.83 In one retrospective cohort,
administration of dopamine for hemodynamic support was associated with nearly triple
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the odds of developing delirium.84 Similarly, norepinephrine excess is associated with
impaired attention, anxiety, mood, and hyperactive delirium. Reuptake inhibition of
serotonin with pharmacologic agents has been associated with delirium.70

1.2.4 Perfusion hypothesis
Given that critical illness is associated with systemic hypotension and impaired cardiac
output, the perfusion hypothesis proposes that resultant global and/or regional changes in
brain perfusion may contribute to development of delirium and long-term cognitive
impairment. Evidence for this hypothesis comes from a number of neuroimaging studies
that documented high prevalence of cortical and sub-cortical ischemic brain injury in ICU
survivors, as well as several studies documenting impairment of cerebral autoregulation
and its association with delirium. In the following sections, we will present a brief
overview of the control of cerebral blood flow (CBF) and summarize existing knowledge
from cerebral autoregulation and neuroimaging studies.

1.3 Control of cerebral blood flow
1.3.1 Determinants of CBF
The human brain is a highly metabolically active organ that, despite only contributing to
the 2% of the total body weight, receives approximately 15-20% of the cardiac output.85
At rest, the brain utilizes nearly 20% of the basal oxygen consumption,86 and any
disruption in brain blood flow can lead to acute and eventually irreversible injury with
corresponding functional impairments.
The prevailing model of CBF defines it as a ratio of cerebral perfusion pressure (CPP)
and cerebrovascular resistance (RCV) (see Equation 1).87
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(Equation 1)

CPP, in turn, is a function of mean arterial pressure (MAP) and intracranial pressure
(ICP) or central venous pressure (CVP). Under normal physiologic conditions, CVP
exceeds ICP and determines CPP (Equation 2). In certain pathophysiologic conditions,
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such as traumatic brain injury, increase in ICP can overcome CVP, and become the
primary determinant of CPP (Equation 3).
!&& = 56& − !8&

(Equation 2)

!&& = 56& − :!& (Equation 3)
Under this model, increase in systemic MAP will augment cerebral blood flow by
increasing CPP. On the other hand, increase in ICP (e.g. as a result of increase in cerebral
blood volume due to hemorrhage), will work to reduce CPP and cerebral blood flow.
Given that hypotension is a common presentation of critical illness, reduction in MAP,
unless counteracted by resuscitative measures and vasopressors, will induce ischemia via
reduction in CPP.
According to Equation 1, cerebrovascular resistance is another important determinant of
CBF. RCV is primarily a function of the cross-sectional diameter of cerebral arterioles,
which is modulated via four primary mechanisms: 1) global vasoactive factors, such as
the arterial partial pressure of carbon dioxide (PaCO2),88 2) reduction in global arterial
oxygen content as a result of hypoxia89 or changes in hemoglobin concentration,90,91 3)
local vasoactive metabolites that are released in response to increase in neural activity (a
process known as neurovascular coupling),92 and 4) autonomic signaling,93 especially
during exercise.94 Figure 1-1 summarizes the relationship between CBF, MAP, arterial
partial pressure of O2 (PaO2) and PaCO2.
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Figure 1-1: Relationship between cerebral blood flow, mean arterial pressure (black
line), arterial PCO2 (red line) and PO2 (green line). Adapted from reference.95
Other factors not mentioned in Equation 1 that may contribute to regulation of CBF are
cardiac output and arterial oxygen content. Cardiac output has recently emerged as an
independent regulator of CBF, with several studies demonstrating cardiac output
mediated changes in CBF on the background of constant MAP.96 Given that at rest the
brain receives 15-20% of total cardiac output, these observations are relevant, and future
work needs to discern how MAP, PaCO2 and cardiac output integrate in the control of
CBF in critically ill patients. CBF is also sensitive to changes in arterial oxygen content
as a result of changes in hemoglobin, hematocrit and PaO2.89,91,97,98 In patients with
anemia, CBF increases as a result of vasodilation to maintain cerebral oxygen delivery.99
Correction of anemia in hemodialysis patients with recombinant human erythropoietin
decreases CBF due to increase in cerebral oxygen delivery.91 However, in patients with
arterial disease higher hemoglobin and hematocrit levels are associated with faster
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decline in cerebral blood flow over 4 years.90 CBF also increases in response to hypoxia,
but only at PaO2 levels less than 50mmHg (Figure 1-1).97

1.3.2 Cerebrovascular function and control of cerebral blood flow
Cerebrovascular function plays an important role in controlling CBF by inducing changes
in the diameter of resistant arterioles in response to various stimuli. The main
cerebrovascular mechanisms responsible for control of cerebral blood flow include
neurovascular coupling, autonomic activity, cerebral autoregulation and cerebrovascular
CO2 reactivity. For the purpose of this work, we will focus on two mechanisms, namely
cerebral autoregulation and cerebrovascular CO2 reactivity.

1.3.2.1 Cerebral autoregulation
Cerebral autoregulation is a mechanism that works by altering the diameter of resistant
arterioles to ensure stable CBF across a range of perfusion pressures.100 For example, a
decrease in MAP would lead to a reduction in CPP and decrease in CBF if
cerebrovascular resistance stays the same (see Equation 1 above). Autoregulation works
to maintain CBF by lowering cerebrovascular resistance via dilation of resistant
arterioles. Two types of cerebral autoregulation have been described: static and
dynamic.101
Static autoregulation refers to studies where MAP is manipulated to achieve several
steady states and corresponding CBF values are recorded. In this model, autoregulation is
said to be intact if CBF stays relatively constant over a range of MAP. Autoregulation is
said to be impaired, if CBF varies with changes in MAP. This description of cerebral
autoregulation was first described by Niels Lassen in 1959.102 Since its publication this
classic description of cerebral autoregulation has been replicated in multiple medical
texts (Figure 1-2). In this model, impairment of autoregulation can occur either at the
extremes of MAP, or due to the loss of the “plateau” relationship between CBF and MAP
as a result of loss of vasomotor control (e.g. with ischemia, stroke or sepsis).95 However,
Lassen used data from multiple patients and studies to construct his classic curve,102 and
recent studies have questioned whether the same phenomenon can be reproduced in
individual subjects.97 One recent study showed that the relationship between CBF and
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MAP in healthy volunteers is in fact linear.103 Furthermore, assessment of static
autoregulation in clinical practice is not often practical, given that it usually requires
pharmacologic manipulation of MAP.

Figure 1-2: Classic representation of the cerebral autoregulation. Adapted from
references.97,104–106 In this model, increase in the mean arterial pressure in the
autoregulation zone is counteracted by progressive vasoconstriction and reduction in the
diameter of resistant arterioles. According to this model, impairment in autoregulation
can occur either at the extremes of MAP (black dashed lines), or due to the loss of
vasomotor control in the “plateau” region of this relationship as a result of
pathophysiological state such as ischemia, sepsis or stroke (red dashed line).95
Dynamic autoregulation has evolved as an alternative method of assessing
cerebrovascular autoregulation. Unlike static autoregulation, it assumes that cerebral
autoregulation works as a high-pass filter and assesses the relationship between
continuously measured CBF and MAP in the time or frequency domains (Figure 1-3).107
In the first case, a moving window is used to compute the correlation coefficient between
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continuously measured CBF and MAP in windows where MAP varies by at least 5
mmHg.108 Dynamic autoregulation is said to be impaired if correlation coefficients
exceed a specific threshold (e.g. >0.3 in traumatic brain injury patients, where it is linked
to poor cognitive outcomes)109 or if correlation between CBF and MAP is statistically
significant (e.g. in patient with respiratory failure or shock).110 Utilizing the model shown
in Figure 1-2, loss of autoregulation can occur as a result of extremes of MAP, or due to
loss of the vasomotor control of CBF and autoregulatory “plateau” as a result of
pathophysiologic state (e.g. sepsis).
In the frequency domain methods, a transfer function is used to compute gain, phase and
coherence between continuously monitored CBF and MAP signals.111,112 Increase in gain
and coherence, and decrease in phase between the two signals are often interpreted as an
impairment in dynamic cerebral autoregulation (Figure 1-3).113,114
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Figure 1-3: Two approaches for assessing dynamic autoregulation. Adapted from
references.108,112,115 Both approaches look at continuous cerebral blood flow (CBF) and
mean arterial pressure (MAP) signals using a time-defined window. Panel A - In the
temporal domain, the signals from the moving window are correlated using Pearson or
Spearman correlation if MAP varies by at least 5mmHg.108 If the correlation coefficient is
≤0.3 and/or the correlation is not significant, then autoregulation is assumed to be intact.
On the other hand, if correlation coefficients >0.3 and/or is statistically significant, then
autoregulation is impaired. Panel B – In the frequency domain, transfer function analysis
is used to calculate gain, phase and coherence between two signals. Gain represents the
damping effect of autoregulation on the magnitude of the blood pressure oscillations.
Low gain represents active autoregulation, whereas an increase in gain represents
impaired autoregulation. Phase is considered a surrogate measure for the time delay of
the autoregulation response. Translating phase shift into time domain, phase shift of zero
indicates no time delays between changes in CBF and MAP, and therefore loss of
autoregulation, while positive phase would translate to a delay between CBF and MAP
fluctuations and active autoregulation. Coherence describes whether the relationship
between input and output signals is linear such that coherence approaching unity in a
specific frequency suggests linear relationship, while coherence approaching zero
suggests no relationships between signals. As a result, increase in coherence is interpreted
as loss of autoregulation.
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While both static and dynamic autoregulation have been assessed in critically ill
patients,100,116–119 dynamic methods have gained popularity because they can be estimated
using spontaneous variations of CBF and MAP (i.e. they do not require interventions that
change MAP).120 Furthermore, while many different methods for measuring CBF exist,
computations of dynamic autoregulation at the bedside imposes several practical
constraints in that the methods for monitoring CBF need to be a) non-invasive, b)
portable and applicable at the bedside, and c) have high temporal resolution. As a result,
while tomographic imaging modalities such as computed tomography (CT) and magnetic
resonance imaging (MRI) provide excellent spatial resolution, they are not appropriate
for monitoring dynamic autoregulation at the bedside. Instead, transcranial Doppler
(TCD) and near infrared spectroscopy have emerged as the methods of choice in this
application.116,120 Another option is to utilize ICP monitor, but given that this an invasive
procedure, it is restricted to patients who already require ICP monitor for clinical
indications, such as patients with traumatic brain injury.120
Several studies have assessed dynamic autoregulation and linked it to clinical outcomes
in critically ill patients. In patients with traumatic brain injury, numerous studies have
demonstrated impaired dynamic cerebral autoregulation and its association with worse
neurologic outcomes as measured by the Glasgow outcome scores.121 This relationship
was observed whether time or frequency domain methods of dynamic autoregulation
were used.107 However, in contrast to studies of animal models or healthy subjects where
the timing of critical illness insult is known and controlled, clinical studies enroll patients
within a specific time frame of ICU admission. This confounds interpretation of clinical
findings since the onset of insult is difficult to estimate precisely. As a result, there is
disagreement between study findings that is most evident from studies in sepsis patients.
In sepsis, effectiveness of cerebral autoregulation appears to depend on the time from
sepsis onset and the methods used to assess cerebral autoregulation.122 In one study, static
autoregulation in early sepsis was intact.123 In other studies of experimental sepsis in
healthy volunteers, dynamic autoregulation is actually enhanced in the early stages of
sepsis.124,125 However, other studies showed that patients with sepsis have impaired
dynamic cerebral autoregulation, and this impairment was associated with development
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of delirium.118,126 In patients with respiratory failure or shock, cumulative duration of
impaired autoregulation during the first 72 hours of the ICU admission is associated with
development of delirium.110 While these studies suggest that cerebral autoregulation is an
important measure of vasomotor control of CBF that is linked to important patientcentred outcomes, the variability in results across patient populations suggests that
additional factors that influence vasomotor control of CBF, including CO2, may be
important.

1.3.2.2 Cerebrovascular CO2 reactivity
Another way to interrogate cerebrovascular function is to quantify CBF responsiveness to
a vasodilatory stimulus. CO2 is a potent vasodilator that induces 3-5% change in CBF per
unit change in PaCO2.127 Given that manipulation of CO2 is relatively easy and noninvasive (i.e. does not require intravenous administration of vasodilating substances),
cerebrovascular reactivity to CO2 (CVR) is commonly used clinically to assess the state
of vasomotor control of CBF.97,128
There are several ways to induce changes in CO2 including 1) breath holding, 2)
hyperventilation , 3) inhalation of exogenous CO2, 4) rebreathing, 5) administration of
acetazolamide, and 6) independent control of CO2 and O2 using dynamic end-tidal
forcing or prospective control methods.129 The advantages and disadvantages of different
CO2 stimuli are summarized in Table 1-1. While breath holding, hyperventilation,
rebreathing, acetazolamide administration and inhalation of exogenous CO2 are all simple
ways to induce changes in PaCO2, they have several disadvantages including 1) lack of
precision in the magnitude of CO2 change, which confounds comparison of CBF
response to CO2 between subjects, 2) slow rate of change in PaCO2, which precludes
accurate assessment of the dynamics of CBF response to CO2, and 3) associated change
in arterial partial pressure of O2 (PaO2), which preclude assessment of true CBF response
to CO2 given that increase in PaO2 can induce vasoconstriction independent of the
changes in CO2,130–132 Dynamic end-tidal forcing methods overcomes these limitations
and have been used extensively in the physiology labs to study the independent effects of
O2 and CO2 on CBF.127,133–135 However, high gas flow requirements of these methods
have limited their use outside of physiology labs.
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Table 1-1: Comparison of different CO2 stimuli for measurement of cerebrovascular
reactivity to CO2 (see 129 for more details)
Method
Breath holding

Advantages
Simple to administer (no
additional equipment
required)

Disadvantages
• Small magnitude of change in
PaCO2 as the rate of rise in
PaCO2 is dependent on
metabolic CO2 production and
participant’s ability to hold
their breath.
• Hard to measure actual change
in PaCO2 (need to estimate
from the end-tidal partial
pressure of CO2, PetCO2)
• Slow rate of rise in CO2
prevents assessment of the
dynamics of CBF response to
CO2.

Hyperventilation Simple to administer (no
additional equipment
required)

•

Associated change in arterial
partial pressure of O2 (PaO2),
which can independently
change CBF 130,131,136

Inhalation of
exogenous CO2

•

Unpredictable change in PaCO2
- The actual change in PaCO2
depends on the participant’s
ventilatory sensitivity to CO2 –
i.e. CO2-induced increase in
alveolar ventilation and CO2
elimination can sometimes
negate (or even exceed) the
increase in inspired CO2,
resulting in no change (or
lowering) of PaCO2.132
Slow rate of rise in CO2
prevents assessment of the
dynamics of CBF response to
CO2.
Associated increasePaO2 unable to discern effect of O2
vs CO2 on CBF

Relatively simple to assemble
and administer via face mask

•

•
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Method
Rebreathing

Advantages
Relatively simple to
administer, can be used to
quantify limits of CBF
response to CO2137

Acetazolamide

Relatively simple to
administer

Dynamic endtidal forcing

•
•

Prospective
targeting 138

•
•

•

Disadvantages
• Slow rate of rise in CO2
(depends on subjects metabolic
CO2 production).
• Variable tolerance by subjects
• Variable O2 (unless servocontrolled)
• Unpredictable rise in PaCO2
• Slow rate of rise in CO2
prevents assessment of the
dynamics of CBF response to
CO2.

Precise and independent
changes in PaCO2 / PaO2
Fast changes in PaCO2
allow assessment of
dynamics of CBF
response

•
•
•

Complex and bulky set up
High rate of use of source gases
Limited to physiology research
laboratories

Precise and independent
changes in PaCO2 / PaO2
Fast changes in PaCO2
allow assessment of
dynamics of CBF
response
Mobile – can be used in
MRI / at the bedside

•

Expensive - requires special gas
blender (RespirActTM)

As part of my Master of Science thesis,139 I developed a novel method to prospectively
target and independently control both CO2 and O2 for the purpose of vascular reactivity
studies. Unlike dynamic end-tidal forcing methods that control end-tidal gases,
prospective targeting actually controls PaCO2 and PaO2.140 In addition to enabling precise
and independent control of PaCO2 and PaO2, this approach allows rapid changes in
arterial gases that enabled studies of the dynamics of CBF response to CO2 using step
141,142

or sinusoidal 143 changes in PaCO2. Its relative portability has enabled a range of

vascular reactivity studies using MRI and PET/CT in both the brain,128, spinal cord,144
heart145, liver146 and kidney.147 The precision in the magnitude of the CO2 change with
prospective targeting also enabled assessment of cerebrovascular reserve, identifying
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thresholds for vasoconstriction and vasodilation of cerebral vasculature in response to
CO2.148
Impairments in CVR have been associated with the increased risk of stroke,149 cognitive
impairment150,151, cortical thinning.152, and leukoaraiosis.153 In concussion, CVR helps
differentiate between concussed and normal patients despite similar anatomic and global
resting CBF measurements in both groups.154,155 In critically ill patients, impaired CVR
has been reported in patients with TBI,156–158 sepsis,159 and subarachnoid hemorrhage.160
The relationship between cerebral autoregulation and CVR is not fully understood. While
both methods likely examine different physiologic control mechanisms (blood pressure
regulation vs. CO2 regulation), there is likely an interplay between the two, especially
given that changes in CO2 also induce changes in MAP161 that can have an independent
effect on CBF and modulate cerebral autoregulation.117 As a result, there is a call for an
integrative approach to assessment of cerebrovascular function at the bedside.97
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1.4 Neuroimaging and neuromonitoring methods
A number of different neuroimaging and neuromonitoring methods have been used to
assess brain structure and function in critically ill patients. These can be broadly
classified into:
1) Invasive bedside techniques – these include measurements with sensors inserted
into brain parenchyma, brain ventricles, or those that require exposure of brain
tissue; these methods include intracranial pressure monitoring (ICP), brain tissue
oxygen monitoring, laser Doppler flowmetry, and thermal diffusion, and are more
commonly used in the patients with traumatic brain injury that otherwise require
invasive procedures;
2) Non-invasive bedside monitors – these include transcranial Doppler (TCD) and
near infrared spectroscopy (NIRS). TCD monitors cerebral blood flow velocity in
large intracranial vessels, while NIRS monitors regional brain tissue oxygenation.
Both monitors have high temporal resolution, which enables calculation of
dynamic cerebral autoregulation indices when their outputs are analyzed against
changes in MAP.120
3) Tomographic imaging methods – these include CT, MRI and positron emission
tomography (PET). All three methods have the advantage of high spatial
resolution for assessment of brain structure, CBF and function, but are at present
not suitable for bedside monitoring due to their size, limited temporal resolution
and radiation exposure.162
The benefits and disadvantages of each methods for assessment and monitoring of
critically ill patients are summarized in Table 1.2.
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Table 1-2: Summary of neuroimaging and neuromonitoring methods
Modality
ICP
monitor

Brain tissue
oxygen
monitoring

Laser
Doppler
flowmetry
TCD

Advantages
Portable, high
temporal resolution,
enables computation
of dynamic
autoregulation index
PRx
Direct measure of
cerebral metabolism
and oxygenation,
although based on
numerous
assumptions
Direct non-invasive
measure of perfusion

Disadvantages
Invasive, parenchymal
monitors may not reflect
global ICP

Use in critical care
Traumatic brain
injury

Poor spatial resolution,
unclear relation to
outcomes

Traumatic brain
injury

Requires tissue exposure,
so is invasive

Experimental use
only

Portable, high
temporal resolution,
non-invasive, enables
computation of
dynamic
autoregulation indices
Mx or Mxa

Operator dependent, only
measures CBFv in large
intracranial vessels,
indirect measure of CBF

NIRS

Portable, high
temporal resolution,
non-invasive, enables
computation of
dynamic
autoregulation index
COx

CT

High spatial
resolution,
assessment of
regional CBF and
perfusion (with
contrast)

Traumatic brain
injury,
subarachnoid
hemorrhage,
hypoxic ischemic
brain injury, sepsis,
brain death
assessment
Limited skull penetration, Traumatic brain
artifacts due to
injury,
contamination from scalp subarachnoid
perfusion, regional
hemorrhage,
monitoring of small
hypoxic ischemic
portion of cerebral cortex, brain injury, sepsis,
limited spatial resolution, respiratory failure
indirect measure of
and shock
perfusion
Not portable, radiation,
Most critically ill
limited temporal
patients that are
resolution (not suitable
stable, based on
for continuous
availability of
monitoring)
imaging modality
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Modality
MRI

PET

Advantages
High spatial
resolution, detailed
examination of brain
structure including
white matter tracts,
assessment of
regional CBF,
functional studies

Disadvantages
Not portable, limited
access in some hospitals,
expensive, limited
temporal resolution

Use in critical care
Most critically ill
patients that are
stable, based on
availability of
imaging modality

Good spatial
Expensive, limited
Most critically ill
resolution, detailed
access, radiation
patients that are
examination of CBF,
stable, based on
brain metabolism and
availability of
function including
imaging modality
inflammation
ICP = Intracranial pressure, PRx = index of dynamic autoregulation computed from
correlation between ICP and cerebral perfusion pressure, TCD = transcranial Doppler,
CBFv = cerebral blood flow velocity, Mx abd Mxa = indices of dynamic autoregulation
computed from correlation between CBFv and cerebral perfusion pressure (Mx) or mean
arterial pressure (Mxa), CT = computed tomography, MRI = magnetic resonance
imaging, PET = positron emission tomography.
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1.5 Neuroimaging studies in ICU patients
Delirium and cognitive impairment in ICU patients represent impairments in brain
function. Several prior studies have examined whether these functional changes are
associated with changes in brain structure. In this section we will review the prevalence
and patterns of structural brain lesions across different ICU patient populations from
previous studies. We will then review the links between these structural lesions, clinical
factors and clinical outcomes.

1.5.1 Prevalence of structural lesions in ICU patients
Neuroimaging studies in ICU patients have identified a various types of brain lesions that
have been associated with clinical factors and clinical outcomes. Among critically ill
patients, common abnormalities on CT and MRI include atrophy, white matter
hyperintensities (WMHs), hemorrhage, infracts and encephalomalacia. The prevalence of
these lesions from different ICU populations is summarized in Table 1-3.
Table 1-3: Prevalence of structural changes on CT/MRI Imaging in ICU patients1

Population

Number
of patients

Normal Atrophy

WMH

Infarcts or
Encephalomalacia

Hemorrhage

Mixed

210

11-36%

41%

30-71%

6-40%

7-11%

Sepsis

88

22-88%

-

21-56%

13-30%

-

ARDS

15

47%

47%

7%

7%

7%

Delirium

8

13%

13%

75%

-

-

ARDS = Acute Respiratory Distress Syndrome, WMH = White Matter Hyperintensity

1

Data was extracted from the following studies 51,163–169
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While many patients have normal structural scans, there is a high prevalence of
generalized atrophy and white matter hyperintensities (WMH) across all populations. The
difference in the prevalence of white matter lesions between populations may suggest
alternative pathophysiologic processes, but it also may be due to difference in imaging
modalities. For example, WMH were detected in 7% of patients with CT in ARDS
patients 163 versus in 75% of delirious patients using MRI.164. More precise quantitative
MRI techniques, such as Diffusion Tensor Imaging, have been used to demonstrate worse
white matter integrity as measured by the fractional anisotropy in patients with
delirium.164 Such techniques may identify pre-clinical injury patterns that may not be
apparent on regular CT or MRI scans.

1.5.2 Patterns of brain lesions in ICU patients
Brain atrophy affects both grey and white matter, as well as distinct brain structures
responsible for specific cognitive functions. Diffuse atrophy, as indicated by higher CT
ventricular volumes and ventricular to brain ratios compared to age and sex matched
healthy controls, was observed in ARDS patients.163 Similar changes were seen in
patients with shock and respiratory failure.170 Compared to healthy controls, ICU
survivors have smaller white matter and hippocampal volumes at 6-24 months following
ICU discharge,171 and left hippocampal atrophy was also shown in sepsis survivors.52
These abnormalities are supported by autopsy findings from patients with ARDS and
sepsis that show ischemic hypoxic injury in hippocampus, pons and striatum.172.
WMH lesions have been demonstrated in multiple locations including periventricular
white matter and centrum semiovale.51 The prevalence of these lesions varies, with the
highest seen in frontal (80%) and parietal (48%) lobes, followed by occipital (19%) and
temporal lobes (14%) as well as brainstem (15%) and cerebellum (5.8%).169 In patients
with septic encephalopathy, hyperintense lesions also localize to frontal and
periventricular brain regions.166 Imaging with quantitative MRI in patients with
respiratory failure or shock revealed abnormalities in white matter integrity in the genu of
corpus callosum and anterior limb of internal capsule at hospital discharge and at 3
months.173
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1.5.3 Associations between structural lesions and clinical factors
In the general ICU population, brain atrophy does not appear to be associated with any of
the clinical factors including age, admission diagnosis, presence of co-morbid medical
conditions, including psychiatric conditions or a history of substance abuse, hospital or
ICU length of stay, duration of mechanical ventilation, severity of illness scores (e.g.
APACHE II), or hypoxemia.51 Similarly, in ICU survivors at 6-24 months post discharge,
clinical factors including severity of illness, duration of stay and duration of mechanical
ventilation were not associated with general atrophy or smaller hippocampal volumes.171
This was also true in the ARDS cohort, where there was no correlations between
ventricle-to-brain ratio or ventricular volumes and clinical variables including ICU and
hospital lengths of stay, duration of mechanical ventilation, APACHE II scores, and
duration and severity of hypoxemia.163
In contrast, hospitalizations for critical illness or major surgical procedures were
associated with increased atrophy as measured by increased ventricular size in a large
population study that included MR imaging from 885 patients.174 In another study,
duration of delirium was associated with higher ventricle-to-brain ratios at hospital
discharge and 3 months, as well as smaller volumes of frontal lobe and hippocampus,
after adjusting for age, severity of illness, and sepsis.170 Autopsy findings suggest that
duration of hypotension may be a risk factor for development of hippocampal lesions in
patients with sepsis and ARDS who develop delirium during their ICU stay.172
White matter hyperintensities are associated with older age, higher severity of illness (as
measured by the Simplified Acute Physiology Score II), prior stroke and smoking in ICU
patients who had MRI imaging done for acute change in neurologic status.169 In patients
with delirium, the severity of these lesions correlates with older age.164 In septic shock
patients, the severity of WMH correlates with the duration of septic shock,167 but not
shock severity or other biologic markers of inflammation or endothelial activation.165
Finally, quantitative MRI methods demonstrate that longer duration of delirium is
associated with worse white matter integrity as measured by fractional anisotropy with
diffusion tensor imaging MRI in patients with respiratory failure and shock.173 However,
delirium duration was not associated with any patterns of activation in a functional MRI
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study that assessed 47 patients with respiratory failure or shock at discharge and at 3
months.175
In ICU patients who develop acute neurocognitive impairment requiring MRI, new
cerebral infarcts are associated with cardiovascular surgery,169 or cardioembolic and
thromboembolic factors.169 In another study, ischemic stroke was independently
associated with disseminated intravascular coagulation and focal neurologic signs, but
not with the severity of hypotension.165
In summary, duration of delirium and hypotension are the only consistent factors that
appears to be associated with brain atrophy. Similarly, longer duration of delirium and
septic shock are associated with worse white matter integrity. These observations suggest
that delirium likely represents a clinical manifestation of subcortical white matter injury
and, given lack of association between inflammation and white matter injury, support the
perfusion hypothesis. Some support for this is gained from neuroimaging studies
employing xenon-enhanced CT that showed > 40% reduction in overall cerebral blood
flow in delirious patients, with greater reduction occurring in subcortical and occipital
regions.176 In another study employing single-photon emission computed tomography,
reduction in regional cerebral blood flow was seen in the frontal and parietal regions of
delirious geriatric patients.177 Impairment in cerebral blood flow can result in reduction of
oxygen delivery to metabolically active brain tissue resulting in ischemia. Indeed, recent
prospective studies showed that low brain tissue oxygenation as measured by cerebral
oximetry was an independent predictor of delirium in the critically ill178 and septic
shock179 patients. Furthermore, impairment of cerebral autoregulation within 72 hours of
ICU admission is also associated with development of delirium,110 suggesting that
dysregulation of adaptive mechanisms such is autoregulation may play a role in delirium
pathogenesis.
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1.5.4 Associations between structural brain lesions and clinical
outcomes
In a large population study, brain atrophy was associated with hospitalization and worse
executive function.174 Atrophy was worse with increasing number of hospitalizations,
hospitalisation for major surgery, and hospitalization for critical illness. The decline in
executive function was worse with increasing number of hospitalizations and
hospitalization for critical illness, although large proportion of observed changes in
executive function occurred independent of observed structural changes.174 In sepsis
survivors, greater loss of left hippocampal volume was associated with impairment in
verbal learning and memory.52 In patients with delirium, generalized brain atrophy and
smaller volumes of superior frontal lobe and hippocampus were associated with worse
global cognitive scores and worse executive function at 12 months.170 In contrast, in
ARDS patients, brain atrophy or ventricular enlargement did not correlate with
neurocognitive scores.163
The degree of white matter hyperintensity appear to correlate with septic shock duration
and functional outcomes as measured by the Glasgow Outcome Scale.167 In patients with
delirium, WMH on MRI were associated with impairments in memory, executive
function, and attention at three months, despite the absence of baseline cognitive
impairment.164 Similarly, pre-clinical impairment of white matter integrity in the corpus
callosum and anterior limb of internal capsule at hospital discharge and 3 months is
associated with worse cognitive scores at 3 and 12 months.173
Among ICU patients with new ischemic lesions on MRI, only 32% (19/59) had clinical
evidence of focal neurologic deficits, suggesting that non-focal ischemia is a common
etiology for acute neurologic status change in the ICU.169 In another study, ischemic
stroke was independently associated with increased mortality and worse functional
outcomes at 6 months as measured by the Glasgow Outcome Scale.165
Functional MRI activation patterns at 3 months following discharge in patients with
respiratory failure and shock were not associated with cognitive outcomes at 12 months
as measured by the Repeatable Battery for the Assessment of Neuropsychological Status
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(RBANS) cognitive battery and Trails B test.175 Interestingly, most patients had difficulty
completing the N-back task as part of their functional MRI paradigm, which reflect poor
working memory ability in this patient cohort. In fact, these patients had worse
performance on the N-back task than other medical populations who suffer from frontal
lobe deficits including patents with multiple sclerosis, Parkinson’s disease, traumatic
brain injury and mild cognitive impairment. Given that RBANS does not include any
direct or indirect measures of working memory, failure to detect association between
brain activation patterns and cognitive outcomes may be due to the limitations of the
cognitive outcomes measure used in this study.
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1.6 Study Aims, Objectives and Hypotheses
Survival with preserved cognitive function is an important outcome of critical illness for
both patients and clinicians. Prior studies have documented high prevalence of delirium
and cognitive impairment in ICU patients that are associated with impairment in dynamic
autoregulation and high prevalence of ischemic lesions on neuroimaging. However, the
proportion of time that critically ill patients experience ischemia or hyperemia earlier in
the course of critical illness is not well established. Furthermore, whether these periods of
perturbation in CBF are associated with impairment in dynamic autoregulation or
spontaneous fluctuations in MAP or CO2 is unknown.
Prior studies have also documented impaired cerebrovascular function during critical
illness. However, it is not clear whether this impairment develops prior to or during
critical illness. Given that certain patient groups are at higher risk of critical illness, it is
important to establish whether they have pre-ICU impairment in cerebrovascular
function. This would be important for interpreting the effects of ICU exposures (such as
ischemia and hyperemia) and therapeutic interventions on post-ICU cognitive outcomes
in these patients, and for patient stratification in future observational and interventional
trials.
Finally, prior studies have used a number of methods to detect cognitive impairment in
ICU patients. However, some of these methods are too simple and unable to detect multidomain cognitive impairment that is common in ICU patients, while other more
comprehensive methods are too cumbersome and impractical for routine use in clinical
practice and are therefore limited to research studies. There is a pressing need to establish
a practical and comprehensive method for assessing neurocognitive outcomes in ICU
patients. Such method would be critical in linking ICU exposures (such as ischemia and
hyperemia) and pre-ICU functional risk factors (such as impairment in cerebrovascular
function) with neurocognitive outcomes.
The overall aim of this work is to: 1) document the cumulative burden of ischemia and
hyperemia during early phases of critical illness, and assess its association with impaired
dynamic autoregulation and perturbations in MAP and CO2, 2) to identify whether
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patients at higher risk of critical illness have pre-ICU impairment in cerebrovascular
function, and 3) to develop a clinically feasible yet comprehensive method for assessing
neurocognitive outcomes in ICU patients. To achieve this, we have identified three
specific aims and corresponding objectives and hypotheses.

Specific Aim 1 (SA1): To determine the proportion of time that cerebral blood flow
velocity (CBFv) deviates spontaneously beyond previously reported ischemic or
hyperemic thresholds in critically ill patients with respiratory failure and/or shock within
48 hours of ICU admission, and to establish whether these deviations are associated with
impairment in dynamic autoregulation and changes in MAP or CO2. Rationale: Ischemia
has evolved as a plausible mechanism for delirium and long-term cognitive impairment in
critically ill patients owning to high prevalence of ischemic injury on neuroimaging and
histopathology. In prior studies of cardiac surgery patients, the cumulative duration of
CBF deviations beyond ischemic thresholds was associated with major clinical
complications including stroke and delirium180 and development of new ischemic lesions
on neuroimaging.181 If similar CBFv deviations occur in critically ill patients with
respiratory failure or shock, it may constitute an important ischemic insult, especially if
accumulated over time in the ICU. Since hemodynamic instability (and associated
perturbations in CBFv) are more likely to occur in the earlier stages of critical illness, we
restricted our observation period to the first 48 hours from ICU admission. Given that
dynamic cerebral autoregulation is commonly impaired in critical illness and that this
impairment is associated with poor clinical outcomes, we assessed whether spontaneous
CBFv deviations were more likely during periods of impaired dynamic cerebral
autoregulation. Finally, since CBF is sensitive to changes in CO2 and MAP and, given
that both of these variables can be controlled and optimized in the ICU as potential
therapeutic targets, we assessed the relative contribution of concurrently measured
spontaneous changes in MAP and CO2 to observed CBFv deviations. Objectives: 1) to
determine the proportion of time that CBFv deviates spontaneously beyond previously
reported ischemic and hyperemic thresholds in critically ill patients with respiratory
failure and/or shock within 48 hours of ICU admission, 2) to assess whether these CBFv
deviations are more common during periods of impaired clinical index of dynamic
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cerebral autoregulation, and 3) to assess the relative contribution of changes in MAP and
CO2 to observed CBFv deviations. Hypotheses: 1) CBFv deviates beyond
ischemic/hyperemic thresholds for a substantial proportion of the observation period, 2)
CBFv deviations will be more common during periods of impaired dynamic cerebral
autoregulation, and 3) spontaneous changes in MAP and CO2 explain over 50% of the
observed CBFv deviations.
Specific Aim 2 (SA2): To assess whether patients with a high risk of critical illness have
impaired baseline cerebrovascular function prior to ICU admission. Rationale: While
previously healthy individuals can develop sudden critical illness (e.g. due to trauma or
infection), the majority of critically ill patients have pre-existing chronic comorbidities
that are rarely accounted for in critical care research.182 Incorporating the pre-ICU
assessment of baseline cerebrovascular function is essential for interpreting the effects of
ICU exposures and interventions, such as those assessed by SA1, on patients outcomes.
Given that hemodialysis (HD) patients are at higher risk of developing critical illness
compared to the general population, they represent a well-defined clinical population that
is at risk for experiencing ischemic insults (such as those studied in SA1) and associated
cognitive impairment during critical illness. Whether HD patients have a pre-ICU
impairment in cerebrovascular function that can make them vulnerable to ischemic
insults during critical illness is unknown. We assessed CVR as a marker of
cerebrovascular function in HD patients, and compared it to that in healthy individuals
and patients with chronic kidney disease (CKD) who are not yet receiving dialysis. Given
that CVR has emerged as an early functional marker of brain tissue at risk for subsequent
injury,183 and since impaired CVR is associated with increased risk of stroke149 and
cognitive impairment,150,151 establishing whether HD patients have pre-ICU impairment
in CVR would be important for interpreting the effects of ICU exposures and
interventions on neurocognitive outcomes in this patient population. Objectives: 1) To
assess cerebrovascular function using CVR in HD patients, and compare it to CVR in
patients with Stage 4 or 5 CKD (i.e. not requiring dialysis) and healthy participants.
Hypothesis: HD patients will have impaired CVR compared to CKD patients and healthy
participants.
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Specific Aim 3 (SA3): To establish a clinically feasible and accurate method for
assessing neurocognitive outcomes in ICU patients. Rationale: Survival with preserved
cognitive function is consistently ranked at the top of clinical outcomes hierarchy by both
patients and clinicians.182,184,185 In order to assess the impact of CBFv deviations
(Specific Aim 1) and impaired CVR (Specific Aim 2) on cognitive outcomes in ICU
patients, we require a clinically feasible method for assessing cognition across multiple
cognitive domains. However, current cognitive instruments that have been used in prior
ICU studies are not optimized for the use in critically ill patients. They include single
cognitive tests or simple screening dementia tools that are inadequate for detection of
multi-domain cognitive impairment seen in ICU patients.37 Comprehensive cognitive
batteries are not practical for routine clinical use as the need specially trained individuals
to administer, require patients to come into clinic, and take long time to complete.37
Modern web-based cognitive batteries represent an attractive alternative that combine
ease of administration and scoring with comprehensiveness. However, whether these
web-based cognitive batteries are feasible for use in ICU patients and can detect
cognitive impairment across multiple cognitive domains is unknown. Given that webbased batteries require patient participation and ability to use computers or tablets, and
since many ICU patients may have cognitive or physical limitation at the time of ICU
discharge, we anticipate that some patients will have difficulty completing web-based
cognitive testing. It is therefore important to establish the feasibility of using web-based
cognitive battery in ICU patients prior to applying it as an outcome measure in future
studies. By establishing the clinical feasibility and accuracy of web-based cognitive
batteries, we will provide a robust method for assessing this important patient-centered
outcome. This method can be utilized in future research studies that assess preventative,
therapeutic and rehabilitative interventions, as well as for delivering prognosis to patients
and families, and assisting with the healthcare utilization planning. Objective: 1) To
assess the clinical feasibility and ability of web-based cognitive battery Cambridge Brain
Sciences to detect cognitive impairment in ICU patients at or following ICU discharge.
Hypotheses: 1) We will identify feasibility issues with using Cambridge Brain Sciences
for cognitive testing in ICU patients, and 2) Cambridge Brain Sciences battery will detect
multi-domain cognitive impairment in ICU patients at or following ICU discharge.
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1.7 Research Approach
1.7.1 Challenges of clinical research
Clinical research is challenging and designing a perfect experiment is difficult due to a
number of conceptual and practical limitations. These challenges are even more acute in
the ICU, where research protocols must be balanced against the severity and dynamics of
evolving critical illness, ongoing active clinical interventions, and the constraints of
available measurement tools and associated analytical methods. In contrast to basic
science experiments and healthy volunteer laboratory studies, where multiple variables
can be controlled and accounted for, clinical research in ICU settings requires
acknowledgement and embracement of potential clinical biases, confounders and
limitations of measurement tools and methods. While basic science and healthy volunteer
experiments can be designed to study and dissect specific physiologic and
pathophysiologic mechanisms, this is rarely possible in ICU patients, especially in the
acute phases of evolving critical illness. Some of the reasons for this include:
1. Heterogeneity of patients – excluding few specific cases, the majority of
critically ill patients are a heterogenous group that varies in age, pre-morbid
health and physiologic reserve. As a result, their responses to the stress of critical
illness differ and are difficult to control for even in large scale randomized
controlled studies.
2. Critical illness syndromes – unlike other clinical specialties that manage defined
diseases with well-established pathophysiologic mechanisms, ICU care,
especially in the early stages of patient presentation, primary deals with clinical
syndromes (i.e. a collection of symptoms and signs rather than a clearly defined
pathophysiologic state). The same syndrome (e.g. acute respiratory distress
syndrome) can result from different underlying pathophysiologic processes (e.g.
pancreatitis versus viral pneumonia), but these differences are often not apparent
in the early stages of critical illness. As a result, while both groups of patients
present with acute respiratory failure and are often lumped together in clinical
ICU studies, their underlying mechanisms of lung injury can be different and may
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not be amenable to the same therapeutic interventions. However, the challenge
here is in balancing the careful scientific dissection of individual pathophysiologic
mechanisms previously identified in basic science or healthy volunteers against
the pragmatic need to identify viable clinical therapeutic targets.
3. Variable time from illness onset to ICU admission – unlike experimental
models of critical illness, where onset of illness and subsequent measurements
and interventions can be carefully timed, critically ill patients tend to present at
various time points in the trajectory of their evolving illness. While most clinical
studies use ICU admission as time zero, few of these acknowledge that the true
time zero varies between patients and is often imprecise (estimated from clinical
history). Given that temporal evolution of illness can affect physiologic
measurements and response to interventions, this is a major limitation of most
clinical studies in this arena.
4. Practical limitations of available instruments – Basic science laboratory studies
benefit from the ability to use precise and often quite invasive instruments to
obtain very accurate measurements under carefully controlled experimental
conditions. Similarly, research in healthy volunteers or ambulatory patients allows
the use of comprehensive research tools (e.g. MRI or PET) that are not practically
available at the bedside in the ICU during acute phases of critical illness.
Critically ill patients are often too unstable for transport to research scanners in
the early phases of critical illness, while use of more precise invasive tools is
limited due to increased risk to the patient and need for consent from already
distressed substitute decision makers. As a result, acute phase studies need to
compromise practicality of available tools against their many limitations and
imprecisions.
5. Practical limitations of available analysis methods – control of cerebral blood
flow is a complex process that involves multiple mechanisms. Studies in basic
science laboratories or in heathy volunteers enable simultaneous collection of
multiple data points that track these various mechanisms, followed by integration
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of these data to obtain comprehensive understanding of the relative contribution
of these mechanisms to observed measurements. While a similar approach is
much needed in the ICU, it remains practically challenging due to limitations of
available equipment, space, and the urgent need for ongoing patient resuscitation
and treatment. As a result, most clinical studies of the physiology in critically ill
patients are limited by the lack of such comprehensive data and have to
acknowledge that their inferences about the truth are limited and incomplete.
This, however, does not preclude interpretation of available data and its use in
clinical practice, especially if observed physiologic findings are linked to
important clinical outcomes (e.g. impairment in dynamic autoregulation indices
with delirium or neurocognitive outcomes).110,116,118,122,186

1.7.2 Choice of instruments and analysis methods
To address some of the clinical research challenges outlined in the previous section, we
had to compromise between comprehensiveness, accuracy and practicality when selecting
instruments and analysis methods for this work. The following section summarizes some
of these compromises and provides the rationale for our choices. Ultimately, the
instruments and analysis methods were selected based on their utility for use in clinical
settings and prior validation against patient-centered outcomes.
Transcranial Doppler for monitoring CBF – to address our Specific Aims 1 and 2, we
chose to use transcranial Doppler to measure CBFv as an index of global CBF.
Transcranial Doppler is frequently used in both clinical and research studies in critically
ill patients for this purpose. In terms of advantages, it offers high temporal resolution that
allows beat by beat measurement of CBFv in large intracranial vessels. The high
temporal resolution enables correlation with the concurrently measured MAP for
calculation of dynamic index of cerebral autoregulation Mxa. The main disadvantages of
transcranial Doppler include poor spatial resolution (i.e. measurement of blood flow
velocity in one of the major intracranial vessels at any given time), its operator
dependence, and the dependence of the measured absolute velocity on the angle of
insonation. However, while tomographic modalities such as CT and MRI provide better
spatial resolution, they are not feasible for continuous monitoring of cerebral blood flow
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over hours since they are too bulky to employ at the bedside in the ICU and patients are
too sick to be transported safely from the ICU to the imaging department. Challenges
with operator dependence and angle of insonation can be mitigated by using experienced
operators and expressing CBFv as the percent change from patient’s own baseline to
facilitate between patient comparisons. Unlike CT or MRI, transcranial Doppler only
measures CBFv and not bulk flow. Assessment of cerebral blood flow requires
simultaneous measurement of the vessel diameter. As a result, changes in cerebral blood
flow velocity are only proportional to changes in cerebral blood flow as long as the vessel
diameter stays constant, which is not the case under some circumstances such as
hypercapnia, where CBFv underestimates changes in CBF by about 8%.187 Using CBFv
to measure CVR may therefore result in underestimated CVR values. However, this does
not preclude comparison of relative differences in CVR between participant groups as
long as the same CBFv method and magnitude of change in CO2 is used in all groups.
Mxa as an index of dynamic cerebral autoregulation – To address part of Specific
Aim 1, we chose to use Mxa as an index of dynamic cerebral autoregulation. This index
is calculated from continuous measurements of CBFv and MAP. In this method, a
moving window advanced in 1-minute steps is used to compute correlation coefficient
between continuously measured CBFv and MAP. In previous studies, the width of the
moving window varied from 5 to 60 minutes.110,119,188 Dynamic autoregulation is said to
be impaired if correlation coefficients exceed a specific threshold (e.g. >0.3 in traumatic
brain injury patients)109 or if correlation between CBF and MAP is statistically significant
(e.g. in patient with respiratory failure or shock).110 One of the theoretical concerns with
this method is that it assumes that within any given window there is enough variation in
MAP to enable correlation of MAP versus CBFv. As a result, if there is no variation in
MAP, then correlation between MAP and CBFv (and hence Mx) cannot be done. While
this is a valid concern, setting MAP window length to at least 5 minutes or more,
advancing the moving window in 1-minute steps and recording the data over several
hours would minimize the potential for windows with no variation in MAP. Additionally,
only calculating Mx in windows where MAP varies by at least 5 mmHg is an accepted
way to mitigate this issue108 and this method was employed in our analysis. Despite these
theoretical limitations, Mxa (and a similar index, COx, derived using near infrared
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spectroscopy) has been validated in many clinical studies of critically ill patients with
various pathologies and has become an established clinical marker of impaired
autoregulation in critical care. Impaired Mxa (or its equivalent, COx), have been
associated with delirium and poor neurologic outcomes in patients with respiratory
failure, shock, sepsis and traumatic brain injury.110,116,186 As a result, existing validation
of Mxa against poor clinical outcomes warrants its use as a marker of dynamic
autoregulation despite its potential technical limitations.
CVR as an index of vasomotor control of cerebral blood flow- To address Specific
Aim 2, we chose to use CVR as an index of cerebrovascular function. The role of
cerebrovascular function in the control of CBF is complex and involves multiple
mechanisms including cerebral autoregulation, neurovascular coupling, CVR and
autonomic activity.87,88 While there are differences between these individual mechanisms,
they all exert their effect on CBF through changes in cerebrovascular resistance by
changing the diameter of resistant arterioles. While the relative contribution of each of
these mechanisms to maintaining brain health is unclear, impairment in cerebral
autoregulation and CVR are both associated with worse neurological outcomes and
disease states. In clinical settings, assessment of cerebral autoregulation is often done
using either controlled manipulation of MAP using pharmacologic agents (i.e. static
autoregulation), or by monitoring CBF response during spontaneous fluctuations in MAP
(i.e. dynamic autoregulation). Pharmacologic manipulation of MAP provides a controlled
assessment of CBF response across a range of MAP but is invasive and cumbersome.
Dynamic autoregulation is non-invasive but has a limited range of MAP across which
CBF response is assessed. In contrast, CVR can assess CBF response across a range of
CO2 values and is relatively non-invasive. The use of prospective targeting and dynamic
end-tidal forcing methods allows precise and reproducible manipulation of CO2, which
enables between participant comparison of global and regional CVR. In the last decade,
prospective targeting method has enabled a series of studies in healthy participants and
patient cohorts using a wide range of instruments for CBF measurements. These studies
have clearly linked impairment in CVR with increased risk of stroke,149 cognitive
impairment150,151, cortical thinning.152, and leukoaraiosis.153 In concussion, CVR helps
differentiate between concussed and normal patients despite similar anatomic and global
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resting CBF measurements in both groups.154,155 In critically ill patients, impaired CVR
has been reported in patients with TBI,156–158 sepsis,159 and SAH.160 As a result, CVR has
emerged as a reliable and reproducible non-invasive clinical marker of brain health and
vasomotor control of CBF, and was therefore chosen in this study as a method to assess
vasomotor control of CBF in HD patients.
Finapres for monitoring arterial blood pressure for SA2 – We used Finapres NOVA
(Finapres, Finapres Medical Systems, Netherlands) to measure hemodynamic parameters
including arterial blood pressure non-invasively. While intra-arterial blood pressure
monitoring is the gold standard for continuous blood pressure measurements, it is
invasive and is associated with complications including hematomas, ischemic necrosis
and infections.189–191 Furthermore, placement of arterial cannulas in HD patients is
technically challenging due to widespread vascular diseases and should be restricted to
ICU settings to preserve vascular access. Given that our study was carried out in the
laboratory settings on ambulatory HD and CKD patients, as well as healthy volunteers,
we elected to use Finapres as the available non-invasive modality. Non-invasive methods
such as Finapres are validated in critical care192,193 and hemodialysis194,195 settings, and
used it prior CVR studies.196–198 While its accuracy and precision are not interchangeable
with direct intra-arterial measurements,199,200 it has become an accepted non-invasive
alternative in physiological and clinical studies.200–204
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Chapter 2
2

Spontaneous Cerebral Blood Flow Deviations in
Critically Ill Patients: Potential Insult Contributing to
Ischemic and Hyperemic Injury.

Delirium and long-term cognitive impairment are a common complication of critical
illness. Cerebral blood flow (CBF) mediated brain injury (i.e. ischemia and hyperemia)
have evolved as plausible biologic mechanisms responsible for these neurocognitive
impairments given high prevalence of ischemic injury on neuroimaging and
histopathology. While dysfunction in cerebral autoregulation, commonly reported in the
critically ill, would make these patients vulnerable to ischemia and hyperemia, the
proportion of time that CBF deviates beyond ischemic and hyperemic thresholds during
early stages of critical illness is not been well established. Furthermore, whether these
deviations are more likely during periods of impaired dynamic cerebral autoregulation is
unknown. Finally, since CBF is sensitive to changes in CO2 and MAP and, given that
both of these variables can be controlled and optimized in the ICU as potential
therapeutic targets, we assessed the relative contribution of changes in MAP and CO2 to
observed CBFv deviations. In this study, we document the proportion of time that CBF
velocity (CBFv) deviates above and below predetermined thresholds in 12 critically ill
patients with respiratory failure or shock within 48 hours of ICU admission. We also
examined whether these CBFv deviations were more likely during periods of disturbed
dynamic autoregulation as measured by clinically validated index Mxa, and assessed the
relative contribution of concurrently measured spontaneous changes in MAP and CO2 on
the observed CBFv deviations. We demonstrated that CBFv deviates from its baseline by
more than 20-30% for 17-24% of the observation time. These CBFv deviations occurred
during periods of both preserved and impaired autoregulation, which was impaired 2035% of the observation time in our cohort, and were not fully explained by associated
spontaneous variations in MAP and CO2. Future work should utilize multimodal
monitoring to better delineate mechanisms responsible for observed deviations in CBFv,
and to assess whether the cumulative burden of these deviations is associate with
clinically relevant outcomes, such as cognitive impairment.
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2.1 Introduction
Critically ill patients have a high prevalence of acute (delirium)1 and long-term cognitive
impairment.2,3 Ischemic and hyperemic injury have both emerged as plausible biologic
mechanisms due to common finding of ischemic lesions on neuroimaging4,5 and
histopathology,6,7 disturbed autoregulation8–11 and circulatory stress12,13 in this patient
population. While spontaneous variation in CBF are common in both healthy adults 14,15
and patients with primary brain pathology 16,17, the proportion of time that CBF deviated
beyond ischemic and hyperemic thresholds in critically ill patients without brain injury
has not been well described.
In a setting of critical illness, failure of protective mechanisms such as cerebral
autoregulation8–11 and brain blood brain barrier18 can make the brain vulnerable to injury
during perturbations in CBF that exceed ischemic or hyperemic thresholds. While such
thresholds have not been explicitly defined in non-brain injured critically ill patients,
prior studies in cardiac surgery patients have shown that the duration of cerebral
oxygenation deviation below 10% from baseline was associated with development of
new ischemic lesions.19 Baseline CBF in healthy humans is higher in grey (~50-55
ml/100g/min) than in white (~20-25 ml/100g/min) matter,20 as are thresholds for cerebral
infarction in patients with stroke.21. As a result, while 10-20% deviation in CBF from
baseline may not induce overt ischemia in the grey matter, it may exceed ischemic
thresholds (17-18 ml/100g/min) in the white matter22,23 and result in functional
impairment or injury, especially if accumulated over time.24 Such mechanism would
explain the high prevalence of white matter abnormalities in the critically ill.5,25
In this study, we aimed to determine the proportion of time that CBFv deviated beyond
previously reported ischemic and hyperemic thresholds in a cohort of critically ill patients
without brain injury early in the course of their critical illness. In secondary analysis, we
assessed whether these deviations in CBFv were more common during periods of
impaired dynamic autoregulation. Finally, we used regression analysis to determine the
relative contribution of variations in MAP and end-tidal partial pressure of CO2 (PetCO2)
to these deviations in CBF.
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2.2 Materials and Methods
Study design and Participants
This was a single-centre prospective observational cohort study that was approved by
Western University Health Sciences Research Ethics Board (protocol number 106955)
and carried out at the Critical Care Trauma Centre, London Health Sciences Centre. We
enrolled consecutive adult (age ≥ 18 years) patients within 48 hours of admission to the
ICU who presented with a diagnosis of respiratory failure requiring mechanical
ventilation > 24 hours and/or shock (defined as the requirement for vasopressors). All
participants had an indwelling arterial catheter for continuous monitoring of arterial
blood pressure. We excluded patients presenting with primary neurologic diagnosis or
known cerebrovascular diseases. Signed informed consent was obtained from patient’s
substitute decision maker prior to enrollment in the study. The measurements were made
on the day of enrollment into the study.
Cerebral blood flow velocity monitoring
We used transcranial Doppler to measures middle cerebral artery blood flow velocity
(CBFv) as an indicator of global CBF. We used 2-MHz transcranial Doppler probes
(ST3, Spencer Technologies, USA) to insonate one/both middle cerebral arteries through
the transtemporal window. The middle cerebral arteries were identified using standard
technique described in the literature,26,27 and the probes were fixed in place using
provided head frame (Spencer Technologies, Redmond, WA, USA). Adequacy of CBFv
signals was continuously monitored throughout the 8 hours of observation by study
investigators, and probes were readjusted as needed to ensure same angle of insonation
within the same patient and good signal power. Blood flow velocity was sampled and
recorded continuously at 125 Hz on ST3 device.
Hemodynamic and CO2 monitoring
Arterial blood pressure was monitored using an indwelling arterial catheter placed into
radial, brachial or femoral arteries. CO2 was monitored using continuous in-line
capnography module integrated into the ventilator circuit (S/5, Datex-Ohmeda, GE
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Healthcare, USA). The transduced arterial pressure and expired CO2 were displayed on
clinical monitors (S/5, Datex-Ohmeda, GE Healthcare, USA) and continuous waveforms
were recorded at 300 Hz on a laptop computer using S5-collect software (Datex-Ohmeda,
GE Healthcare, USA).
Study protocol and data collection
Following enrollment in the study, baseline demographic, comorbidity and clinical data
were obtained from patients’ medical charts and recorded in dedicated case report forms.
Waveform cerebral blood flow velocity, arterial pressure and CO2 data were recorded
continuously for up to 8 hours and exported as coma-separated values for offline analysis.
The data was then uploaded into a custom waveform viewer (LabView, National
Instruments, Austin, Texas, USA), where it was aligned using time stamps and processed
to ensure adequacy of all signals. Artifacts and sections with poor signals (e.g. CO2 and
blood pressure calibration artifacts, coughing, movement resulting in poor signals) were
excluded from the analysis. The software then used LabView peak detector function to
identify end-tidal CO2 and systolic, diastolic and mean arterial pressures and cerebral
blood flow velocity, which were then checked by investigators to ensure appropriate
identification of these values from continuous traces. Inappropriately picked values were
manually readjusted or excluded from the analysis (e.g. double end-tidal picking due to
ventilator asynchrony). Resulting data were averaged over 5 second intervals and
exported as comma-separated values for further analysis in Python and Excel. To allow
comparison between participants, CBFv was expressed as percent change from
participant’s baseline. To calculate primary outcome, we computed the proportion of total
recording time that CBFv deviated from baseline above or below thresholds of 5, 10, 15,
20, 25 and 30%. Given that CBF ischemia thresholds have not yet been defined in this
patient population, we used a range of thresholds that encompasses previously reported
thresholds for ischemia in other patient populations,19 as well as thresholds that would
equate to white matter ischemia.22,23
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Figure 2-1: Method for computing the proportion of time that patient’s CBFv (black
line) deviated from baseline above and below pre-determined thresholds (blue
shaded areas). The three panels above are taken from a single 20-min window from one
patient and show CBFv data plotted versus time. The total time that CBFv deviates from
baseline into shaded areas in each 20-min window is shown in blue (both absolute and
percent of total).

Dynamic autoregulation analysis
For our secondary analysis, we computed a clinically validated index of dynamic
autoregulation (Mxa)28 by calculating Spearman’s correlation coefficient between CBF
and MAP values within a moving time window advanced in 1-minute steps. In keeping
with previous definitions, we defined disturbed autoregulation as Mxa values >0.3 that
were statistically significant (p<0.05).29 Spearman’s method was used instead of
Pearson’s as we could not assume the linearity in the relationship between MAP and
CBF. To determine the impact of window length on calculation of Mxa, we varied the
window length across a range of values (5, 10, 15, 20, 30 and 60 minutes). Mxa was only
computed in windows that had at least 5 mmHg variation in MAP.30 We expressed the
duration of disturbed autoregulation for each patient as a fraction of the total analysis
time minus the time that Mxa could not be assessed. Figure 2-2 demonstrates how Mxa
was computed using data from a representative patient.
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Figure 2-2: Sample data from a representative patient showing computation of Mxa.
Panel A shows 20 minute tracing of CBFv and MAP from a representative patient. Two 5
minute windows are shown to demonstrate periods where autoregulation was impaired
(red) versus preserved (green). Panel B zooms in on CBFv and MAP data from the red
window in Panel A. Panel C shows Spearman correlation of data from Panel B, with Mxa
(r=0.738) exceeding threshold (>0.3) and correlation being statistically significant (p <
0.001). This suggest impaired dynamic cerebral autoregulation for the selected window.
Panel D zoom zooms in on CBFv and MAP data from the green window in Panel A.
Panel E shows Spearman correlation of data from Panel D, with Mxa (r=0.038) below
threshold (>0.3) and non-significant correlation (p < 0.772), suggesting preserved
dynamic cerebral autoregulation for the selected window.
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Relationship between CBFv deviations and state of dynamic autoregulation
To establish whether CBFv deviations beyond thresholds were longer in duration if
dynamic autoregulation was impaired, we compared the fraction of time that CBFv
deviated above and below thresholds when autoregulation was impaired versus when it
was preserved. In each patient, we used 5-min moving windows to compute Mxa as
described above in order to assess whether autoregulation was preserved or impaired. We
then computed the time (as a fraction of the 5-min window) that CBFv deviated
above/below CBF thresholds within the same window. We summarized the data within
patients by comparing the cumulative time that CBFv deviated above/below CBF
thresholds depending on the state of dynamic autoregulation (preserved vs. impaired).
We then compared results across patients. We used 2-way ANOVA and Sidak’s multiple
comparison test to assess statistical difference between groups.
Regression analysis to determine the relative impact of MAP and CO2 on CBFv
To establish the contribution of variations in MAP and CO2 to observed deviations in
CBF, we performed a multiple linear regression analysis with MAP and CO2 as
independent variables and CBF as a dependent variable. Regression analysis was done
within the same moving time window as Mxa that was advanced at 1-minute interval. To
determine the impact of window length on the outcome of regression analysis, we varied
it across a range of values (5, 10, 15, 20, 30 and 60 minutes). Regression analysis was
completed only in windows that had at least 5mmHg variation in MAP and at least
1mmHg variation in CO2 (the lower magnitude of variation in CO2 was accepted since
CBFv is exquisitely sensitive to changes in CO2, ~3-5% change per mmHg change in
CO2).31 Regression coefficients of determination (R2) for each window length were
summarized in each patient and across patients.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism software version 8.3 for
macOS (GraphPad Software, San Diego, CA, U.S.A.). Categorical variables are reported
as counts and percentages of total. Continuous data were analyzed for normal distribution
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using the Shapiro-Wilk normality test and were reported as mean and standard deviation
for normally distributed data; otherwise, data were summarized using median and
interquartile range. We used 2-way ANOVA and Sidak’s multiple comparison test to
assess for difference in the duration of CBFv deviations above/below thresholds between
windows with preserved vs impaired autoregulation. For all statistical comparisons, a pvalue of <0.05 was considered significant.

2.3 Results
Seventeen patients were enrolled in the study. Five patients were excluded (2 due to loss
of signals, 2 due to recording equipment malfunction, 1 due to inability to obtain
transcranial Doppler signal), leaving 12 patients in the final analysis (Figure 2-3).
Inclusion criteria:
• Age ≥ 18 years
• Resp failure or shock

Enrolled
• 17 patients

Excluded
5 patients
• 2 due to loss of TCD signal
• 2 due to equipment failure
• 1 unable to obtain TCD signal

•

Included in final analysis
12 patients

Figure 2-3: Patient enrollment flow diagram.
Patients baseline characteristics are summarized in Table 2-1. Median (interquartile
range, IQR) age was 62 (43, 80) years, there were fewer females in our cohort (3/12
patients), and all patients had respiratory failure and required vasopressors for shock. The
most common comorbidities included dyslipidemia, obstructive lung disease, and
cardiovascular disease. Median (IQR) SOFA score on the day of testing was 10 (7, 12)
and arterial to end-tidal PCO2 difference was 8 (4, 17) mmHg.

72

Table 2-1: Patient baseline characteristics
Number of patients
Age (years)

12
62 (43, 80)

Females, n (%)

3 (25)

MODS score, median (IQR)

6 (5, 8)

NEMS score, median (IQR)

39 (28, 39)

SOFA score, median (IQR)

10 (7, 12)

Arterial-end-tidal PCO2 difference (mmHg)

8 (4, 17)

Admission diagnosis, n (%)
Respiratory failure requiring mechanical ventilation

12 (100)

Shock requiring vasopressors

12 (100)

Ventilation mode, n (%)
Spontaneous

4 (33)

Controlled

8 67)

Comorbidities, n (%)
Hypertension

3 (25)

CAD

3 (25)

CHF

3 (25)

Afib

2 (17)

DM

3 (25)

Dyslipidemia

4 (33)

Obstructive lung disease

4 (33)

Restrictive lung disease

1 (8)

Values are expressed as counts (%) or as medians (IQR). MODS = multiple organ
dysfunction syndrome, NEMS = nine equivalents of nursing manpower, SOFA =
sequential organ failure assessment, CAD = coronary artery disease, CHF = congestive
heart failure, Afib = atrial fibrillation, DM = diabetes mellitus.
Figure 2-4 shows mean CBFv (expressed as percent change from baseline), MAP and
PetCO2 data for all patients. Mean ± standard deviation CBFv was 0.4 ± 17.1%, MAP
78.1 ± 11.5 mmHg, and PetCO2 was 36.0 ± 8.7 mmHg.

Mean CBFv (% Δ from baseline)
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Figure 2-4: Mean cerebral blood flow velocity (CBFv), mean arterial pressure
(MAP), and end-tidal PCO2 (PetCO2) across all patients. Error bars represent
standard deviation. CBF was expressed as percent change from baseline to enable
comparison across patients.
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CBFv deviation above and below thresholds
Mean ± standard deviation of the observation periods was 462.6 ± 39.8 min across all
patients. After removal of artifacts, the mean ± standard deviation of observation period
available for analysis was 379.2 ± 72.6 min. Table 2-2 summarizes the proportion of time
that CBFv was above or below specific thresholds across patients (individual results are
provided in Appendix A in Table 6-1)
Table 2-2: Proportion of time CBFv was above or below specific thresholds
Proportion of analysis time that CBFv was
Above & Below

CBFv Threshold
(% from baseline)

Above threshold

Below threshold

5

0.43 ± 0.31

0.31 ± 0.23

0.74 ± 0.15

10

0.31 ± 0.31

0.21 ± 0.2

0.52 ± 0.24

15

0.2 ± 0.31

0.14 ± 0.16

0.34 ± 0.28

20

0.15 ± 0.31

0.09 ± 0.13

0.24 ± 0.3

25

0.13 ± 0.31

0.06 ± 0.11

0.19 ± 0.3

30

0.12 ± 0.3

0.05 ± 0.1

0.17 ± 0.29

threshold

CBFv deviated by more than 10, 20 or 30% from baseline for approximately 52, 24 and
17% of the observation time (Table 2-2). There were more deviations above than below
the baseline (Figure 2-5). CBFv deviated by 10-20% below baseline for an average of 921% of the observation time.
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Figure 2-5: Proportion of time that cerebral blood flow velocity (CBFv) deviated
from baseline (y axis) above (Panel A) or below (Panel B) CBFv thresholds (x-axis).
Error bars represent standard deviations.

Dynamic Autoregulation
Across patients, dynamic autoregulation was disturbed 20-35% of the observation time
depending on the length of the window used to calculate Mxa (Table 2-3). In keeping
with the previous studies,32 longer window length was associated with the larger fraction
of observation time with disturbed autoregulation (Figure 2-6).

76

Table 2-3: Duration of disturbed autoregulation as a function of window length for
calculating Mxa.
Fraction of observation time with

(min)

disturbed autoregulation (median, IQR)

5

0.20 ± 0.16

10

0.23 ± 0.20

15

0.25 ± 0.22

20

0.27 ± 0.24

25

0.30 ± 0.25

30

0.35 ± 0.28

Fraction of time
with disturbed autoregulation

Window Length

0.8
0.6
0.4
0.2
0.0
0

10

20

30

40

50

60

Window length (min)

Figure 2-6: Fraction of the observation time with disturbed autoregulation as a
function of window length used to calculate Mxa. Circles are mean values, Error bars
are SD.
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Relationship between CBFv deviations and state of dynamic autoregulation
Individual patient data are shown in Figure 6-1, Figure 6-2 and Table 6-2 in Appendix B.
While the proportion of time that CBFv deviated above/below CBF thresholds varied
across patients, the state of autoregulation within patients had little effect on the duration
of these CBFv deviations. In fact, in some patients (e.g. patient 7) CBFv deviations were
more common during periods of preserved autoregulation. In another patient (patent 1),
CBFv deviations above thresholds were longer during periods of impaired autoregulation
while those below thresholds were longer during periods of preserved autoregulation.
Across patients, the state of dynamic autoregulation had no impact on the duration of
CBFv deviations above or below thresholds (Figure 2-7 and Table 2-4).

Figure 2-7: Relationship between CBFv deviations above/below thresholds and state
of dynamic autoregulation across patients. Circles denote preserved autoregulation,
while squares denote impaired autoregulation.
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Table 2-4: Relationship between CBFv deviations above/below thresholds and state
of dynamic autoregulation across patients.
Time CBFv ABOVE threshold
(fraction of 5-min window time)

CBF
threshold
5
10
15
20
25
30

AR
Preserve
d
mean ±
SD
0.449 ±
0.306
0.335 ±
0.324
0.212 ±
0.314
0.152 ±
0.318
0.138 ±
0.313
0.128 ±
0.305

AR
Impaired
mean ±
SD
0.398 ±
0.217
0.268 ±
0.194
0.181 ±
0.204
0.125 ±
0.214
0.100 ±
0.210
0.086 ±
0.202

p-value
0.9979
0.9899
0.9999
>0.9999
0.9996
0.9993

Time CBFv BELOW threshold
(fraction of 5-min window
time)
AR
AR
Preserv
Impaired
ed
mean ±
mean ±
p-value
SD
SD
0.309 ±
0.342 ±
0.9975
0.230
0.213
0.218 ±
0.246 ±
0.9989
0.206
0.189
0.152 ±
0.172 ±
0.9999
0.178
0.163
0.104 ±
0.108 ±
>0.9999
0.149
0.141
0.07 ±
0.071 ±
>0.9999
0.126
0.127
0.052 ±
0.056 ±
>0.9999
0.115
0.117

While CBFv deviations during periods of impaired autoregulation are expected, the
surprising finding in this analysis was that CBFv deviations occurred for substantial
proportion of time during periods of preserved dynamic autoregulation. For example,
during periods of preserved autoregulation, across patients CBFv deviated by 10-20%
above baseline for 15-34% of observed time and by 10-20% below baseline for 10-22%
of observed time.
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Regression analysis
Multiple regression analysis with MAP and CO2 as independent variables and CBFv as a
dependent variable yielded very low R2 values across patients. Figure 2-8 shows sample
analysis from a representative patient.
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Figure 2-8: Sample regression analysis from a representative patient. Panel A shows
CBFv, MAP and PetCO2 data for the entire duration of the recording. Panel B shows a 5min moving window (same as used to calculate Mxa) from which multiple linear
regression is calculated (Panel C) revealing low R2 for this window. Panel D shows an
adjacent 5-min window (2 minutes across), where again multiple linear regression is
calculated (Panel E), revealing slightly higher, yet still small, R2. This analysis was
repeated for each patient using moving windows of various lengths.
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Table 2-5 shows within patient results of the regression analysis.
Table 2-5: Within patient results of the multiple linear regression analysis with
MAP and CO2 and independent variables and CBF as a dependent variable.
Patient

1
2
3
4
5
6
7
8
9
10
11
12
Grou
p
mean
± SD

5
0.166 ±
0.129
0.176 ±
0.179
0.323 ±
0.276
0.125 ±
0.119
0.081 ±
0.085
0.148 ±
0.162
0.108 ±
0.141
0.060 ±
0.073
0.181 ±
0.180
0.198 ±
0.178
0.119 ±
0.146
0.100 ±
0.106

10
0.166 ±
0.129
0.192 ±
0.185
0.390 ±
0.279
0.106 ±
0.118
0.051 ±
0.054
0.107 ±
0.125
0.094 ±
0.104
0.043 ±
0.062
0.184 ±
0.207
0.186 ±
0.172
0.157 ±
0.185
0.066 ±
0.081

Window length (min)
15
20
0.164 ±
0.18 ±
0.160
0.177
0.210 ±
0.219 ±
0.184
0.184
0.419 ±
0.451 ±
0.275
0.274
0.100 ±
0.106 ±
0.104
0.109
0.043 ±
0.039 ±
0.040
0.032
0.102 ±
0.097 ±
0.134
0.140
0.110 ±
0.127 ±
0.128
0.142
0.038 ±
0.035 ±
0.052
0.048
0.202 ±
0.224 ±
0.228
0.246
0.186 ±
0.184 ±
0.176
0.183
0.196 ±
0.213 ±
0.209
0.214
0.050 ±
0.043 ±
0.062
0.055

0.133 ±
0.153

0.141 ±
0.178

0.154 ±
0.192

0.165 ±
0.204

30
0.205 ±
0.197
0.217 ±
0.184
0.506 ±
0.269
0.115 ±
0.124
0.035 ±
0.029
0.092 ±
0.127
0.160 ±
0.164
0.032 ±
0.042
0.269 ±
0.269
0.195 ±
0.184
0.229 ±
0.214
0.039 ±
0.048

60
0.234 ±
0.216
0.173 ±
0.170
0.583 ±
0.237
0.138 ±
0.157
0.028 ±
0.032
0.079 ±
0.091
0.197 ±
0.162
0.027 ±
0.022
0.333 ±
0.272
0.213 ±
0.188
0.279 ±
0.189
0.042 ±
0.045

0.182 ±
0.219

0.205 ±
0.231
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Across patients, The R2 varied from 0.13 ± 0.15 to 0.21 ± 0.23 depending on the window

R2 for multiple linear regression

length used to complete regression analysis (Figure 2-9).

1.0
0.8
0.6
0.4
0.2
0.0
5

10 15 20 30 60

Window length (min)

Figure 2-9: Results of multiple linear regression analysis with MAP and CO2 and
independent variables and CBF as a dependent variable. The figure shows changes
in coefficient of determination (R2) as a function of window length use for regression
analysis.
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2.4 Discussion
Main findings
Our study shows that in critically ill patients with respiratory failure or shock, CBFv
deviates from its baseline by more than 20-30% for 17-24% of the observation time.
There were more CBFv deviations above than below the baseline (15 ± 31 vs 9 ± 13% of
the observation time). These CBFv deviations occurred both during periods of preserved
and impaired dynamic autoregulation, which was impaired 20-35% of the observation
time in our cohort, nor were they fully explained by associated variations in MAP and
CO2. Given that CBF thresholds used in our study are similar to those associated with
ischemic injury and neurologic symptoms from previous studies in cardiac surgery
patients, our findings represent biologically plausible insult that may lead to CBFmediated brain injury in critically ill patients independently from the state of dynamic
autoregulation or changes in MAP and CO2.
CBF deviations in healthy subjects and patients with neurologic disorders
To our knowledge this is the first study to quantify the magnitude and duration of
spontaneous CBFv deviations beyond specific thresholds in patients with respiratory
failure or shock. Spontaneous deviations in CBF have been previously described in
healthy participants and in patients with neurologic disorders. In one study that recorded
CBF over 5-10 minutes, the mean ± standard error range of CBF variations was 11± 4%
in healthy participants and 14 ± 13% in neurosurgical population. Five of 11 healthy
participants had at least one wave with a range of more than 20% compared to 13 of 22
neurosurgical patients.16 In another study that recorded CBF over 2 hours in resting
supine healthy participants, the range of CBF variation was 77 ± 8 % and coefficient of
variation of 9.3 ± 2%.14 Most of these CBF deviations occurred at frequencies lower than
0.1 Hz, where dynamic autoregulation appeared to be most effective.14,15
More recent research in traumatic brain injury suggests that deviation in cerebral
perfusion are common and considerable in duration. Davie et al. used cerebral oximetry
to show that 12 of 18 patients experience an episode of cerebral desaturation (defined as
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regional cerebral oxygen saturation of < 65%, which is ~7-10% reduction from baseline)
and that the duration of these desaturations episodes over 72 hours varied from 2.6 to
26% of observation time, with a median of 8.1%.24 This magnitude and duration of
reduction in cerebral perfusion pressure is comparable to our study, where the mean time
with CBFv deviation of more than 20 % below baseline was 9 ± 13% of total
observation time.
What CBF thresholds are associated with brain injury?
While much work has been done on ischemic thresholds in animal models and human
studies of stroke, information in other clinical populations is less clear. Synaptic failure
threshold corresponds to reduction of CBF below 15-20 ml/100g/min, which causes loss
of EEG signal in humans,33 cortical SSEP signals in baboons,34 and loss of spontaneous
neuronal firing in cats.35 The threshold for membrane failure is lower, reported at 6-7
ml/100g/min.34 The threshold for infarction is around 10 ml/100g/min,36 but development
of infarction takes time such that low flows of 5 to 8 ml/100g/min can be tolerated of up
to 1 hours without resulting in infarction.36,37 More recent MRI studies from human
stroke suggest higher thresholds for ischemic injury that vary between grey (median 34.6
ml/100g/min) and white (median 20.8 ml/100g/min) matter.21 In fact, functional brain
impairment likely occurs at higher thresholds than are required for infraction. For
example, cellular protein synthesis is inhibited at CBF values of 35-55 ml/100g/min,38
and reduction in CBF below 37 ml/100 g/min causes reversible deterioration in sustained
attention in patients undergoing occlusion of the internal carotid artery as part of
inoperable cavernous sinus aneurism management.39. These thresholds represent about
20-30% reduction in global CBF, which is similar to the thresholds used in this study.
More recent clinical studies in cardiac surgery patients suggest that the time below
cerebral oxygenation thresholds of only 7-10% from baseline is associated with major
clinical complications including stroke and delirium40 and development of new ischemic
lesions on neuroimaging.19 Interestingly, in the latter study, the majority (70%) of new
lesions developed in the watershed areas of the brain,19 suggesting that sub-cortical white
matter tracts are at higher risk of this subclinical ischemic injury. Given high prevalence
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of subcortical white matter injury in the critically ill,4,5 and its association with the
duration of ICU delirium 41, the deviations of CBF by 20-30% from baseline reported in
this study may be of clinical significance. Assuming baseline white matter CBF of 20-22
ml/100g/min,42 20-30% reduction in CBF below the baseline would correspond to a
reduction in white matter CBF to ischemic levels of 15-17 ml/100g/min. Since critical
illness is associated with the disruption of the brain blood barrier 18, hyperemic response
may also contribute to injury by increasing intracranial pressure43 and contributing to
formation of brain edema, especially in settings of disturbed autoregulation.44
The duration of CBF deviations beyond thresholds – “time is brain”
In stroke literature, the concept of “time is brain” is well established. Each minute delay
without treatment corresponds to 1.9 million neurons, 14 billion synapses, and 12 km (of
myelinated fibers being destroyed, which is equivalent to accelerated ageing at a rate of
3.6 per hour of no treatment.45 While ischemic injury in stroke may be an extreme case of
neuronal injury, similar evidence is evolving for more subtle injury in cardiac surgery
patients. In patients undergoing aortic surgery, the duration of time that regional cerebral
oxygenation deviates below 65% (which is ~7-10% below baseline) is associated with
greater number of major post-operative clinical complications (including stroke, delirium,
respiratory and renal failure) and longer duration of mechanical ventilation, ICU and
hospital length of stay.40 In another study of elective cardiac surgery patients, the
duration of time that regional cerebral oxygenation was 10% below baseline was
associated with development of new ischemic lesions, 70% of which were in the
watershed areas of the brain.19 The median time that regional cerebral oxygenation was
10% below baseline in patients with new ischemic lesions was 11 minutes, which
corresponds to ~5% of the total observation time, highlighting that even short cumulative
duration of modest impairment in cerebral perfusion can result in subclinical watershed
ischemic brain injury. This duration of cerebral perfusion deviation into ischemic zone is
comparable to our study, where CBFv deviated by more than 20-30% below baseline for
a mean 5-9% of the observation time. The importance of time in development of brain
dysfunction is further highlighted by a recent study from critically ill patients showing
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that the cumulative duration of dysfunctional cerebral autoregulation is associated with
the development of ICU delirium.32
Cerebral autoregulation and deviations in CBFv
In our study, dynamic cerebral autoregulation was disturbed 20-35% of the observation
time, depending on the length of the window used to compute Mxa (Figure 2-6).
However, the disturbance in autoregulation had no impact on the duration of CBFv
deviations above/below thresholds (Figure 2-7). In fact, during periods of preserved
autoregulation CBFv deviated by 10-20% above/below baseline for 10-34% of
observation time. These findings suggest that preserved dynamic autoregulation does not
prevent substantial variations in CBFv.
The prevalence of disturbed dynamic autoregulation and its association with poor
outcomes in critically ill patients are well established. In patient with head injury,
disturbed dynamic autoregulation is associated with worse neurologic outcomes and
higher mortality.46 In sepsis, disturbed autoregulation occurs in up to 50% of patients and
is associated with the development of sepsis-associated brain dysfunction.29 In patients
with respiratory failure or shock who were monitored continuously for 72 hours, dynamic
cerebral autoregulation was impaired for a median of 5.2% of the observation time in
never delirious patients and 10.4% of the observation time in delirious patients, and the
duration of time with disturbed autoregulation correlated with the duration of delirium.32
The disturbance of dynamic autoregulation is clearly associated with the brain
dysfunction in critically ill patients, likely by making the brain vulnerable to ischemic
and hyperemic injury during variations in CBF. While we confirmed long periods of
disturbed dynamic autoregulation in our patients, we were surprised to find prolonged
and substantial deviations in CBFv during periods of preserved autoregulation.
Our findings suggest that in critically ill patients prolonged deviations in CBFv from
baseline can occur independently of disturbances in dynamic autoregulation. Whether
cumulative burden of these CBFv deviations is an independent predictor of poor clinical
outcomes requires further dedicated studies.
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Association of CBFv deviations with MAP and CO2
Arterial blood pressure and CO2 are important determinants of CBF. Changes in MAP
result in changes in cerebral perfusion pressure and CBF, especially if cerebral
autoregulation is impaired. CBF is also exquisitely sensitive to arterial CO2, which can
induce changes in CBF by altering cerebrovascular resistance (1 mmHg change in arterial
PCO2 is associated with approximately 2-5% change in CBF in subjects with preserved
cerebrovascular reactivity).31 Given that both MAP and CO2 are important determinants
of CBF, and since both of these variables fluctuate spontaneously in critically ill patients,
we used multiple regression analysis to determine whether CBF deviations can be
explained by concurrent changes in MAP and CO2.
Our analysis revealed that across patients variation in MAP and CO2 explain only 1321% of the observed variance in CBFv (Figure 2-9). These findings suggest that variables
other than MAP and CO2 are responsible for a large proportion of the observed CBFv
deviation. Alternative mechanisms responsible for observed CBFv deviations may
include changes in cardiac output, which has been shown to be an important determinant
of CBF independent of cerebral autoregulation and MAP,47–49 as well as changes in
regional cerebral metabolism and cerebrovascular resistance. Our results highlight the
complexity of CBF regulation in the critically ill patients and warrant further multimodal
studies to delineate the relative contribution of various control mechanisms to observed
deviations in CBF.
Future work
Future studies should assess whether the cumulative burden of observed deviations in
CBFv from baseline is associated with clinically relevant outcomes including delirium
and long-term cognitive impairment. Furthermore, given that after accounting for
variations in MAP and CO2, ~80% of variance in CBFv remained unexplained, future
work should concurrently assess additional variables that may affect CBF including
cardiac output and measures of cerebral metabolism and regional cerebral perfusion.
While tomographic imaging modalities such and PET and MRI would be ideal for these
measurements, it may not be feasible or safe to transport critically ill patients outside of
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ICU for prolonged periods of monitoring using these tomographic modalities.
Furthermore, given that assessment of dynamic autoregulation requires high frequency
monitoring of CBF and MAP, the lower temporal resolution of MRI and PET may not be
ideal for the assessment of dynamic autoregulation in these patients. Multimodal
monitoring with transcranial Doppler, near infrared spectroscopy, diffuse correlation
spectroscopy and non-invasive continuous cardiac output monitors is likely an optimal
compromise to enable simultaneous assessment of global and regional CBF, regional
cerebral metabolism, dynamic autoregulation and cardiac output at the bedside of
critically ill patients. Our plans are to explore this approach in future studies.
Limitations
Our study had several limitations. Due to the pilot nature of our study, we had a relatively
small sample size and as a result of consecutive patient enrollment strategy our sample
was not equally balanced between females and males. However, we were still able to
demonstrate that, similar to patients with traumatic brain injury,24 critically ill patients
experienced 20-30% deviations in CBF from baseline for substantial periods of time. We
also showed that our patients experienced substantial periods of disturbed dynamic
cerebral autoregulation. Another limitation of our study is that the use of transcranial
Doppler limited our assessment of cerebral blood flow velocity to middle cerebral artery,
and therefore represent only portion of global cerebral blood flow. However, the portable
nature of transcranial Doppler relative to comprehensive tomographic modalities allowed
its application at the bedside early in the course of critical illness when these patients are
usually very unstable for transfer to neuroimaging department. Furthermore, its high
temporal resolution made it an ideal tool for monitoring and discerning high frequency
changes in CBFv over prolonged period of observation used in this study. Finally,
whether the observed deviations in CBFv are associated with ischemic bran injury and
brain dysfunction, or are simply an epiphenomenon, remains unknown. However, our
study provides biologic rationale for future studies to establish whether observed
deviations in CBF from baseline in this patient population are associated with imaging
markers of brain injury or functional brain impairment.
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2.5 Conclusions
In critically ill patients with respiratory failure or shock, CBFv deviates by 20-30% from
baseline for 17-24% of observation time early in the course of ICU admission. These
deviations occurred both during periods of preserved and impaired autoregulation, and
were not fully explained by corresponding changes in MAP and CO2. Future studies
should use multimodal neuromonitoring to establish the mechanisms responsible for
these CBF deviations, and assess whether cumulative burden of these deviations is
associated with imaging markers of brain injury and poor neurologic outcomes.
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Chapter 3
3

Impairment in Baseline Cerebrovascular Function in
Patients at High Risk of Critical Illness.

In the previous chapter we showed that critically ill patients experience substantial
deviations in cerebral blood flow (CBF) beyond ischemic and hyperemic thresholds early
in the course of their critical illness. Such deviations can lead to ischemic or hyperemic
injury, especially in patients with impaired cerebrovascular function. However, the
functional status of cerebral vasculature in patients who are at high risk of critical illness
has not been systematically studied or taken into account when interpreting the effects of
ICU exposures and interventions.
Cerebrovascular reactivity to CO2 (CVR) has emerged as a reliable marker of
cerebrovascular function,1 and impaired CVR is associated with increased risk of stroke2
and cognitive impairment.3,4 Given that patients with end-stage renal disease receiving
hemodialysis (HD) are at higher risk of developing critical illness and requiring
admission to the ICU,5 we used CVR to assess their cerebrovascular function and
compare it to CVR in patients with Stage 4 or 5 chronic kidney disease (CKD, i.e. not
requiring dialysis) and healthy participants.
We found that HD patients have impaired CVR compared to CKD patients and healthy
participants. We also showed that there was no difference in CVR between CKD patients
and healthy participants, suggesting that the impairment in CVR was not simply due to
reduction in renal function, but is likely related to the hemodialysis treatment. Our results
suggest that certain patient groups may have pre-ICU impairment in cerebrovascular
function which can make them vulnerable to ischemic and hyperemic insults during
critical illness. Future studies should assess whether pre-ICU impairment in CVR is
associated with poor neurocognitive outcomes during and following critical illness.
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3.1 Introduction
Critically ill patients suffer from high rates of acute (delirium) and long-term cognitive
impairment. The risk for developing delirium and long-term cognitive impairment is
thought to be dependent on an interplay between predisposing and precipitating factors.
In a recent systematic review of risk factors for ICU delirium age, hypertension and
dementia were identified as predisposing factors, and pre-ICU trauma or emergency
surgery, severity of illness score (APACHE II score), mechanical ventilation, metabolic
acidosis, delirium on the prior day and coma were identified as precipitating factors.
Delirium and delirium duration appear to be the only consistent risk factors for long term
cognitive impairment.6,7 While these demographic and clinical risk factors are important
for identifying at risk patients, the underlying mechanisms responsible for delirium are
poorly understood, which impedes development of targeted interventions.
Ischemia has emerged as a plausible mechanism for ICU related brain dysfunction given
common occurrence of hemodynamic instability and shock in the critically ill.8,9 Data
from neuroimaging studies supports the ischemic hypothesis given high prevalence of
subcortical white matter injury that is associated with the duration of delirium 10 and
septic shock.11 It remains unknown whether certain patient populations are at higher risk
of ischemic or hyperemic injury during critical illness due to baseline impairment in
cerebrovascular function.
Patients with end-stage renal disease who require dialysis are at higher risk of requiring
hospitalization and admission to the intensive care units, with a 30-fold risk of critical
care requirements compared to the general population.5,12–14 While in the ICU, chronic
dialysis patients are more critically ill, having higher severity of illness scores,12 and have
more comorbidities that the general population including higher rates of diabetes and
peripheral arterial disease.15 They also have higher ICU mortality rates 12 that are related
with physiologic disturbances including hypotension12 and the need for inotropic
support,16 suggesting impaired physiologic reserve and, potentially, cerebrovascular
function.
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HD patients also have high prevalence of cognitive impairment, with as many as 70%
having moderate to severe cognitive impairment.17,18 Unlike ageing or Alzheimer’s
disease that predominately affects memory, cognitive impairment in HD patients spans
multiple domains including orientation and attention, language, construction and motor
function, concept and reasoning, memory, and executive function.17,18. The most severe
deficits occur in the domains of attention and executive function,18 which corresponds to
changes seen in patients with vascular 19 rather than neurodegenerative dementia. The
vascular hypothesis for cognitive impairment is supported by a recent findings that
cerebral ischemia occurs in almost 25% of hemodialysis sessions 20 and that global CBF
falls by an average of 10%, with concurrent reduction in regional CBF in the frontal,
parietal, temporal, and occipital lobes, as well as cerebellum and thalamus.21
Furthermore, incident HD patients develop new diffuse subcortical white matter injury
that is independent of the traditional cardiovascular risk factors (smoking, diabetes and
ischemic heart disease), but is associated with the multi-domain cognitive impairment
and with hemodynamic instability during dialysis sessions as measured by the mean
arterial pressure (MAP) extrema points.22 Interventions to improve hemodynamic
stability, such as dialysate cooling, appear to completely protect HD patients from this
pattern of brain injury.23 While the circulatory stress of hemodialysis is a plausible
ischemic insult in HD patients, it may be superimposed on the impaired cerebrovascular
function that provides an optimal milieu for development of observed subcortical white
matter injury. Whether HD patients have impairment in cerebrovascular function as
measured by CVR is unknown.
In this study we measured CVR as a marker of cerebrovascular function in prevalent HD
patients and compared it to CVR in stage 4 or 5 CKD patients and healthy participants.
We hypothesized that CVR will be impaired in HD patients compared to those in healthy
participants and CKD patients. Given that HD patients represent a well-defined group
that is at high risk of critical illness, identifying whether they have impaired
cerebrovascular function at baseline prior to critical illness will help interpret the effects
of ICU exposures such as CBFv deviations reported in Chapter 2, and inform future

97

observational and interventional studies seeking to understand the mechanisms of ICU
delirium and long-term cognitive impairment.

3.2 Materials and Methods
Study design and Participants
This was a single-centre prospective observational study that was approved by Western
University Health Sciences Research Ethics Board (protocol number 109548) and carried
out at the Kidney Clinical Research Unit in London, Canada. HD and CKD patients were
recruited form the prevalent patient population of the hemodialysis and chronic kidney
disease programs at Kidney Care Centre, London Health Sciences Centre. Healthy
participants were recruited from the general population using poster advertisements.
Inclusion criteria varied by participant group. For healthy participants we included adults
(age ≥ 18 years) with no history of cardiovascular disease, cerebrovascular disease,
diabetes or CKD. For CKD patients, we included adults (age ≥ 18 years) with a diagnosis
of stage 4 or 5 CKD. For HD patients, we included adults (age ≥ 18 years) who were
receiving hemodialysis treatment at least 3 times per week at a London Health Sciences
Centre facility. Dialysis patients were tested on the day between their dialysis sessions.
Exclusion criteria in all participants were: severe chronic obstructive lung disease or
asthma, past history of cerebrovascular accident (stroke or transient ischemic attack),
carotid stenosis or carotid surgery, prior neurosurgery, history of vasculitis, pregnancy
and mental incapacity for consent. All participants signed an informed consent form prior
to participation in the study.

Cerebral blood flow monitoring
We used transcranial Doppler to measures middle cerebral artery blood flow velocity
(CBFv) as an indicator of global cerebral blood flow. We used 2-MHz transcranial
Doppler probes (ST3, Spencer Technologies, USA) to insonate one/both middle cerebral
arteries through the transtemporal window. The middle cerebral arteries were identified
using standard technique described in the literature,24,25 and the probes were fixed in
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place using provided head frame (Spencer Technologies, Redmond, WA, USA). CBFv
was sampled and recorded continuously at 125 Hz on an ST3 device.
CO2 changes
We used an automated gas blender and gas delivery breathing circuit (RA-MR,
RespirActTM, Thornhill Medical, Toronto, Canada) to prospectively target and control
end-tidal gases. The RespirActTM is based on theory of sequential gas delivery26 to
provide a quantitative and reproducible CO2 stimulus that has been previously used to
quantify cerebrovascular response to CO2 in healthy participants27,28 and patients.29,30
Unlike other vasodilatory stimuli such as transient or pharmacologically induced changes
in MAP, administration of acetazolamide, breath holding, or addition of CO2 to inspired
gas, prospective targeting offered by RespirActTM allows for a non-invasive, rapidly
reversible and reproducible stimulus that greatly reduces between subject variability in
the CO2 stimulus, allowing for a more accurate measurement of cerebrovascular
response.31 Methods that use increased inspired fraction of CO2 often result in
unpredictable end-tidal partial pressure of CO2 (PetCO2) due to variable ventilatory
sensitivity to CO2 among participants, sometimes resulting in paradoxical reduction in
PetCO2.32 Furthermore, with inspired CO2 methods the variable difference between
PetCO2 and arterial PCO2 (PaCO2) between participants adds error to estimation of the
stimulus magnitude.31 In contrast, the prospective targeting method used in this study has
been shown to accurately reflect changes in PaCO2 from PetCO2.33
Hemodynamic monitoring
We used Finapres NOVA (Finapres, Finapres Medical Systems, Netherlands) to record
global hemodynamic parameters non-invasively. The Finapres measures hemodynamics
by continuous non-invasive pulse-wave analysis at the digital artery. The Finapres
utilizes a finger-cuff with infra-red photoplethysmograph to detect beat-to-beat changes
in digital artery blood pressure and calibrates this to oscillometric brachial artery
pressure. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean arterial (MAP) blood
pressures, and cardiac output (CO) were derived and measured continuously. The fingercuff was placed on an appropriate finger (preferably the middle finger of the non-fistula
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arm) and on the upper arm of the same arm. Non-invasive methods such as Finapres are
validated in critical care34,35 and hemodialysis36,37 settings, and used it prior CVR
studies.38–40 While its accuracy and precision are not interchangeable with direct intraarterial measurements,41,42 it has become an accepted non-invasive alternative in
physiological and clinical studies.42–46
Study protocol and data collection
Participants were tested in the Kidney Clinical Research Unit at Victoria Hospital,
London Health Sciences Centre. Baseline participant demographic and relevant clinical
data for patient participants were recorded in dedicated case report forms. Participants
were seated in a comfortable recliner chair for the duration of the study. After application
of the transcranial Doppler probes, the non-invasive hemodynamic monitor probe and a
RespirActTM facemask, baseline respiratory and hemodynamic data were acquired after 5
minutes of acclimatization to the experimental apparatus. The CO2 sequence consisting of
three 5-minute stages was then applied: 1) patient’s own resting PetCO2 (baseline); 2)
increase in PetCO2 by 10 mmHg above baseline (intervention); and 3) return to resting
PetCO2 (recovery) (Figure 3-2). RespirActTM eliminates the usual end-tidal to arterial
difference in PCO2, so that changes in PetCO2 actually reflect changes in PaCO2.33 Endtidal partial pressure of O2 (PetO2) was kept constant at normoxia. CBFv, hemodynamics
and changes in end-tidal gases were recorded continuously and exported as commaseparated values for offline analysis. Data analysis was performed using custom Python
software, where CBF, hemodynamic and respiratory data were aligned using time stamps.
To allow comparison between participants, CBFv was expressed as percent change from
participant’s baseline. The average values for CBFv, hemodynamic variables (MAP, HR,
CO), PetCO2 and PetO2 for each experimental stage were calculated using data from the
last minute of each 5-minute stage. To assess for hysteresis, CVR was calculated as the
percent change in CBFv divided by the change in PetCO2 for both increase in PetCO2
from baseline to hypercapnia (CVR intervention) and decrease in PetCO2 from
hypercapnia back to baseline (CVR recovery).
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Statistical analysis
Statistical analysis was performed using the GraphPad Prism software version 8.3 for
macOS (GraphPad Software, San Diego, CA, U.S.A.). Continuous data were analyzed for
normal distribution using the Shapiro-Wilk normality test. Descriptive statistics were
reported as mean and standard deviation for normally distributed data; otherwise, data
were summarize d using median and interquartile range. To compare differences between
participant groups (healthy vs. CKD vs. HD patients), we used one and 2-way ANOVA
with Tukey’s multiple comparisons test for normally distributed variables, and Kruskal–
Wallis test for non-normally distributed variables. We used Pearson’s correlation or nonparametric (Spearman’s rank) correlation analysis to assess the strength of relationship
between CVR and change in MAP, HR, CO, estimated glomerular filtration rate (eGFR,
for CKD patients only) and dialysis vintage (length of time on dialysis, for HD patients
only) within participant groups. We reported correlation coefficients (r-values) and the
significance level of the p-value. A p-value of <0.05 was considered significant.

3.3 Results
A total of 24 healthy participants, 12 CKD and 15 HD patients met the inclusion criteria
and were enrolled in the study. Of these, 7 healthy participants, 2 CKD patients and 7 HD
patients were excluded due to equipment malfunction (5 healthy, 3 HD), poor CO2
intervention due to leak around facemask (2 healthy, 1 CKD, 2 HD), inability to tolerate
intervention (1 CKD, 1 HD) and inability to obtain good quality TCD signals (1 HD). A
total of 17 healthy participants, 10 CKD and 8 HD patients completed full protocol and
were included in the final analysis (Figure 3-1).
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Enrolled
• 24 Healthy participants
• 12 CKD patients
• 15 HD patients
Excluded:
7 Healthy participants
• 5 equipment malfunction
• 2 poor CO2 intervention (mask leak)
2 CKD patients
• 1 unable to tolerate intervention
• 1 poor CO2 intervention (mask leak)
7 HD patients
• 3 equipment malfunction
• 2 poor CO2 intervention
• 1 unable to tolerate intervention
• 1 unable to obtain TCD signals
Included in final analysis:
• 17 Healthy participants
• 10 CKD patients
• 8 Dialysis patients
Figure 3-1: Patient enrollment flow diagram.
Participant baseline characteristics are summarized in Table 3-1.
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Table 3-1: Participant baseline characteristics.
H

CKD

HD

P-values

n

17

10

8

0.0022

Females,
n (%)

8 (47%)

3 (30%)

3 (38%)

0.6735

Age (yrs)

31 (26, 41)

71 (56, 73)

69 (61, 71)

0.0002

Weight
(kg)

68 (64, 85)

94 (84, 102)

91 (85, 105)

0.0077

168 (165, 174)

175 (163, 182)

172 (163, 175)

0.5257

52 (43, 60)

48 (46, 56)

45 (21, 58)

0.5956

38 (35, 42)

36 (34, 38)

42 (37, 46)

0.0400

PO2
(mmHg)

103 (102, 112)

111 (107, 114)

108 (92, 112)

0.1739

SBP
(mmHg)

129 (119, 137)

136 (116, 145)

127 (107, 178)

0.7120

MAP
(mmHg)

96 (90, 103)

90 (82, 100)

87 (71, 103)

0.4681

76 (70, 82)

68 (60, 80)

63 (56, 70)

0.0718

76 (67, 83)

73 (56, 85)

68 (58, 79)

0.6330

5.7 (5.1, 6.4)

5.7 (5.5, 7.4)

7.8 (6.7, 9.8)

0.0625

-

-

27 (14, 62)

-

Height
(cm)
CBFv
(cm/s)
PCO2
(mmHg)

DIA
(mmHg)
HR
(bpm)
CO
(L/min)

eGFR
22 (17, 27)
(mL/min/1.73 m2)
Dialysis vintage (months)

Values are expressed as medians (interquartile range). Abbreviations: H= Healthy
participants, CKD = chronic kidney disease patients, HD = hemodialysis patients, CBFv
= mean cerebral blood flow, PCO2 = end-tidal partial pressure of CO2, PO2 = end-tidal
partial pressure of O2, SBP = systolic blood pressure, MAP = mean arterial blood
pressure, DIA = diastolic blood pressure, HR = heart rate, CO = cardiac output, eGFR =
estimated glomerular filtration rate. * p<0.05 values highlighted are in italics.
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Healthy participants were younger (median 31.0 years, IQR 26, 41) than CKD patients
(median 71 years, IQR 56, 73, p = 0.0009) and HD patients (median 69 years, IQR 61,
71, p=0.0034). There was no difference in age between CKD and HD patients
(p>0.9999). Healthy participants also had a lower weight (median 68 kg, IQR 64, 85)
than CKD (median 94 kg, IQR 84, 102, p = 0.0142) and HD (median 91 kg, IQR 85, 105,
p = 0.0418) patients, with no difference noted between CKD and HD patients (p =
0.7227). HD patients had a higher baseline PetCO2 (median 42 mmHg, IQR 37, 46) than
CKD patients (median 36 mmHg, IQR 34, 38, p = 0.0344), but not healthy participants
(median 38 mmHg, IQR 35, 42, p = 0.2546). There were no differences between
participant groups in terms of sex, height, and baseline CBFv, PetO2, SBP, MAP, DBP,
HR and CO. Figure 3-2 shows experimental data from representative participants from
each group.
Table 3-2 shows within group changes in variables across experimental stages. Across all
groups, PetCO2 and CBFv increased from baseline during intervention and returned back
to baseline during recovery, with no corresponding changes in PetO2. In healthy
participants and HD patients, MAP increased from baseline during intervention and did
not return back to baseline during recovery. In CKD patients, the same trend in MAP was
observed, but the difference between baseline and intervention did not reach statistical
significance. CKD patients a small increase in HR with intervention that returned back to
baseline during recovery, while HR did not change across stages in healthy participants
and HD patients. Healthy participants had an increase in CO during intervention that
returned back to baseline, while CKD and HD patients had no change in their CO.
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Figure 3-2: Sample data from representative healthy (Panel A), chronic kidney
disease (Panel B) and hemodialysis (Panel C) participants demonstrating study
protocol. Following 5 minutes of baseline, there is an ~10 mmHg square-wave increase
in PetCO2 from baseline (intervention) while PetO2 is kept constant at normoxia. After 5
minutes of hypercapnia, the PetCO2 is returned back to baseline (recovery), followed by
another 5 minutes of recording. The corresponding change in CBFv and MAP are also
shown. Note that most of the response in CBFv is due to change in PetCO2 rather than
modest increase in MAP that continues to rise following return of PetCO2 to baseline.
Red dotted lines represent the 1-min data samples used for the each experimental stage
(BL= baseline, INT=intervention, REC=recovery). Note reduced CBFv response in
hemodialysis patient despite similar PetCO2 stimulus across patients.
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Table 3-2: Within group changes in variables between baseline, intervention and
recovery stages.
Variable
BL
PetCO2 (mmHg)
38 (35, 42)
PetO2 (mmHg) 103 (102, 112)
CBFv (%)
0 (0, 0)
MAP (mmHg)
96 (90, 103)
HR (b/min)
76 (67, 83)
CO (L/min)
5.7 (5.1, 6.4)

Healthy
INT
47 (44, 51)*†
108 (103, 112)
38 (27, 47)*†
110 (92, 115)*†
78 (67, 88)
6.6 (5.3, 7.4)*†

REC
38 (35, 42)
106 (102, 112)
-2 (-7, 4)
99 (89, 108)
79 (67, 88)
5.8 (5, 6.8)

p-value
<0.0001
0.4525
<0.0001
<0.0001
0.1966
0.0003

Variable
BL
PetCO2 (mmHg)
38 (34, 39)
PetO2 (mmHg) 108 (105, 114)
CBFv (%)
0 (0, 0)
MAP (mmHg)
94 (87, 103)
HR (b/min)
69 (56, 81)
CO (L/min)
5.6 (5.5, 6.4)

CKD
INT
48 (44, 48)*†
108 (105, 114)
40 (34, 51)*†
104 (93, 114)
73 (59, 89)*
6.6 (6, 7.3)

REC
38 (34, 39)
110 (105, 114)
-1 (-3, 2)
103 (91, 108)*
69 (59, 84)
5.9 (5.2, 6.9)

p-value
<0.0001
0.4040
<0.0001
0.0367
0.0038
0.5933

Variable
PetCO2 (mmHg)
PetO2 (mmHg)
CBFv (%)
MAP (mmHg)
HR (b/min)
CO (L/min)

HD
INT
51 (47, 55)*†
109 (97, 112)
20 (9, 37) *†
102 (82, 111)*†
74 (61, 86)
8.4 (7.4, 10.7)

REC
42 (39, 44)
108 (98, 112)
-2 (-5, 0)
92 (74, 109)*
70 (59, 78)
8.2 (7.1, 10.6)

p-value
<0.0001
0.3632
0.0039
0.0004
0.2139
0.0901

BL
42 (37, 46)
108 (92, 112)
0 (0, 0)
87 (71, 103)
68 (58, 79)
7.8 (6.7, 9.8)

Values are expressed as median (IQR). * p<0.05 vs BL, † p<0.05 vs REC. Abbreviations:
BL=baseline, INT=intervention, REC=recovery, CKD=chronic kidney disease patients,
HD=hemodialysis patients, PetCO2=end-tidal PCO2, PetO2=end-tidal PO2,
CBFv=cerebral blood flow velocity, MAP=mean arterial pressure, HR=heart rate,
CO=cardiac output.
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Table 3-3 summarizes the magnitude of change in physiologic parameters across patients
groups during intervention and recovery. Hemodialysis patients had a smaller change in
CBFv during intervention compared to healthy participants and CKD patients. The same
pattern was observed during recovery, but it only reached statistical significance for
healthy vs HD patients. There was no difference between groups in any other parameters.
Table 3-3: Changes in physiologic parameters during intervention and recovery.
VARIABLES
∆CBFv (%)
∆PetCO2(mmHg)
∆PetO2 (mmHg)
∆MAP (mmHg)
∆HR (bpm)
∆CO (L/min)
CVR (%/mmHg)

INTERVENTION
H
CKD
38.5 (27, 46.6)
36.8 (29.1, 48.7)
9.6 (8.9, 10.1)
9.6 (9.6, 10)
0 (-0.2, 1)
0.1 (-0.4, 0.5)
8.3 (5, 15.5)
9.7 (-0.6, 12.7)
4 (1.6, 6.2)
4.4 (-0.6, 5.9)
0.6 (0.1, 1)
0.7 (-0.2, 0.9)
4 (2.9, 4.8)
4 (3.4, 5.1)

RECOVERY
VARIABLES
H
CKD
∆CBFv (%)
-37 (-49.5, -30.5) -40 (-44.8, -28.8)
∆PetCO2(mmHg) -9.6 (-9.9, -8.8)
-9.7 (-9.8, -9.5)
∆PetO2 (mmHg)
0 (-0.4, 0.7)
0.1 (-0.2, 0.3)
∆MAP (mmHg)
-7.2 (-11, -2.6)
-3.4 (-6.9, 1.4)
∆HR (bpm)
-0.3 (-4.5, 4.4)
-0.5 (-4.3, 0.9)
∆CO (L/min)
-0.5 (-1, -0.1)
-0.4 (-0.9, 0.1)
CVR (%/mmHg)
4.1 (3.1, 5.2)
4.3 (3.6, 5)

HD
19.7 (8.9, 36.6)*†
9.8 (9.5, 10)
0 (-0.5, 0.3)
12.6 (7.5, 16.2)
4.5 (0.7, 7.4)
0.8 (-0.1, 1.5)
2.1 (0.9, 3.7)*†

p-value
0.0228
0.7914
0.4997
0.3247
0.9026
0.4148
0.0031

HD
-20 (-39.8, -12.3)*
-9.6 (-10, -9.3)
0.2 (0.1, 0.4)
-6.7 (-11.1, -1.3)
-2.3 (-5.5, 2.1)
-0.3 (-0.7, 0.3)

p-value
0.0397
0.8562
0.6092
0.1373
0.5942
0.4857
0.0120

2 (1.4, 4.1)*†

Values are expressed as median (IQR). * p<0.05 vs H, † p<0.05 vs CKD. Abbreviations:
H= Healthy participants, CKD = chronic kidney disease patients, HD = hemodialysis
patients, ∆CBFv = change in cerebral blood flow velocity expressed as percent change
from participant baseline, ∆PetCO2 = change in end-tidal PCO2, ∆PetO2 = change in
end-tidal PO2, ∆MAP = change in mean arterial blood pressure, ∆HR = change in heart
rate, ∆CO = change in cardiac output, CVR = cerebrovascular reactivity calculated as
∆CBFv/∆PetCO2.
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Figure 3-3 shows individual participant changes in CBFv, MAP and PetCO2 during
intervention and recovery across participant groups.
*p=0.0258
*p=0.03488

ΔCBFv (%)

80

*p=0.0486
p=0.1207

60
40
20
0
-20

ΔMAP (mmHg)

30
20
10
0
-10

ΔPetCO2 (mmHg)

-20

20
10

Baseline
Intervention
Recovery

0
-10

H

CKD
HD
Patient Group

Figure 3-3: Main results. Change in cerebral blood flow (∆CBFv), mean arterial
pressure (∆MAP), and end-tidal PCO2 (∆PetCO2) from baseline during intervention (red
lines) and recovery (blue lines) in healthy participants (H), chronic kidney disease (CKD)
and hemodialysis (HD) patients. Note variable CBFv and MAP responses across
participants despite similar changes in PetCO2. Only changes in CBFv were statistically
significant across participant groups.
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Compared to healthy and CKD participants, HD patients had a lower CBFv response to a
change in PetCO2 during intervention (p=0.0258 vs healthy, p=0.0486 vs CKD) and
recovery (p=0.0349 vs healthy, p=0.1207 vs CKD). This translated into significantly
lower CVR in HD patients compared to healthy and CKD participants during both
intervention (p=0.0082 vs healthy, p=0.0041 vs CKD) and recovery (p=0.0162 vs
healthy, p=0.0237 vs CKD, Figure 3-4). There were no differences in CVR between
healthy and CKD participants during either intervention (p=0.7777) or recovery
(p=0.988).
*p=0.0082
*p=0.0162

8

*p=0.0041

CVR
(%/mmHg)

*p=0.0237
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0
-2

H
CKD HD
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Figure 3-4: Summary of cerebrovascular reactivity across participant group.
Scatter plots of individual (circles) cerebrovascular reactivity (CVR) values in healthy
participants (H), chronic kidney disease (CKD) and hemodialysis (HD) patients during
intervention (red) and recovery (blue). The median (thick horizontal line), 25th and 75th
percentiles (thin horizontal lines) are also shown for each data set. Compared to healthy
participants and CKD patients, HD patients had significantly lower CVR both during
intervention and recovery stages of the experiment.
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Correlation analysis showed that there was no relationship between CVR and change in
MAP, HR, CO and PetO2 during both intervention and recovery within each participant
group (Table 3-4). In CKD group, there were no correlations between CVR and eGFR. In
HD group, there were no correlations between CVR and dialysis vintage.

Table 3-4: Correlation analysis between CVR, CBF, end-tidal gases, hemodynamic
variables, and dialysis vintage (for HD patients only) across participant groups.
Variable 1

Variable 2

CVR
CVR
CVR
CVR

∆MAP
∆HR
∆CO
∆PetO2

Healthy
Intervention
Recovery
r
p-value
r
p-value
0.313
0.221
-0.291
0.257
-0.256
0.322
-0.270
0.295
0.276
0.284
-0.241
0.351
-0.237
0.36
0.239
0.356
CKD

CVR
CVR
CVR
CVR
CVR

∆MAP
∆HR
∆CO
∆PetO2
eGFR

0.402
0.207
-0.351
0.16
-0.175

0.249
0.565
0.320
0.659
0.629

-0.069
-0.352
0.316
-0.143
-0.626

0.849
0.318
0.374
0.694
0.053

HD
∆MAP
-0.102
0.811
-0.316
0.446
∆HR
0.275
0.509
-0.143
0.736
CVR
∆CO
0.116
0.784
-0.313
0.450
CVR
∆PetO2
-0.397
0.330
-0.031
0.942
dialysis
CVR
-0.112
0.792
-0.198
0.638
vintage
Abbreviations: CKD = chronic kidney disease patients, HD = hemodialysis patients,
CVR = cerebrovascular reactivity, ∆MAP = change in mean arterial blood pressure, ∆HR
= change in heart rate, ∆CO = change in cardiac output, ∆PetO2 = change in PO2, eGFR
= estimated glomerular filtration rate, dialysis vintage = duration of time that the patient
has been receiving dialysis.
CVR
CVR
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3.4 Discussion
In this study we showed that HD patients have impaired CVR compared to CKD patients
and healthy participants. Given that CVR is an established marker of cerebrovascular
function that predicts neurocognitive outcomes, our results suggest that HD patients may
be at higher risk of poor neurocognitive outcomes compared to CKD patients and healthy
participants at baseline prior to the onset of critical illness. Such functional stratification
of baseline cerebrovascular risk is important for interpreting the effects of ICU
exposures, such as CBFv deviations described in Chapter 1, on neurocognitive outcomes
during and following critical illness.
CVR provides a non-invasive means to quantify cerebrovascular function and has been
investigated as a marker of cerebrovascular health in different pathologies. Impaired
CVR is associated with increased risk of stroke,2 cognitive impairment3,4 and cortical
thinning.47 In concussion, it helps differentiate between concussed and normal patients
despite similar anatomic and global resting CBF measurements in both groups.48,49
Impaired CVR has also been central to understanding the pathophysiology of
leukoaraiosis. Compared to normal appearing white matter, areas with white matter
hyperintensities are associated with approximately 10% reduction in resting CBF, 60%
reduction in CVR and 45% reduction in fractional anisotropy, the latter being a measure
of white matter integrity.50 Interestingly, areas of normal white matter that had impaired
CVR also showed significant reductions in resting CBF, cerebral blood volume, and
impairment in the imaging markers of white matter integrity (fractional anisotropy and
mean diffusivity), suggesting that CVR is likely an early functional marker of brain tissue
at risk for subsequent injury.1 This hypothesis was confirmed in another study, where
non-affected white matter that progressed to white matter hyperintensities in one year had
significantly lower CVR than preserved non-affected white matter.51
In the previous chapter (Chapter 2), we showed that critically ill patients experience
prolonged CBFv deviations beyond ischemic thresholds early in the course of the ICU
admission. In patients with preserved CVR, such ischemic episodes would be
counteracted by vascular dilation in response to local increase in CO2 in ischemic regions
in order to preserve tissue oxygen delivery. In patients with impaired CVR, this
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vasodilatory response is attenuated. This would facilitate ischemic injury via two
mechanisms. First, failure to vasodilate would prevent local compensatory increase in
CBF further worsening ischemia. Second, vasodilation in brain regions with preserved
CVR would divert the blood flow from the regions with impaired CVR that are unable to
dilate via vascular steal. Interestingly, regional assessment of CVR in healthy participants
revealed that such “steal” phenomenon is predominately localized to white matter where
elderly patients develop leukoaraiosis (i.e. white matter injury).52 This may explain why
HD patients develop new diffuse subcortical white matter injury that is independent of
the traditional cardiovascular risk factors (smoking, diabetes and ischemic heart disease)
when they first start receiving dialysis.22 Whether the same injury occurs in HD patients
during hemodynamic stress of critical illness, such as CBFv deviations demonstrated in
Chapter 2, should be explored in future studies.
The mechanism of CVR impairment in HD patients is unclear. Preserved CVR in CKD
patients that is independent of eGFR suggests that CVR impairment in HD patients is not
simply due to reduction in renal function, but is in some way related to the hemodialysis
treatment. Prior work suggested that impairment in CVR may be linked to impairment in
endothelial function,53,54 which is commonly reported in hemodialysis paitents.55,56 The
circulatory stress of hemodialysis can induced direct ischemic brain injury, or results in
chronic endotoxemia by inducing repetitive gut ischemia that that facilitates bacterial
translocation. In fact, HD patients have higher levels of circulating endotoxin than
peritoneal dialysis or CKD patients,57 which can affect cerebrovascular function.58 Other
potential mechanisms for impaired CVR in HD patients could include chronic
inflammatory state, 59,60 increased vascular stiffness,61,62 decreased baroreflex sensitivity
63

and chronic uremic stress.

In our study, CVR impairment in HD patients was not associated with dialysis vintage,
suggesting that the onset of CVR impairment is not linked to the duration of time that
patients have been on dialysis and likely occurs shortly after dialysis initiation. This
would be in keeping with previous studies that demonstrated development of white
matter injury22 and cognitive impairment64 shortly after initiation of dialysis.

112

Another observation in our study was that CVR responses across participant groups were
independent from CO2-induced changes in MAP. This suggests, that CVR assesses
aspects of vasomotor control of CBF that are distinct from cerebral autoregulation and
therefore provides an additional means of stratifying functional cerebrovascular risk in
patients prior to the onset of critical illness. Such functional risk stratification would be
important for interpreting the consequences of ICU exposures, such as CBFv deviations
described in Chapter 2, and for planning future interventional studies aimed at improving
neurocognitive outcomes in critical illness.
Limitations
Our study had several limitations. Due to its pilot nature, we had a relatively small
sample size. However, our sample size was still sufficient to demonstrate significant
difference in CVR between HD patients, CKD patients, and healthy participants, which
was the primary objective of our study.
We used transcranial Doppler and CBFv as a marker of global CBF based on prior
research showing that CBFv measured in the middle cerebral artery is a reliable and valid
index of CBF.65–69 However, changes in CBFv are only proportional to changes in CBF
as long as the vessel diameter stays constant. In this study, we insonated middle cerebral
artery and prior studies have shown that hypercapnia is associated with small dilation of
this vessel, which underestimates changes in CBF by about 8%.43 Using CBFv to
measure CVR may therefore result in underestimated CVR values. However, this does
not preclude comparison of relative differences in CVR between participant groups as
long as the same CBFv method and magnitude of change in CO2 is used in all groups.
The use of transcranial Doppler limited our results to computation of global CVR from a
single major intracranial vessel. Comprehensive evaluation of regional CVR in HD and
CKD patients will require tomographic modalities such as magnetic resonance imaging.
Nonetheless, our results provide much needed pilot data to support detailed study of CVR
in HD and CKD populations using more comprehensive neuroimaging modalities.
Furthermore, the relative portability of transcranial Doppler and its ability to identify
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CVR impairment in HD patients would make it a practical tool for CVR screening in
clinical settings.
CBF responds to changes in PaCO2. However, in this study we used PetCO2 as an
estimate of PaCO2. Such approach may present a bias due to end-tidal to arterial PCO2
difference that occurs as a result of alveolar dead space. However, prospective targeting
method that was used to manipulate blood gases in this study (RespirActTM) practically
eliminates alveolar dead space and corresponding end-tidal to arterial PCO2 difference,
such that PetCO2 actually correspond to PaCO2.33 Unlike other methods that control CO2,
prospective targeting method limits the amount of fresh gas that is delivered into the
alveoli, with the balance of the tidal breath made up by previously exhaled gas with a
PCO2 that closely approximates alveolar gas.26 This raises the PCO2 in alveoli with high
ventilation to perfusion ratio (i.e. alveoli that make up alveolar dead space) towards the
PCO2 in alveoli with good ventilation-perfusion match, resulting in a more homogenous
alveolar PCO2 throughout the lungs. As a result of this, PaCO2 is less dependent on the
regional inhomogeneities in lung blood flow and that PetCO2 closely approximated
PaCO2.33
In our study, the starting baseline PetCO2 was higher in HD patients. As a result, a
standard 10 mmHg increase in PetCO2 in HD group during intervention would result in
higher PetCO2 (and correspondingly PaCO2) levels during hypercapnia. With respect to
baseline PetCO2, there are two approaches to assess CVR. In the first approach, you
would start CVR assessment at participant’s own resting PetCO2 prior to induction of
hypercapnia. In the second approach, you would start all participants at the same absolute
baseline PetCO2. The benefit of the first approach is that CVR assessment is done relative
to participant’s own homeostatic set point. In healthy participants the absolute value of
this set point differs between participants but is always in the middle of their individual
CBFv-PetCO2 relationship curve.70 The same is likely true in CKD and HD patients. As a
result, adopting a second approach (i.e. imposing the same absolute starting PetCO2 on all
participants) may bias CVR assessment. For example, if the baseline PetCO2 in a given
participant is adjusted from 37 to 40 mmHg to ensure that all participants start at 40
mmHg, then this particular participant may have lower CBFv response to the same 10

114

mmHg increase in PetCO2 by virtue of their starting PetCO2 and corresponding CBFv
being closer to the upper limit of their CBFv-PetCO2 curve. Establishing the shape and
the limits of the CBFv-PetCO2 relationship in CKD and HD patients requires ramp
PetCO2 protocols.31,70 While this was beyond the scope of the present study, future
studies should explore the shape, limits and PetCO2 set-point of the CBFv-PetCO2
relationship in CKD and HD patients. The higher resting PetCO2 in HD patients is not
uncommon and is usually related to high prevalence of obstructive sleep apnea in this
patient population.71
We did not measure arterial blood gases and corresponding bicarbonate levels in this
study. While bicarbonate levels may differ between groups (especially in HD group),
they are unlikely to influence the results of this study. While the debate whether CBF
responds to changes in PaCO2, brain tissue PCO2 or pH is ongoing, most data support the
notion that PaCO2 (and likely brain tissue PCO2) are more important than changes in
pH.72 Furthermore, the relationship between PaCO2 and bicarbonate in most patients who
are not acutely ill is to balance the pH towards normal. Most participants would therefore
have normal pH levels at baseline despite different starting PCO2 and bicarbonate levels.
Given that PaCO2 changes in this study were rapid, there would not be enough time for
compensatory change in bicarbonate irrespective of resting bicarbonate levels. As a
result, while difference in resting bicarbonate levels between patients are possible they
areunlikely to affect the results of this study.
Finally, since we did not measure imaging markers of ischemia or neurocognitive
outcomes in our study, we cannot comment on the clinical relevance of impaired CVR in
HD patients. However, future detailed studies can explore whether impaired CVR in HD
patients is associated with ischemic injury or worse neurocognitive outcomes as a result
of hemodynamic stress of critical illness.

3.5 Conclusion
HD patients have impaired CVR compared to healthy participants and patients with
CKD. Given that impaired CVR predicts ischemic injury and worse neurocognitive
outcomes, we propose that HD patients would be at higher risk of ischemic injury and
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worse neurocognitive outcomes if they are exposed to hemodynamic stressors such as
CBFv deviations described in Chapter 2. Impaired CVR may render HD patients
vulnerable to ischemia by preventing vasodilatory response to ischemia during
spontaneous CBFv deviations and promoting vascular steal in regions with impaired
CVR. Future studies should confirm whether impaired CVR in HD patients is associated
with subcortical white matter brain injury and worse neurocognitive outcomes during and
following critical illness.
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Chapter 4
4

Optimizing web-based neurocognitive battery for
assessment of cognitive outcomes in ICU survivors.

This chapter is based on a previously published work in PLoS One. 2019 Apr
12;14(4):e0215203. doi: 10.1371/journal.pone.0215203.
In order to link ischemic insults during critical illness, such as CBFv deviations described
in Chapter 2, and impairments in cerebrovascular function, such as impaired CVR in HD
patients in Chapter 3, with neurocognitive outcomes we need to establish a clinically
feasible and accurate method for detecting cognitive impairment in ICU patients.
However, existing cognitive assessment methods are either too simple and fail to detect
multi-domain cognitive impairment in ICU patients, or too complex requiring long time
and specially trained personnel for completion, rendering them impractical for routine
clinical use.1
In this study we assessed the feasibility of a comprehensive web-based cognitive battery
Cambridge Brain Science (CBS) in detecting multi-domain cognitive impairment in a
cohort of ICU survivors. We showed that CBS is both feasible in clinical settings and
detected multi-domain impairment in ICU survivors. After identifying battery length as
an important feasibility threat, we showed that shortening the battery from 12 to 6 tests
yields similar cognitive results and could cut testing time in half.
Our results suggest that the shortened 6-test version of the Cambridge Brain Sciences
cognitive battery may be an optimal clinical tool for assessing cognitive outcomes in ICU
patients. This new tool fills an important gap in existing cognitive toolset used in critical
care by balancing comprehensiveness with brevity and ease of administration. This tool
will enable future work exploring links with ischemic insults, such as CBFv deviations
described in our first study, and impairments in cerebrovascular function, such as
impaired CVR in HD patients in our second study, as well as enable monitoring of
cognitive recovery in ICU survivors.
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4.1 Introduction
Long-term cognitive impairment is a common complication in critical illness survivors.1–
3

The mean prevalence of cognitive impairment in ICU survivors varies from 35 to 81%

at 3 months following ICU discharge depending on whether subjective or objective
cognitive measures are used, the type of cognitive tests used, and the etiology of critical
illness.1 While a recent systematic review attempted to use published cognitive data to
describe the natural history of cognitive recovery in ICU survivors,1 heterogeneity in the
types of cognitive batteries used, ICU patient populations studied, and the timing of
cognitive testing following ICU discharge made it challenging to meta-analyze these
data.
Understanding the natural history of cognitive recovery is critical for identifying
associated modifiable risk factors and insults during and following critical illness,
selecting therapeutic targets and assessing impact of therapeutic interventions, offering
prognosis to patients and their caregivers, and allocating healthcare resources. However,
existing neurocognitive assessment tools have a number of limitations that prevent their
use for monitoring cognitive recovery in individual patients, as well as in large cohort or
interventional studies. Simple cognitive tests or screening cognitive batteries familiar to
most clinicians, such as Trails Making Tests A and B, and Mini-Mental State
Examination, detect less cognitive impairment in ICU survivors compared to
comprehensive cognitive batteries.1 On the other hand, comprehensive cognitive batteries
are able to detect cognitive impairment across multiple cognitive domains, but are too
cumbersome, labour intensive and therefore impractical for routine use in clinical
settings, which may explain why their use is largely restricted to research studies and no
more than 3 time points following ICU discharge.1
Additional factors that may contribute to lack of routine monitoring of cognitive
outcomes in ICU survivors is that existing comprehensive cognitive batteries are paperbased and require specially trained staff for test administration, take a long time to
administer, and necessitate patients to attend testing sessions in person, which often
excludes those who have limited mobility, are institutionalized, live far away from the
testing centre, or are unwilling to return to the hospital where they were admitted due to
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associated traumatic memories. Furthermore, limited number of paper test versions
makes them especially prone to floor/ceiling and learning effects with repeated
administration.
Cambridge Brain Sciences (CBS) is a web-based cognitive battery that can overcome
many of these limitations and offer a paradigm shift in neurocognitive assessment and
follow up of ICU survivors.4 CBS battery can be self-administered by patients using their
own computer or a tablet, negating the need to travel to clinic. CBS minimizes
floor/ceiling and learning effects by adjusting test difficulty to patient’s performance and
randomizing the order of tests. While it has been used in a number of large-scale
population-based studies,5–7 as well as clinical populations,8–11 its feasibility and ability
to detect cognitive impairment in ICU survivors is unknown.
In this study, we assessed the feasibility of using CBS to detect cognitive impairment in a
cohort of ICU survivors. We hypothesized that the use of CBS would be feasible and that
its comprehensive nature would enable detection of cognitive impairment in ICU
survivors across multiple cognitive domains.
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4.2 Methods
Study design and participants
We conducted a prospective observational study of patients admitted to two adult tertiary
care centre intensive care units (ICUs) in London, Canada. The study was approved by
Western University Health Sciences Research Ethics Board (protocol number 108156).
We enrolled adult patients (18 to 80 years of age) who were mechanically ventilated for a
minimum of 24 hours. The latter criterion was added in order to exclude patients who
require brief ventilation (e.g. admitted for routine post-operative monitoring or following
for acute intoxication). We excluded patients with a pre-existing diagnosis of dementia,
new or pre-existing diagnosis of neurological disease known to affect cognitive function
(e.g. stroke, head trauma, intracranial hemorrhage, traumatic brain injury, or intracranial
malignancy), impaired vision or significant upper extremity weakness precluding use of a
computer, inability to communicate in English or were unable to or declined to provide
informed consent, or active delirium as determined by the Intensive Care Delirium
Screening Checklist (ICDSC).12
Cognitive Testing
To assess cognitive function across multiple domains, we used a web-based computerized
cognitive battery Cambridge Brain Sciences (CBS). CBS battery consists of 12 tests that
evaluate a broad range of cognitive processes. The individual tests include: Feature
Match, Odd One Out, Polygons, Rotations, Spatial Planning, Monkey Ladder, Paired
Associates, Spatial Span, Spatial Search, Digit Span, Double Trouble, and Grammatical
reasoning. These tests evaluate cognitive performance across major cognitive domains –
reasoning skills, planning, short-term memory, and verbal ability, which are considered
the main determinants of general intelligence.6 CBS was designed specifically to enable
self-administration by individuals without the need for a trained personnel, which enabled
its use in large-scale studies enrolling 11,600-44,000 participants 5–7 that would otherwise
be prohibitively expensive and impractical. Other useful features of this battery include
randomization of the order of tests, which minimizes learning effects with repeated
administration, and adjustment of test difficulty based on participant performance, which
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avoids ceiling or floor effects seen with cognitive testing. CBS battery has been shown to
be a very sensitive measure of cognition in various clinical populations including
patients with anatomically-specific brain lesions,8,9 neurodegenerative disease,10,11 in
pharmacological intervention studies.13,14 CBS neural correlates have been well studied
using functional neuroimaging in healthy adults,15,16 and in neuropathological
populations,17,18 and were shown to be highly sensitive to changes in sleeping habits and
duration.19 With over 7 million users, including a normative database of 75,000
participants, CBS is the largest databases of its kind in the world.
Screening for pre-ICU cognitive impairment
To screen our participants for a previous history of cognitive deficits, we asked a relative
or friend who knows the patient well to complete the Informant Questionnaire on
Cognitive Decline in Elderly (IQCODE). The IQCODE has been shown to have high
reliability in measuring cognitive decline and correlates well with other neurocognitive
tests.20 Family assessors are presented with 16 specific tasks (e.g., remembering where
things are usually kept) and asked to rate the patient’s current status on that task relative
to 10 years ago on a scale of 1 (much improved) to 5 (much worst) with a score of 3
indicating “no change”. A cut-off score of 3.44 was used as a positive screen for preexisting dementia.20
Assessment of Feasibility
Our aim was to assess the feasibility of using a web-based, neurocognitive battery to
assess cognition in ICU survivors at the time of ICU discharge. Our primary measure of
feasibility was the number of patients who completed the entire 12-test cognitive battery.
In addition, we took notes about any issues that arose throughout the administration of
the cognitive battery and any concerns that were raised by patients throughout testing so
that these challenges could be addressed in future ICU studies using the CBS battery.
Study protocol
We screened patients for eligibility using medical charts and discussion with bedside
nurses. We approached eligible patients and obtained written informed consent prior to
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commencing the study. Patients were deemed to be adequately alert and capable of
providing consent if they were able to participate in the consent discussion.
We recorded demographic and clinical variables including age, sex, admission diagnosis,
hospital and ICU admission dates, and Nine Equivalents of Nursing Manpower Use
Score (NEMS) as a measure of patients illness severity 21 on the day of testing from each
patient’s chart or electronic medical record.
Patients completed cognitive assessment using a laptop computer with an attached
computer mouse in their hospital bed in the ICU or shortly after discharge to the ward.
Investigators assisted patients by creating a personalized login and password on the CBS
study webpage. A standardized set of written and pictorial instructions and a short
instructional video preceded each cognitive test. Patients were provided with as much
time as they needed to review the instructions prior to beginning each test. Patients
completed each of the tests in sequence until the entire battery of 12 tests was completed
or they were unable to continue due to testing related fatigue.
Data analysis
Demographic and clinical variables were reported using descriptive statistics, expressed
as frequency and percentage for categorical variables and mean and standard deviation
(SD) or median and interquartile range (IQR) for continuous variables as applicable.
In keeping with definitions of cognitive impairment in the literature, patients were
defined as having cognitive impairment on a given test if their raw test score was ≥ 1.5
SDs below age- and sex-matched controls derived from the CBS normative database.6
We then compared patients’ cognitive performance with available data from healthy ageand sex-matched control data by converting raw scores into z-scores.
To determine patients’ scores on each of the three cognitive domains (reasoning skills,
short-term memory, and verbal processing), the z-score for each individual test was
multiplied by a value that reflected the contribution of that test to each cognitive domain
(i.e., factor loading) as established by Hampshire and colleagues.6 Patients’ overall score
on each cognitive domain was therefore the sum of the weighted (factor loaded) scores
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for that domain across all 12 tests. Data imputation was only used to compare domain
scores for patients who completed all 12 tests. The scores are designed such that the
healthy population mean on each cognitive domain is 0 and the SD is 1.0.
Abbreviated 6-test CBS battery
One of the identified feasibility challenges that our patients identified in this study was
the length of time required to complete the 12-test CBS battery. In direct response to this
challenge, we explored whether the scores from the abbreviated 6-test battery would
yield similar results as the full 12-test battery for our patient cohort. We defined an
abbreviated CBS battery that included six of the 12 CBS tests which most strongly reflect
one of the three cognitive domains based on previously published data (Reasoning Skills:
Odd One Out and Rotations; Short-term Memory: Paired Associates and Monkey Ladder;
and Verbal Processing: Digit Span and Verbal Reasoning).6 We replaced the scores for
the omitted tests with their expected values given the six observed test scores and the
known correlation structure among the tests in the population. The correlation structure
between the 12 tests in the CBS battery was derived from a sample of 44,600.6 This
method has been shown to be most accurate when calculating principle component
analysis scores in the presence of missing data.22 We then calculated a z-score for each
patient on each of the three cognitive domains based on the abbreviated 6-test CBS and
compared this score to the z-scores calculated based on the complete 12-test CBS battery
using simple linear regression.
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4.3 Results
Of 45 patients approached, 25 declined to participate in this study, most commonly due to
self-reported inability to participate or limited availability due to required clinical care
activities (e.g., diagnostic tests). Twenty patients (7 females) were included in the
analysis (Figure 4-1).
Inclusion criteria:
• Age 18-80 yrs
• Mechanical ventilation > 24 hrs

Approached
• 45 patients
Declined consent
• 23 patients
Eligible and agreed to participate
• 22 patients
Excluded
• 1 no valid written consent
• 1 never intubated
Enrolled
• 20 patients

Figure 4-1: Patient enrollment flow diagram
Patient demographic and clinical characteristics are summarized in Table 4-1. Patients
median (interquartile range, IQR) age was 58.5 (41-66) years, our cohort had slightly
more males (65%) that were admitted with a range of diagnoses and had median (IQR)
duration of ventilation and ICU stay of 2.5 (1-3) and 5 (4-9) days respectively. They also
required a substantial amount of ICU nursing workload at the time of enrollment as
indicated by a median NEMS score of 18 (full NEMS score ranges from 0-63 points).
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Table 4-1: Baseline patient characteristics
Characteristic

Statistic

Age, median (IQR)

58.5 (41-66)

Sex
Males

13

Females

7

Admission Diagnosis
Respiratory, n

3

Cardiac, n

2

Sepsis, n

2

Cardiac arrest, n

4

Neurologic, n

1

Non-head trauma, n

2

Surgical, n

3

Other, n

3

Duration of Mechanical Ventilation, median (IQR)

2.5 (1-3)

ICU length of stay (days), median (IQR)

5 (4-9)

Nine equivalents of nursing manpower use score, median (IQR)

18 (18-22)
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We reached family members or friends of 15 (75%) of enrolled patients for completion of
the IQCODE. None of these patients were found to have pre-morbid dementia as assessed
by the IQCODE.
Cognitive testing
Thirteen patients were tested in the ICU and seven were tested within one to four days of
transfer to the ward. Patients were tested after a median of 4 days (IQR 3.75) following
ICU admission. Three patients completed testing on two separate days at the patient’s
request. Seventeen of 20 patients completed the full 12-test CBS battery (the other three
patients completed four, six and seven tests). Of the three patients who did not complete
the full battery, two were tested on the ward and one was tested while still in the ICU.
The mean duration for completion of the 12-test CBS battery was 45.5 minutes (SD 11.1)
excluding the three patients who did not complete the entire battery and one patient
whose testing who had a long break between tests.
All patients were impaired on at least two tests, and 18 were impaired on at least three
tests relative to healthy controls. Among the 17 of 20 patients who completed the full
CBS battery, patients were impaired on a median of eight tests (IQR 4.5-10, range 2-11).
Individual patient performances as well as cohort means on each of the 12 CBS tests
relative to normative data are presented in Figure 4-2. Patients had poorer performance
on all CBS tests compared to healthy controls (Table 4-2). Patients also had poorer
performance on all three cognitive domains compared to healthy controls (Figure 4-3 and
Table 4-2).
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INDIVIDUAL TESTS IN CBS-12 BATTERY
Figure 4-2: Patient performance on the 12-test Cambridge Brain Sciences (CBS)
neurocognitive battery. . Individual patient (circles) and cohort (solid lines) test
performance presented as z-scores corrected for age and sex. Cognitive domains that are
mostly represented by the individual tests are shown at the top.
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Table 4-2: Cognitive performance of ICU survivors relative to healthy controls
using CBS 12-test battery.
COGNITIVE TEST /
DOMAIN

MEAN Z-SCORE (SD)

STATISTICS

CBS COGNITIVE TESTS
Feature Match

-2.21 (1.16)

t(17) = -8.10, p < 0.0001

Odd One Out

-2.1 (1.83)

t(19) = -5.14, p < 0.0001

Polygons

-1.35 (0.67)

t(16) = -8.28, p < 0.0001

Rotations

-1.58 (0.84)

t(18) = -8.22, p < 0.0001

Spatial Planning

-1.12 (0.92)

t(16) = -5.04, p < 0.0001

Monkey Ladder

-2.21 (1.93)

t(19) = -5.13, p < 0.0001

Paired Associates

-1.42 (1.04)

t(16) = -5.64, p < 0.0001

Spatial Span

-1.97 (1.56)

t(18) = -5.51, p < 0.0001

Spatial Search

-1.4 (0.92)

t(16) = -6.30, p < 0.0001

Digit Span

-1.85 (0.91)

t(16) = -8.40, p < 0.0001

Double Trouble

-1.43 (0.62)

t(19) = -10.40, p < 0.0001

Grammatical Reasoning

-2.46 (0.65)

t(19) = -16.89, p < 0.0001

COGNITIVE DOMAIN
Reasoning Skills

-2.13 (1.45)

t(16) = -6.05, p < 0.0001

Short-term Memory

-1.92 (1.41)

t(16) = -5.60, p < 0.0001

Verbal Processing

-1.66 (1.21)

t(16) = -5.65, p < 0.0001
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COGNITIVE DOMAIN
Figure 4-3: Patient performance on the three Cambridge Brain Sciences cognitive
domains: reasoning skills, short-term memory, and verbal processing. Individual
patient (circles) and cohort (solid lines) test performance on each cognitive domain
presented as z-scores.
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Feasibility issues
We identified two feasibility issues with the web-based CBS platform. First, three of our
patients reported testing related fatigue due to battery length and requested to stop the test
prior to completion of the entire 12-test battery. Second, one of our patients reported
inexperience with use of a computer mouse and had to be instructed on how to use a
mouse by one of the investigators.
Abbreviated 6-test battery
To address the issue of test fatigue related to battery length, we compared the scores from
the full 12-test battery with the scores that would have been obtained if we used
abbreviated 6-test battery. The 6-tests in the abbreviated battery were selected empirically
so that they would most strongly reflect performance on of the three cognitive domains
based on previously published data.6 Correlation analysis yielded good agreement
between 6- and 12-test battery scores in each of the three cognitive domains (Fig 4).
B
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Figure 4-4: Scatterplots including a linear fit (solid line) of the abbreviated 6-test vs
the full 12-test Cambridge Brain Sciences (CBS) battery on the three CBS cognitive
domains. (A) Reasoning (R2 = 0.91), (B) Memory (R2 = 0.80), and (C) Verbal
Processing (R2 = 0.94).
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4.4 Discussion
Our results confirm that a web-based cognitive battery, CBS, can identify domainspecific cognitive impairment in critical illness survivors. Battery length was identified as
an important feasibility risk, as four (20%) of our patients were unable to complete the
full 12-test battery in one sitting due to testing-related fatigue and asked to stop. We
showed that shortening the battery from 12 to 6 tests would have yielded similar
cognitive domain scores while shortening the testing time in half. Given that CBS battery
can be self-administered by patients, it represents a paradigm shift in cognitive recovery
monitoring in ICU patients by circumventing the needs for ICU survivors to come back
to clinic for cognitive assessments. Web-based cognitive batteries like CBS can enable
comprehensive cognitive recovery monitoring in ICU survivors. CBS provides an
objective patient-centred outcome that can be used to identify associated modifiable risk
factors and insults during and following critical illness, select therapeutic targets and
assess the impact of therapeutic interventions, offer prognosis to patients and their
caregivers, and help allocate healthcare resources.
Why monitor cognitive recovery in ICU survivors?
Cognitive function is one of the best predictors of life quality, including academic and
work success, levels of happiness and even life expectancy.23–25 ICU survivors suffer
from high prevalence of multi-domain cognitive impairment that may impede their
functional recovery, return to the workforce, and social functioning. 1,2 This problem is
likely to get worse in the coming years due to ageing of global populations 26 and
increase in the number of ICU survivors due to projected increase in the incidence of
critical illness 27 and reduction in ICU mortality. Furthermore, unlike Alzheimer’s disease
that primarily occurs in older adults, ICU-related cognitive impairment affects patients
across the age spectrum,2 which has important healthcare system and societal
implications. In summary, ICU-related cognitive impairment represents an important
public health problem that requires urgent and innovative solutions. Establishing a
clinically feasible, comprehensive and objective outcome measure of cognitive function
is an important first step in addressing this public health problem.
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What are the advantage of using CBS?
Unlike paper-based cognitive assessment tools, the web-based CBS battery can be selfadministered by patients from any location (ward, rehabilitation facility, home) after
minimal instructions on logging in and starting the tests, obviating the need for patients to
travel to hospital to be tested by specially trained staff. The self-administering nature of
web-based battery may enable large-scale studies similar to those completed in other
populations,5–7 and provides opportunity for repeated remote monitoring of cognitive
recovery in patients who are unable (or unwilling) to return to clinic. Given high
prevalence of functional disability, post-traumatic stress disorder, and challenging travel
logistics, remote web-based testing of cognition provides a more patient-centred
approach to monitoring cognition in ICU survivors.
The majority of previous ICU studies have used traditional paper-based tests.1 These tests
range from simple single tests such as Trails Making Test A/B or screening batteries for
dementia such as Mini-Mental State Examination, to more comprehensive cognitive
batteries such as Repeatable Battery for the Assessment of Neuropsychological Status
and Wechsler Adult Intelligence Scale-Fourth Edition.1 Given multi-domain nature of
cognitive impairment in ICU survivors, single tests or screening dementia batteries are
ineffective at detecting subtle, yet consequential cognitive deficits in critical illness
survivors. On the other hand, comprehensive cognitive batteries detect cognitive
impairment across multiple domains in a number of studies, but are not practically
feasible for routine monitoring of cognitive recovery in the clinic as they require trained
personnel, take a long time to complete, have limited number of versions (which makes
them prone to learning effects), and do not adjust for individual patient performance
(which makes them prone to floor/ceiling effects).
Web-based batteries like CBS offers a compromise to the paper-based approach by
enabling comprehensive multi-domain assessment while preserving clinical feasibility
through patient self-administration. Furthermore, randomization of the order of tests
limits learning effects, while automated adjustment of test difficulty based on patients’
performance avoids floor/ceiling effects. With a normative database of 75,000
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participants, and over 7 million users, CBS is the largest databases of its kind in the
world. This enables point-of-care benchmarking of patient’s performance against ageand sex-matched data from healthy controls.
Limitations
This study has several limitations. First, our sample size was small. While we showed
that CBS batter was feasible for use in clinical settings, and that it was able to detect
multi-domain cognitive impairment, we cannot make any definitive conclusions
regarding its ability to track cognitive recovery in ICU survivors. This will require future
dedicated studies. Second, web-based cognitive testing in general is not without
limitations. The inability to monitor patients during testing to determine their level of
engagement, patients’ access to and inexperience with use of a computer, and attrition in
follow-up studies are limitations inherent to the use of web-based (remote) cognitive
testing that must be addressed prior to large-scale use of such testing platforms in ICU
survivors. Patients’ performance in our study may have been affected by their ability to
use a computer mouse to navigate through the tasks. In future studies, we plan to test
tablets as an alternative to computer-mouse combination based on patient preference.
Finally, in the absence of a “gold standard” test for cognitive impairment in this study,
the psychometric characteristics of the CBS could not be assessed, although previous
studies in healthy controls 6 and elderly neuropsychiatric patients 28 have confirmed that
it is comparable to standard neuropsychological test batteries in terms of its latent
structure and relation to age. We identified that the length of the CBS cognitive battery
may be one challenge to its feasibility in larger studies. The proposed abbreviated CBS
battery is one potential solution to this challenge. Future studies are needed to assess the
feasibility of the abbreviated CBS battery.
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Future directions
By enabling remote monitoring of cognitive recovery in critical illness survivors, webbased cognitive testing using CBS battery represents a new frontier in ICU cognition
research. This tool will enable future work exploring links with ischemic insults, such as
CBFv deviations described in our first study, and impairments in cerebrovascular
function, such as impaired CVR in HD patients in our second study. The web-based
nature of this cognitive battery will allow patients to complete cognitive assessments
remotely without the need to come to clinic and would make tracking of cognitive
recovery economically feasible by obviating the need for specially trained personnel for
test administration. Furthermore, since Cambridge Brain Science has neuro-anatomical
correlates, it would enable mapping of cognitive outcomes to specific neuroimaging
findings in ICU patients, which would allow more precise identification of underlying
mechanisms responsible for cognitive dysfunction in this patient population.
In our next study, we aim to assess the feasibility of the abbreviated 6- test CBS battery
to monitor cognitive recovery over time in a cohort of ICU survivors (this study is
currently enrolling patients). In the future, in order to identify potential therapeutic
targets, we plan to correlate cognitive recovery trajectories obtained with the CBS against
1) modifiable risk factors that occur during and following critical illness and 2)
neuroanatomical injury patterns using multimodal neuroimaging (CT, MRI, PET). This
would enable development of targeted interventions that can be evaluated for
effectiveness in properly designed randomized control studies. Finally, we plan to engage
patient partners and healthcare services stakeholders in analyzing the burden of cognitive
disability in ICU survivors and to help establish care pathways that will support
rehabilitation and reintegration of ICU survivors into society.

4.5 Conclusions
We demonstrated that a comprehensive, web-based neurocognitive testing platform is
feasible for clinical use in critical illness survivors and detects domain-specific cognitive
impairment. We identified battery length as a potential challenge to wider scale use of the
CBS battery, and showed that abbreviated version of the CBF tool would be as effective
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in detecting cognitive impairment. In future work, we plan to use this tool to explore
links with ischemic insults, such as CBFv deviations described in our first study, and
impairments in cerebrovascular function, such as impaired CVR in HD patients in our
second study. We also plan to explore its utility in monitoring cognitive recovery in ICU
survivors over time. Further optimization of this tool for ICU patients will enable
identification of therapeutic targets for preventative, therapeutic and rehabilitative
interventions, and enable informed planning of healthcare resources for ICU survivors.
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Chapter 5
5

Summary, Limitations, Future Work and Significance.

5.1 Overview and Summary
In our first study, we aimed to determine the proportion of time that CBF deviates
spontaneously beyond previously reported ischemic or hyperemic thresholds in critically
ill patients with respiratory failure and/or shock within 48 hours of ICU admission, and to
establish whether these deviations are associated with impairment in dynamic
autoregulation and changes in MAP or CO2. We used transcranial Doppler to measure
CBFv as an indicator of global CBF and showed that CBFv deviates by 20-30% from
baseline for 17-24% of observation time in a cohort of patients with respiratory failure or
shock within 48 hours of an ICU admission. We used transcranial Doppler derived index
of dynamic autoregulation Mxa to show that dynamic autoregulation was impaired for
20-35% of observation time in our cohort. However, contrary to our hypothesis, the
observed CBFv deviations occurred during periods of both impaired and preserved
autoregulation, suggesting that failure of autoregulation alone does not fully explain the
observed CBFv deviations. Furthermore, occurrence of CBFv deviations during periods
of preserved autoregulation suggest that intact autoregulation does not fully protect the
brain from periods of ischemia and hyperemia during early stages of critical illness. In
attempt to understand the factors that are responsible for observed CBFv deviations, we
used regression analysis to determine the relative contribution of concurrently measured
fluctuation of MAP and PetCO2 to observed CBFv deviations. Again, contrary to our
hypothesis, our analysis showed that spontaneous fluctuations in PetCO2 and MAP
explain less than 25% of the observed CBFv deviations, suggesting that other
unmeasured factors, such as cardiac output or regional changes in cerebral metabolism
and cerebrovascular resistance, may play a role.
Prior studies in cardiac surgery have shown that cumulative duration of CBF deviations
beyond ischemic thresholds was associated with major clinical complications including
stroke and delirium1 and development of new ischemic lesions on neuroimaging2. Our
results suggest that critically ill patients with respiratory failure or shock may experience
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similar insults during early stages of their critical illness, which may explain high
prevalence of ischemic lesions on neuroimaging3,4 and histopathology,5,6 delirium7 and
long-term cognitive impairment8,9 in ICU patients. Future studies should establish
whether the cumulative burden of CBFv deviation reported in this study is associated
with imaging markers of ischemia and neurocognitive outcomes in this patient
population.
While prior studies suggested that the cumulative duration of impaired autoregulation
may be associated with development of delirium in patients with respiratory failure or
shock,10 our study suggests that ischemic insult in this population can occur even in the
settings of preserved autoregulation. This implies that assessment of autoregulation status
alone may not be sufficient in predicting neurocognitive outcomes, and future studies
should explore whether cumulative duration of CBFv deviations is a better predictor that
assessment of autoregulation alone.
Since MAP and PetCO2 are considered important determinants of CBF, we were
surprised to find that variation in these variables predicted <25% of observed CBFv
deviations. Other factors, such as cardiac output, have emerged as important determinants
of CBF that are independent of changes in MAP11 and their relative contribution to
observed CBFv deviations should be explored in future work. Additionally, regional
changes in cerebral metabolism may play a role and warrant further detailed examination.
In our second study, we aimed to assess whether patients with a high risk of critical
illness have impaired cerebrovascular function prior to the ICU admission. We chose to
examine HD patients since they are at higher risk of developing critical illness than the
general population.12 We used cerebrovascular reactivity to CO2 (CVR) to assess
cerebrovascular function in HD patients, and compare it to patients with CKD and
healthy participants. We showed that HD patients have impaired CVR, while there was
no difference in CVR between CKD patients and healthy participants. Our findings
suggest that certain patient groups may have pre-ICU impairment in their cerebrovascular
function that may render them more susceptible to ischemic injury and worse

147

neurocognitive outcomes when exposed to hemodynamic stress during critical illness,
such as CBFv deviations reported in our first study.
CVR has emerged as a robust marker of cerebrovascular function. Impairment in CVR is
associated with increased risk of stroke,13 cognitive impairment,14,15 cortical thinning,16
and leukoaraiosis.17 Furthermore, areas of normal white matter that have impaired CVR
show significant reductions in resting CBF, cerebral blood volume, and impairment in the
imaging markers of white matter integrity (fractional anisotropy and mean diffusivity),
suggesting that CVR is likely an early functional marker of white matter at risk for
subsequent injury.18 These findings may also explain why HD patients are more
vulnerable to developing subcortical white matter ischemic injury and associated
cognitive impairment when exposed to circulatory stress of hemodialysis.19
Our results suggest that HD patients are less likely to mount an effective compensatory
response during critical illness if they experience CBFv deviations seen in our first study.
In patients with preserved CVR, reduction in CBFv would lead to compensatory
vasodilation to maintain effective cerebral perfusion and oxygen delivery. Patients with
impaired CVR would not be able to mount an effective vasodilatory response and would
be more likely to experience ischemia. Furthermore, during episodes of global ischemia,
brain regions with impaired CVR may suffer worse ischemia than brain regions with
preserved CVR, as preserved vasodilation in the latter would divert blood flow from the
former by means of vascular steal. This phenomenon would be more pronounced in white
matter regions of the brain that are already more susceptible to vascular steal,20 and may
explain the high burden of white matter injury in critically ill patients (see Table 1-3).21,22
Future studies should explore whether impaired CVR in HD patients is associated with
higher risk of white matter injury and worse neurocognitive outcomes during critical
illness.
By demonstrating that certain patients have different baseline cerebrovascular function
prior to the onset of critical illness, we highlight the importance of incorporating such
functional assessments into interpretation of the effects of ICU exposures and
interventions on neurocognitive outcomes. The value of such functional assessment is
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highlighted in our study by the ability of CVR to differentiate cerebrovascular function
between CKD and HD patients, despite both groups sharing impaired renal function.
Functional stratification of baseline cerebrovascular risk advances this field of research
beyond simple assessment of baseline comorbidities and enables a more detailed
stratification of the relative risk of ischemic injury due to critical illness in individual
patients. Such individualized approach represents a new frontier in this field of research
and opens opportunities for identification of individualized therapeutic targets for specific
patients or groups of patients (i.e. personalized medicine).
In order to link ischemic insults during critical illness, such as CBFv deviations described
in our first study, and impairments in cerebrovascular function, such as impaired CVR in
HD patients in our second study, with neurocognitive outcomes we needed to establish a
clinically feasible and accurate method for detecting cognitive impairment in ICU
patients. However, existing cognitive assessment methods were either too simple and fail
to detect multi-domain cognitive impairment in ICU patients, or too complex requiring
long time and specially trained personnel for completion, rendering them impractical for
routine clinical use.8 In our third study, we therefore aimed to establish a clinically
feasible and accurate method for detecting cognitive impairment in ICU patients. Given
that ICU patients suffer from multi-domain cognitive impairment, we thought to use a
comprehensive cognitive battery that assesses multiple cognitive domains. However,
traditional paper-based comprehensive cognitive batteries are nor practical for routine use
in clinical settings as they take long time to administer and require specially trained
personnel. Cambridge Brain Sciences,23 an established and widely used web-based
cognitive battery that assess multiple cognitive domains, presented an attractive
compromise between comprehensiveness and ease of administration. We thought to
establish its clinical feasibility and ability to detect cognitive impairment in ICU patients.
We administered Cambridge Brain Sciences to a cohort of ICU patients prior to or shortly
after ICU discharge and showed that this battery was able to detect cognitive impairment
across multiple domains in all participants. Since the duration of battery administration
was identified as common limiting feasibility factor in our study, we also demonstrated
that shortening the battery from 12 to 6 tests would have yielded similar cognitive results.

149

Our results suggest that the shortened 6-test version of the Cambridge Brain Sciences
cognitive battery may be an optimal clinical tool for assessing cognitive outcomes in ICU
patients. This new tool fills an important gap in existing cognitive toolset used in critical
care. Similar to traditional paper-based comprehensive cognitive batteries, it assesses
cognition across multiple domains, but it does not require trained personnel to administer,
can be remotely self-administered by patients allowing for remote monitoring of
cognitive recovery and saving time during clinical appointments, and avoids learning and
floor-ceiling effects by randomizing the order and adjusting the difficulty of individual
tests based on patient performance. Similar to simple screening tools like Mini Mental
State Examination (MMSE), it is short and easy to administer, while also being able to
detect subtle cognitive impairment across multiple domains that is often missed by
screening tests like MMSE.8
Given that cognitive health is an important patient-centred outcome that determines the
overall function,24–26 our clinical validation of the shortened version of the Cambridge
Brain Sciences tool opens a new frontier for monitoring cognitive outcomes in ICU
survivors. This tool will enable future work exploring links with ischemic insults, such as
CBFv deviations described in our first study, and impairments in cerebrovascular
function, such as impaired CVR in HD patients in our second study. The web-based
nature of this cognitive battery will allow patients to complete cognitive assessments
remotely without the need to come to clinic and would make tracking of cognitive
recovery economically feasible by obviating the need for specially trained personnel for
test administration. Furthermore, since Cambridge Brain Science has neuro-anatomical
correlates, it would enable mapping of cognitive outcomes to specific neuroimaging
findings in ICU patients, which would allow more precise identification of underlying
mechanisms responsible for cognitive dysfunction in this patient population.
In summary, in this work we demonstrated that critically ill patients experience
substantial duration of CBFv deviations beyond previously described ischemic and
hyperemic thresholds that occur irrespective of the state of dynamic cerebral
autoregulation and are not fully explained by concurrent variations in MAP and CO2. We
then showed that HD patients have impaired cerebrovascular function that may render
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them more susceptible to ischemic injury during critical illness when exposed to CBFv
variations identified in our first study. Finally, we optimized an existing comprehensive
web-based cognitive battery for monitoring cognitive outcomes in ICU patients, which
should enable linkage between clinical observations (such as CBFv deviations and
impaired cerebrovascular function in our first two studies) with an important patientcentred outcome.
Our work highlights the importance of studying the problem of neurocognitive outcomes
in ICU patients across the continuum of critical illness framework (Figure 5-1).

Figure 5-1: Continuum of Critical Illness Framework for studying the problem of
neurocognitive outcomes in ICU patients.
Under this framework, it is important to consider pre-ICU, ICU and post-ICU factors
related to neurocognitive health. At the pre-ICU stage, consideration of risk factors
should move beyond epidemiologic considerations of traditional comorbidities and
incorporate functional assessment of brain health (e.g. cerebrovascular function as
assessed by CVR), especially in patient populations that are at high risk of critical illness
(e.g. HD patients). Such functional stratification would help stratify patients in future
observational and interventional trials assessing ICU exposures and interventions. During
ICU-stage, we should employ modern multimodal neuromonitoring methods to better
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delineate biologically plausible insults (e.g. CBFv deviations beyond ischemic and
hyperemic thresholds), and utilize these methods over prolonged observations periods to
quantify the burden of such insults (e.g. the cumulative time of CBFv deviations).
Combining different monitoring modalities (e.g. transcranial Doppler with invasive MAP
and exhaled PetCO2 monitoring) can help explore mechanisms behind identified insults
(e.g autoregulation), while adding novel monitors (e.g. diffuse correlation spectroscopy)
in future studies can provide a more in-depth assessment of the various contributing
factors (e.g. cerebral metabolism and oxygen delivery). At the post-ICU stage it is critical
to establish clinically feasible yet comprehensive tools for detecting relevant patientcentred outcomes (e.g. cognitive function). Such tools will enable linkage of patientcentred outcomes with pre-ICU functional risk factors (e.g. CVR) and ICU exposures
(e.g. CBFv deviations) and interventions. They will also enable longitudinal studies to
better understand the natural history of cognitive recovery in ICU patients, identify
optimal time windows for interventions, and assess outcomes of targeted therapeutic
interventions.

5.2 Limitations of current work
There were several limitations in our studies. First, our sample sizes were relatively
small. However, all three studies were of pilot nature and aimed to: 1) explore the
potential burden of CBFv deviations beyond ischemic/hyperemic thresholds in the early
stages critical illness, 2) assess whether certain patients at high risk of critical illness may
have impaired cerebrovascular function that can render them more susceptible to
ischemic injury during critical illness, and 3) develop clinically feasible yet
comprehensive method for monitoring cognitive outcomes in ICU patients following
resolution of critical illness.
Another limitation is that we used transcranial Doppler to monitor CBFv velocity in the
middle cerebral artery as an indicator of global CBF. This method, while having excellent
temporal resolution, lacks in spatial resolution. Given that CVR differs between gray and
white matter,27 we cannot conclude whether CVR impairments in HD patients was
secondary to impaired gray or white matter CVR, or both. Furthermore, subtle changes
and CVR in specific brain regions may have been missed.
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Lastly, CBF velocity is proportional to CBF as long as the diameter of insonated vessel
remains the same. One recent study reported that hypercapnia dilates middle cerebral
artery, which would cause CBF velocity to underestimate CBF.28 Another study
suggested that middle cerebral artery diameter stays relatively constant at modest
elevations of CO2.29 The reason for difference between these studies remains unclear, but
may be related to different magnetic resonance imaging protocols, and the relationship
between MCA diameter and PCO2 may in fact be sigmoid based on main published
studies in this area.30 Since we did not measure middle cerebral artery diameter during
this study we cannot comment whether our results have been affected by its changes.
Either way, despite the uncertainties regarding the changes in middle cerebral artery
diameter during CO2 challenges, transcranial Doppler has been previously used to study
CVR in the middle cerebral artery,31–33 and impaired CVR has been associated with
pathologies such as hypertension and vascular disease,34, as well as increased risk of
death.35 Furthermore, in our first study the changes in CO2 were equivalent between the
three patient groups, so differences in CVR are likely representative of difference in
global CBF. However, this would need to be confirmed with more accurate CBF
measures such as magnetic resonance imaging.
In our first two studies, we did not link observed changes in CVR and CBF with imaging
markers of ischemia or cognitive outcomes. Such linkage would require larger sample
size studies that control for important covariates and the use tomographic imaging
modalities such as magnetic resonance imaging, which would be make pilot study
complex and expensive. As a result, we chose to first determine whether our hypotheses
were supported by plausible physiologic data prior to embarking on large scale clinical
studies. Our results from the first two studies provide important empiric rationale for
design of larger scale studies that should explore potential associations of impaired CVR
and CBFv deviations beyond ischemic thresholds with imaging markers of ischemia and
clinical outcomes. Furthermore, results of our third study provide a feasible and objective
outcome measure that can be utilized in these future studies.
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5.3 Future work
In the future, we plan to further characterize impairment in CVR in HD patients. First, we
will use tomographic imaging methods such as MRI to better delineate whether the
impairment occurs in gray or white matter, and whether it is associated with imaging
markers of ischemic injury. Given that CVR was preserved in CKD group, we will test
the hypothesis that transition of CKD to hemodialysis is associated with the development
of impaired CVR. Finally, we would like to determine the functional consequences of
decreased CVR by establishing whether it is associated with cognitive impairment in the
settings of hemodialysis and critical illness. From epidemiological perspective, we would
like to determine if HD patients have a higher risk of developing ICU-related delirium
and long-term cognitive impairment compared to CKD patients and non-CKD controls.
In the ICU settings, we plan to determine if the cumulative burden of observed deviations
in CBFv is associated with the imaging markers of ischemia and cognitive impairment.
We will also determine if this phenomenon occurs in other critically ill populations
including those with acquired brain injury. Given that patients with ARDS have higher
prevalence of cognitive impairment 8 and are also exposed to higher PaCO2 due to
permissive hypercapnia,36 we would like to explore whether permissive hypercapnia
contributes to cognitive impairment in these patients by impairing cerebrovascular
function and facilitating ischemic brain injury. Finally, if we confirm that CBFv
deviations are associated with ischemic injury and cognitive impairment using
Cambridge Brain Sciences battery that we developed in our third study, we will plan
interventional trials to reduce such injury, perhaps by improving cerebrovascular function
through optimization of PaCO2.
Finally, we plan to use the 6-test version of Cambridge Brain Sciences cognitive battery
from our last study to describe the natural history of cognitive recovery following
resolution of critical illness. Specifically, our aim would be to determine if there are
different cognitive recovery phenotypes (Figure 5-2), and utilize neuroimaging modalities
to assess whether such phenotypes are associated with different patterns of brain injury.
We will also 6-test version of Cambridge Brain Sciences as a feasible outcome measure
in both pre-ICU and ICU studies proposed early.

CBS cognitive domain scores
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Figure 5-2: Hypothetical Cognitive Recovery Phenotypes in ICU Survivors. Regular
follow-up testing of individual ICU survivors using Cambridge Brain Sciences
(CBS) battery may identify different trajectories of cognitive recovery phenotypes
among patients.
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5.4 Significance
While cognitive impairment in ICU patient is very common,7,8 and associated
demographic and clinical risk factors have been identified,37,38 the underlying biologic
mechanisms responsible for these functional impairments remain elusive. This lack of
knowledge of underlying pathophysiologic mechanisms prevents development of targeted
interventions and limits therapeutic options. In this body of work, we identified
previously under-appreciated insult (i.e. CBFv deviations) that is not fully counteracted
by a known homeostatic mechanism (i.e. cerebral autoregulation) and is not fully
explained by two established physiologic variables (i.e. fluctuations in MAP and
PetCO2). We then showed that for the first time that certain patients at high risk of critical
illness have impaired in cerebrovascular function that may render them more susceptible
to ischemic injury when exposed to insults such as the one identified in the first study.
Finally, we developed a clinically feasible outcome measure for detecting and tracking
the functional consequences of pre-ICU impairments in cerebrovascular function and
ICU insults, such as CBFv deviations reported in the first study.
Our approach is a paradigm shift in this area of research by refocusing efforts from
ongoing description of association between cognitive impairment and clinical risk
factors, to in depth discovery of the underlying biologic mechanisms and insults
grounded in established models of ischemic injury in other clinical populations, such as
CKD and HD patients. We demonstrate that similar processes may be at play during
circulatory stress of critical illness. As a result, our work provides much needed pilot data
and substantiates the rationale for further detailed enquiry into the mechanisms of brain
injury in this patient populations using state of the art neuroimaging techniques,
functional assessment of cerebrovascular function, and the newly developed cognitive
outcome measure. By focusing on understanding the underlying mechanisms and linking
them to imaging and functional markers of injury, we should be able to discover new
therapeutic targets and position this field of research for designing targeted interventional
trials to improve neurocognitive outcomes in ICU patients.
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6

Appendices

Appendix A: Within patient analysis of the time that CBFv deviated above or below
CBFv thresholds.
Table 6-1: Within patient analysis of the proportion of the observation time that
CBFv was above or below CBFv thresholds
Proportion of observation time CBFv was above threshold
CBF threshold (% above baseline)
Patient
5
10
15
20
25
30
1
0.429
0.245
0.101
0.044
0.018
0
2
0.283
0.198
0.149
0.07
0.026
0.007
3
0.334
0.204
0.068
0
0
0
4
0.083
0.043
0.02
0.008
0.002
0
5
0.191
0.08
0.025
0.006
0.002
0.001
6
0.844
0.629
0.114
0.002
0
0
7
0.966
0.966
0.965
0.962
0.953
0.936
8
0.469
0.236
0.091
0.021
0.006
0.002
9
0.133
0.044
0.021
0.011
0.007
0.003
10
0.901
0.79
0.712
0.641
0.58
0.544
11
0.259
0.165
0.071
0.024
0.008
0.003
12
0.297
0.076
0.019
0.005
0.001
0
Proportion of observation time CBFv was below threshold
CBF threshold (% below baseline)
Patient
5
10
15
20
25
30
1
0.293
0.185
0.087
0.031
0.007
0.001
2
0.471
0.303
0.189
0.107
0.04
0.016
3
0.439
0.391
0.343
0.332
0.331
0.33
4
0.722
0.619
0.516
0.38
0.232
0.139
5
0.43
0.248
0.126
0.053
0.016
0.004
6
0.033
0.011
0.004
0
0
0
7
0.016
0.01
0.005
0.001
0
0
8
0.143
0.061
0.025
0.012
0.008
0.005
9
0.395
0.2
0.096
0.029
0.002
0
10
0.013
0.005
0.002
0.002
0
0
11
0.55
0.441
0.299
0.164
0.094
0.053
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Appendix B: Within patient analysis of the relationship between CBFv deviations
and state of dynamic autoregulation.
Figure 6-1, Figure 6-2 and Table 6-2 below provide within patient data on the
relationship between CBFv deviations above/below thresholds and state of dynamic
cerebral autoregulation (preserved/impaired).
.
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Figure 6-1: Relationship between CBFv deviations above/below thresholds and state of dynamic autoregulation (patients 1-6)
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Figure 6-2: Relationship between CBFv deviations above/below thresholds and state of dynamic autoregulation (patients 7-12)
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Table 6-2: Within patient comparison of the duration that CBFv deviated above/below CBF thresholds between windows with
preserved versus impaired autoregulation (AR).
Time CBFv ABOVE threshold
Time CBFv BELOW threshold
(fraction of 5-min window time)
(fraction of 5-min window time)
AR Preserved
AR Impaired
AR Preserved
AR Impaired
Subject CBF threshold
mean ± SD
mean ± SD
p-value
mean ± SD
mean ± SD
p-value
5
0.416 ± 0.345
0.595 ± 0.346
<0.0001
0.352 ± 0.017
0.236 ± 0.041
<0.0001
1
10
0.233 ± 0.264
0.381 ± 0.325
0.0006
0.29 ± 0.014
0.175 ± 0.031
<0.0001
1
15
0.092 ± 0.191
0.206 ± 0.281
0.0155
0.181 ± 0.009
0.126 ± 0.022
<0.0001
1
20
0.04 ± 0.158
0.078 ± 0.184
0.8975
0.107 ± 0.005
0.059 ± 0.01
<0.0001
1
25
0.017 ± 0.086
0.019 ± 0.061
>0.9999
0.036 ± 0.002
0.014 ± 0.002
<0.0001
1
30
0 ± 0.004
0±0
>0.9999
0.004 ± 0
0.003 ± 0.001
0.9656
1
2
2
2
2
2
2

5
10
15
20
25
30

0.315 ± 0.406
0.211 ± 0.355
0.145 ± 0.304
0.068 ± 0.189
0.026 ± 0.102
0.007 ± 0.038

0.34 ± 0.422
0.271 ± 0.427
0.245 ± 0.408
0.139 ± 0.262
0.065 ± 0.172
0.018 ± 0.056

0.9842
0.5118
0.0495
0.3145
0.8893
0.9999

0.425 ± 0.392
0.261 ± 0.336
0.149 ± 0.275
0.073 ± 0.194
0.022 ± 0.073
0.001 ± 0.004

0.369 ± 0.397
0.256 ± 0.357
0.183 ± 0.328
0.099 ± 0.242
0.044 ± 0.16
0.027 ± 0.117

0.5257
>0.9999
0.912
0.9761
0.9887
0.9759

3
3
3
3
3

5
10
15
20
25

0.509 ± 0.503
0.468 ± 0.485
0.192 ± 0.283
0±0
0±0

0.281 ± 0.412
0.184 ± 0.355
0.093 ± 0.254
0.001 ± 0.003
0±0

<0.0001
<0.0001
0.1379
>0.9999
>0.9999

0.421 ± 0.489
0.404 ± 0.495
0.402 ± 0.493
0.4 ± 0.491
0.397 ± 0.49

0.512 ± 0.464
0.405 ± 0.485
0.395 ± 0.489
0.394 ± 0.487
0.393 ± 0.486

0.8241
>0.9999
>0.9999
>0.9999
>0.9999
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Time CBFv ABOVE threshold
(fraction of 5-min window time)
AR Preserved
AR Impaired
mean ± SD
mean ± SD
p-value
0±0
0±0
>0.9999

Time CBFv BELOW threshold
(fraction of 5-min window time)
AR Preserved
AR Impaired
mean ± SD
mean ± SD
p-value
0.393 ± 0.488
0.39 ± 0.485
>0.9999

Subject
3

CBF threshold
30

4
4
4
4
4
4

5
10
15
20
25
30

0.068 ± 0.14
0.032 ± 0.099
0.015 ± 0.081
0.005 ± 0.043
0.002 ± 0.018
0 ± 0.002

0.134 ± 0.25
0.08 ± 0.192
0.042 ± 0.123
0.016 ± 0.06
0.004 ± 0.02
0 ± 0.002

<0.0001
0.0002
0.1197
0.9205
>0.9999
>0.9999

0.752 ± 0.332
0.653 ± 0.377
0.554 ± 0.368
0.41 ± 0.335
0.246 ± 0.276
0.137 ± 0.242

0.68 ± 0.378
0.595 ± 0.395
0.487 ± 0.384
0.367 ± 0.351
0.261 ± 0.326
0.183 ± 0.289

0.4111
0.6428
0.4925
0.886
0.9995
0.846

5
5
5
5
5
5

5
10
15
20
25
30

0.192 ± 0.13
0.08 ± 0.079
0.025 ± 0.045
0.005 ± 0.015
0.001 ± 0.006
0 ± 0.003

0.199 ± 0.139
0.11 ± 0.088
0.046 ± 0.047
0.016 ± 0.029
0.008 ± 0.015
0.003 ± 0.008

0.9958
0.1136
0.4471
0.9506
0.9946
>0.9999

0.421 ± 0.189
0.238 ± 0.18
0.122 ± 0.126
0.054 ± 0.079
0.017 ± 0.044
0.005 ± 0.02

0.559 ± 0.199
0.398 ± 0.209
0.21 ± 0.147
0.08 ± 0.078
0.008 ± 0.019
0.004 ± 0.01

<0.0001
<0.0001
0.0021
0.8748
0.9994
>0.9999

6
6
6
6
6
6

5
10
15
20
25
30

0.862 ± 0.261
0.661 ± 0.33
0.133 ± 0.157
0.003 ± 0.013
0±0
0±0

0.66 ± 0.28
0.325 ± 0.28
0.072 ± 0.086
0±0
0±0
0±0

<0.0001
<0.0001
0.604
>0.9999
>0.9999
>0.9999

0.044 ± 0.173
0.024 ± 0.107
0.014 ± 0.06
0±0
0±0
0±0

0.049 ± 0.128
0.008 ± 0.035
0±0
0±0
0±0
0±0

>0.9999
0.9469
0.9772
>0.9999
>0.9999
>0.9999
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Time CBFv ABOVE threshold
(fraction of 5-min window time)
AR Preserved
AR Impaired
mean ± SD
mean ± SD
p-value

Time CBFv BELOW threshold
(fraction of 5-min window time)
AR Preserved
AR Impaired
mean ± SD
mean ± SD
p-value

Subject

CBF threshold

7
7
7
7
7
7

5
10
15
20
25
30

0.967 ± 0.179
0.967 ± 0.179
0.967 ± 0.179
0.965 ± 0.178
0.962 ± 0.179
0.95 ± 0.183

0.663 ± 0.429
0.663 ± 0.429
0.663 ± 0.429
0.663 ± 0.429
0.663 ± 0.429
0.652 ± 0.42

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

0.019 ± 0.107
0.009 ± 0.059
0.005 ± 0.035
0.002 ± 0.012
0 ± 0.002
0±0

0.33 ± 0.417
0.287 ± 0.356
0.154 ± 0.197
0.039 ± 0.058
0.007 ± 0.011
0±0

<0.0001
<0.0001
<0.0001
0.7224
>0.9999
>0.9999

8
8
8
8
8
8

5
10
15
20
25
30

0.468 ± 0.219
0.233 ± 0.193
0.089 ± 0.109
0.02 ± 0.036
0.006 ± 0.019
0.002 ± 0.008

0.5 ± 0.191
0.312 ± 0.151
0.142 ± 0.09
0.044 ± 0.039
0.015 ± 0.025
0.005 ± 0.011

0.7248
0.0106
0.191
0.921
0.9996
>0.9999

0.142 ± 0.131
0.059 ± 0.09
0.024 ± 0.059
0.011 ± 0.041
0.008 ± 0.033
0.005 ± 0.024

0.174 ± 0.141
0.103 ± 0.132
0.052 ± 0.101
0.022 ± 0.057
0.014 ± 0.047
0.013 ± 0.047

0.1798
0.0175
0.314
0.9813
0.9984
0.9953

9
9
9
9
9
9

5
10
15
20
25
30

0.149 ± 0.243
0.044 ± 0.147
0.021 ± 0.134
0.018 ± 0.128
0.014 ± 0.107
0.007 ± 0.05

0.172 ± 0.288
0.101 ± 0.247
0.07 ± 0.2
0.033 ± 0.106
0.014 ± 0.056
0.007 ± 0.037

0.7127
0.0091
0.0366
0.9463
>0.9999
>0.9999

0.348 ± 0.339
0.151 ± 0.234
0.057 ± 0.142
0.016 ± 0.06
0.001 ± 0.008
0 ± 0.002

0.388 ± 0.397
0.182 ± 0.305
0.073 ± 0.206
0.009 ± 0.045
0 ± 0.002
0±0

0.3282
0.6507
0.9778
0.9998
>0.9999
>0.9999
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Time CBFv ABOVE threshold
(fraction of 5-min window time)
AR Preserved
AR Impaired
mean ± SD
mean ± SD
p-value
0.899 ± 0.259
0.719 ± 0.382
0.0761
0.847 ± 0.349
0.573 ± 0.454
0.0009
0.766 ± 0.385
0.513 ± 0.486
0.0027
0.67 ± 0.458
0.472 ± 0.487
0.0369
0.614 ± 0.466
0.4 ± 0.473
0.0183
0.56 ± 0.467
0.334 ± 0.444
0.011

Time CBFv BELOW threshold
(fraction of 5-min window time)
AR Preserved
AR Impaired
mean ± SD
mean ± SD
p-value
0.023 ± 0.091
0.042 ± 0.094
0.0603
0.012 ± 0.05
0.01 ± 0.027
>0.9999
0.007 ± 0.03
0±0
0.9361
0.005 ± 0.023
0±0
0.981
0.002 ± 0.007
0±0
>0.9999
0.002 ± 0.007
0±0
>0.9999

Subject
10
10
10
10
10
10

CBF threshold
5
10
15
20
25
30

11
11
11
11
11
11

5
10
15
20
25
30

0.26 ± 0.368
0.17 ± 0.284
0.075 ± 0.162
0.028 ± 0.094
0.01 ± 0.06
0.004 ± 0.038

0.192 ± 0.266
0.104 ± 0.174
0.049 ± 0.104
0.026 ± 0.071
0.011 ± 0.04
0.005 ± 0.021

0.0524
0.0685
0.9003
>0.9999
>0.9999
>0.9999

0.57 ± 0.431
0.455 ± 0.417
0.294 ± 0.363
0.165 ± 0.306
0.109 ± 0.256
0.073 ± 0.224

0.589 ± 0.371
0.467 ± 0.392
0.358 ± 0.375
0.22 ± 0.279
0.113 ± 0.183
0.055 ± 0.126

0.9985
0.9999
0.619
0.7702
>0.9999
0.9989

12
12
12
12
12
12

5
10
15
20
25
30

0.286 ± 0.298
0.08 ± 0.161
0.022 ± 0.085
0.007 ± 0.039
0.002 ± 0.01
0±0

0.326 ± 0.291
0.115 ± 0.174
0.036 ± 0.083
0.009 ± 0.03
0.003 ± 0.017
0±0

0.2204
0.3644
0.9786
>0.9999
>0.9999
>0.9999

0.194 ± 0.215
0.063 ± 0.124
0.021 ± 0.081
0.007 ± 0.04
0.003 ± 0.018
0.001 ± 0.007

0.175 ± 0.214
0.071 ± 0.159
0.031 ± 0.11
0.014 ± 0.054
0.003 ± 0.019
0.001 ± 0.009

0.7713
0.9961
0.9878
0.9969
>0.9999
>0.9999
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